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Large volumes of antisera were generated against Apis melli/era venom with which to 
develop a novel, platform technology for the inexpensive production of anti venoms. 
The ovine sera contained high levels of specific antibodies which neutralised the 
myotoxic, phospholipase A2 and in vivo activities of the venom. 
Methods of processing the antisera to provide Fab or F(ab')2 were investigated. F(ab')2 
was thought to be clinically advantageous and, by determining the conditions 
necessary for the preferential breakdown of Fc and serum components other than 
F(ab')2' it was possible to avoid salt precipitation. Diafiltration was then used to 
remove most of the unwanted small fragments and anion-exchange chromatography to 
remove any remaining acidic impurities such as pepsin and large aggregates. The 
F(ab')2 was -97% pure and the yield - 199 per L of serum. This is the first specific 
therapy for mass envenoming by European or Africanised bees. 
Spiders of the genus Latrodectus (black widows) are distributed widely and about 
2,500 bites are reported annually in the USA. The neurotoxic effects of the venom 
were studied on the isolated phrenic nerve diaphragm preparation. Low venom 
concentrations (ImgIL) were stimulatory while high concentrations (IOmg/L) caused 
nerve blockade which was potentiated by increased calcium levels. 
Although effective, the Merck antivenom, which is unprocessed horse serum, causes 
unacceptable risks. The second purpose of this project was to prepare an improved 
Latrodectus spider antivenom using the new platform technology. 
Different immunisation schedules were studied to optimise the humoral immune 
response. Sheep immunised with 2mg La. hesperus venom produced the highest levels 
of specific antibodies as assessed by ELISA, using the isolated nerve diaphragm 
preparation or in vivo in mice. The new process provided a pure F(ab')2 antivenom 
retaining 78% of the original antisera ED so neutralising power and was - twice as 
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1.1.1 History and General Introduction 
Arthropods are invertebrates with jointed limbs, a segmented body, and an 
exoskeleton made of chitin. This Phylum includes three-quarters of all known species 
of animals and is subdivided into several diverse classes such as Arachnids, Insects, 
Crustaceans and Myriapods (centipedes). The Order of Araneae (spiders) from the 
Arachnids and Order Hymenoptera from the Insects will be considered in this work. 
Currently, about 30,000 species of spiders have been recognised and many more have 
yet to be discovered (preston-Mafham & Preston-Mafham, 1993a). Evolutionary 
adaptation has allowed them to occupy nearly every terrestrial habitat, from the peaks 
of the highest mountain ranges to the depths of the largest caves and from damp 
marsh to dry desert; indeed anywhere that they can find other arthropods to feed upon. 
Phylogenetically the spiders are very old, with the first fossil spiders belonging to the 
Carboniferous period (Bettini & Brignoli, 1978). 
The development of the venom apparatus and the evolution of different types of web 
have ensured their evolutionary success. The venom is of equal, or greater, importance 
to spiders than silk and natural selection must have had a pronounced influence on its 
toxic and pre-digestive constituents. Many spiders have developed enzymes that 
neutralise most of the defensive toxic substances secreted, or simply contained, by the 
arthropods on which they prey (Bettini & Brignoli, 1978). 
All spiders are venomous, with the sole exception of the small family of Uloboridae, 
which has lost its poison glands (Bettini & Brignoli, 1978). However, fortunately for 
man, only a few species have evolved venoms that are poisonous to mammals, 
together with the apparatus needed to pierce the skin and allow envenoming. 
1.1.2 Anatomy, Including Venom Injecting Apparatus 
At the front of the cephalothorax or head are the jaws (or chelicerae) which cause the 
spider's deadly bite (Figure 1.1). They consist of a stout basal segment, which often 
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bears sharp teeth along the inner edge, and a sharp fang, which hinges onto the basal 
segment and is used to pierce the exoskeleton of the prey. These fangs often fit into 
grooves on the basal segment and the way in which the chelicerae work is used as a 
means of separating the more primitive (mygalomorph) from the more advanced true 
spiders (Labidognatha). In the mygalomorphs (e.g. Tarantulas and Funnel Web 
spiders), the chelicerae strike forwards and downwards whereas, in the true spiders, 
they are turned through 90° and work from side to side, in a pincer-type movement. 
The mygalomorph fang arrangement is suitable for spiders which live mainly at 
ground level, since the downward thrust of the fangs is opposed by the ground on 
which the prey is standing. However, it is of little use on a leaf or in a web and it is in 
such situations that the greater span between the fangs, possible in the true spiders, 
confers benefit. Near the end of each fang is a tiny hole which is connected to the 
poison sacs and through which venom is injected into the victim (Wright et al., 1973). 
The fangs measure between 0.32 - 0.45mm in length for both Latrodectus and 
Loxosceles species (Bucher!, 1971). The poison glands may be contained entirely 
within the basal segment of the chelicerae or may extend back into the head. Each is 
enveloped with several muscle layers, whose contraction expels the stored venom 
(Wright et al., 1973). 
Unlike spiders, honey bees (Apis melli/era) use their venom only for defence. The 
morphology and function of the sting from an Africanised bee is almost identical to 
that of a European bee. The stinger is composed of two barbed lancets supported by 
hard plates and powerful muscles, connected to a venom sac and to specialised glands 
that produce alarm odours. When a bee stings, the lancets scissor their way into the 
victim, and barbs anchor the sting so that it remains in the skin when the bee pulls 
away leaving the entire distal segment of the bee's abdomen, along with a nerve 
ganglion, various muscles, a venom sac, and the end of the insect's digestive tract 
(Visscher et al., 1996). The sting continues to throb for 30-60 seconds injecting at 
least 90% of the venom within 20 seconds and all the venom by 60 seconds. On 
average each Africanised bee injects 94J.1g of venom compared to 147J.1g for the 
slightly larger European bee (Schumacher et al., 1990; 1994). Alarm odours are 
released by the sting that alert other bees and mark the victim for continued attack 
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(Schumacher et al., 1994). Honey bees are unusual among stinging insects in that the 
bee dies following stinging. 
1.1.3 Classification of American Arthropods of Clinical Importance 
Although the classification of various Arthropods has changed periodically over the 
years, the structured form of biological classification, developed by Linnaeus during 








ORDER - Araneae (the spiders) 
SUB-ORDER - Araneomorph 
F AMIL Y - Theridiidae 
- Latrodectus GENUS 
SPECIES - hesperus (Western black widow) 
Those Arthropods thought to be of clinical significance in North America are listed in 
Figure 1.2. 
1.1.4 Spider Venom 
The purpose of the venom is to kill or immobilise the prey and it is injected into the 
victim via two sharp hypodermic like fangs. Digestion of the prey is normally external 
with some spiders injecting the digestive enzymes directly while others crunch up the 
prey first to expose the soft internal tissue onto which they pour digestive fluid. The 
liquefied contents of the insect are then pumped up by the muscular stomach into the 
alimentary canal of the spider. 
1.1.4.1 
1.1.4.1.1 
Venom extraction methods 
Venom gland extract 
Spiders are first killed in a closed atmosphere of ether or chloroform or by freezing 




Class: Arachnida Insecta 
I I I 
Order: 
Araneae Scorpionida Hymenoptera 
(Spiders) (fme Scorpions) 
I I I I 
Sub-Order: 
Araneomorph Mygalomorph Apocrita 
("Modem" spiders) ("Primitive" spiders) 
I 
I I I I I I 
Family: Theridiidae Loxoscelidae Qubionidae Agelenidae Salicidae Apidae 
I I I I I I 
Genus: 
Latrodectus Loxosceles Chiracanthium Tegenaria Phidippus A~s 
(Widow spiders) (Fiddle back or (Sac spiders) (Hobo or aggressive Oumping spiders) (Bees) 
brown recluse spiders) house spiders) 
-
Figure 1.2. Classification of clinically important Arthropods of North America 
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careful dissection (Frontali & Grasso, 1964; Bettini & Brignoli, 1978). Venom glands 
from Latrodectus species measure between 1.5 - 2.1mm in length and 0.2 - O.4mm in 
width (Bucher!, 1971). These may then be ground up, with or without the fangs and 
chelicera, using washed sand in a small volume of saline. Alternatively, they may be 
homogenised with saline, borate or Tris-HCI buffer followed by centrifugation to 
remove the precipitate (Frontali & Grasso, 1964; Frontali et al., 1976; Bettini & 
Brignoli, 1978; Grasso & Mastrogiacomo, 1992; Krasnoperov et al., 1992). The 
buffer used for extraction should provide the best conditions for the solubility of the 
venom toxins without denaturing them. This method has the advantage of providing 
relatively large quantities of venom protein. However, it requires large numbers of 
spiders and the product is contaminated with cellular material from the gland tissues 
(Bettini & Brignoli, 1978). Gentler methods have been used to extract the venom from 
the glands but, while limiting contamination, are usually associated with a greatly 
reduced recovery (Berger, 1973). 
1.1.4.1.2 Electrical stimulation 
Spiders can be anaesthetised with CO2 to the point where they can be picked up 
without danger to the handler and without trauma to themselves (Meadows & Russell, 
1970; Bascur et al., 1980; Jack, 1996). Mild electrical stimulation (60 volts, 9 hertz, 
0.1 rnA) causes the slow (20-40 sec) extrusion of venom from the fangs into a 
micromanipulated pipette. Mean volumes of 0.291l1 (80llg protein) and of 0. 151l1 
(40llg protein) are obtained from female and male Loxosceles reclusa respectively 
(Morris & Russell, 1975). Loxosceles laeta yields on average 350llg and 150llg (wet 
weight) respectively (Bascur et al., 1980). The venom produced by this method is less 
contaminated than that from either dissection or more vigorous electrical stimulation 
(Morris & Russell, 1975). A similar approach is used by our suppliers (Spider Pharm 
Inc. in the United States) with the addition of a small suction tube placed in the mouth 
to remove any contaminating secreted digestive juices or vomit caused by the 
stimulation (Kristensen personal communication). This method has the additional 
advantage of allowing several extraction's from the same spider since it is unharmed. 
Many others have used crude electrical stimulation and collection from the fang pits, 
where the collected venom is likely to be contaminated with a large amount of 
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digestive fluids. This explains why large quantities (of 600 and 700Jlg dry weight) of 
material are collected from Latrodectus and Loxosceles species respectively, using 
this method (Buched, 1971). 
1.1.4.1.3 Other methods 
Venom collected when Latrodectus tredecimguttatus was induced to bite a cotton 
wool tampon was found, by Lebez (1953), to be contaminated with oral juices 
containing proteolytic and glycogenolytic enzymes and adrenaline oxidase, whereas 
such enzymes were not found in venom gland extracts. The first experiments carried 
out using Latrodectus venom involved getting the spider to bite the test animal 
directly. However, results were highly variable with some animals biting more 
vigorously than others (Marx, 1890; Baerg, 1922). 
The future promise of almost unlimited spider toxins has been advanced by the 
sequencing of DNA encoding the putative a-Iatrotoxin precursor and the synthesis of 
this and other black widow spider neurotoxins in insect cells (Kiyatkin et al., 1990; 
Kiyatkin et al., 1995; Ichtchenko et al., 1998; Volynski et al., 1999). Spider venom 
production may also be possible using a similar method to that demonstrated by 
culturing snake venom gland cells in vitro (Sells et al., 1989). 
1.1.5 Bee Venom 
1.1.5.1 Venom extraction methods 
Venom can be extracted from homogenates of the sting apparatus which have been 
removed from ethanol-fixed, deeply frozen, recently killed, or immobilised insects, or 
by collecting venom ejected through the sting as a result of mechanical, electrical or 
chemical stimulation. Electrical stimulation is normally used as thousands of bees can 
be induced to sting in a relatively short time. The equipment consists of a wooden 
frame with wires stretched across it at 3 mm intervals. Alternate wires carry an 
electric charge and the circuit is completed when the bee comes into contact with two 
adjacent wires carrying 115V (Ae) applied with 4 sec breaks at 3 sec intervals (Piek, 
1986). The bees sting through a nylon sheet stretched beneath the wires and the 
venom is easy to collect. 
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1.1.6 Epidemiology 
The poison control centres within the United States receive about 2,500 and 2,300 
annual reports of bites by black widow and brown recluse spiders respectively .. This 
compares to just 900 rattlesnake bites (Figure 1.3a). However, in 1999, only 383 and 
619 of the spider envenomings were classified as causing significant clinical features 
(viz moderate/major/death) (Figure 1.3b). These figures comprise data collected from 
- 80 - 95% of the poison control centres and probably represent a considerable 
underestimate of the real number (Litovitz et al., 1991; 1992; 1993; 1994; 1995; 1996; 
1997; 1998; 1999; 2000). 
1.1.7 Clinical Manifestations of Envenoming 
1.1.7.1 Latrodectus 
Poisoning caused by the bite of the Latrodectus spider can run a serious and dramatic 
course, although death is unusual. Thus the victims suffer great pain and, although the 
most severe effects may start to dissipate after about 24 to 36 hours, recovery is often 
protracted for three or four weeks (Southcott, 1976; Banham et al., 1994; White et al., 
1995). The mortality rate, before the introduction of antivenom therapy, was an 
estimated 5% (Ingram & Musgrave, 1933). 
The bite itself is superficial and may be like a slight needle prick or not even 
perceived. From the time of the bite to the first clinical manifestations is normally 
short (- 10 - 20 minutes), although it may extend to one or two hours (Maretic & 
Stanic, 1954). The clinical features may vary greatly which has led to some confusion 
in the literature (Banham et al., 1994). However, most of the clinical manifestations, 
as described around the world, appear identical. 
In America during the 1920's and 1930's the circumstantial evidence linking the 
severe clinical picture seen by physicians with the small, timid black widow spider 
caused considerable scepticism. Experimental results also demonstrated marked 
differences in the susceptibility of various animal species with rabbits, cats, dogs and 
sheep little affected while mice, guinea-pigs, chickens and horses demonstrated severe 
effects (Blair, 1934; Maretic & Stanic, 1954; Wiener, 1961). This scepticism was 
resolved conclusively by two independent experiments in which Latrodectus mactans 
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was stimulated to bite a human subject and the effects recorded in full (Baerg, 1922; 
Blair, 1934). In particular, intense pain and localised sweating at the site of the bite 
were noted as important early diagnostic features (Wiener & Fraser, 1956; Wiener, 
1961). The signs and symptoms of Latrodectus envenoming are considered further in 
Chapter 5. 
1.1.7.2 Loxosceles 
The initial bite by a Loxosceles spider is relatively painless so that patients often 
remain unaware until they experience the fIrst symptom, a local burning-stinging 
sensation (Atkins et 01., 1957; Atkins et 01., 1958; Schenone & Suarez, 1978; Rees et 
01., 1987). The venom may then bring about either of two clinical variants of 
Loxoscelism, namely the cutaneous or the systemic (viscerocutaneous) form. The 
systemic form is much less common in North America than the cutaneous form and is 
associated with the rare instances of death associated with Lo. reclusa envenomation 
(Nance, 1961; Madrigal et 01., 1972; Novak et 01., 1979; Litovitz et 01., 1999). More 
deaths appear to be related to the South American species Lo. laeta, with 
approximately 13% of the cases of Loxoscelism in Chile resulting in the systemic 
form (Schenone & Suarez, 1978; Schenone et 01., 1989), possibly due to the large 
amounts of venom available (see earlier). 
1.1.7.2.1 Cutaneous form of Loxoscelism 
The cutaneous form may result in local skin necrosis or local oedema without 
necrosis, with the patient seeking medical help from 12 - 36 hours after the bite 
(White et 01., 1995). Both lesions are associated with pain after 2 - 8 hours, which 
varies from mild to severe (Atkins et 01., 1957; Atkins et 01., 1958; Schenone & 
Suarez, 1978; Rees et 01., 1987; Masters, 1998). There may be two small puncta and 
transient erythema, with itching, swelling and mild to severe tenderness. This is 
followed by the development of a bleb or blister after ~ 12 - 24 hours, surrounded by a 
erythematous halo (Atkins et 01., 1957; Schenone & Suarez, 1978). The bleb or blister 
is dark in colour, varies in size from 3 - 35cm, and is gradually replaced by a 
characteristic blackish eschar (scab), which was earlier called the 'gangrenous spot of 
Chile' (Macchiavello, 1947). The eschar sloughs within 2 - 5 weeks, either 
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superficially (67%) or leaving a necrotic ulcer (33%). The latter is frequently slow to 
heal and may extend to, but not involve, the underlying muscle layers (Schenone & 
Suarez, 1978). Secondary lesions with their subsequent eschar and necrotic ulcer may 
appear below the primary lesion, perhaps due to gravitational spread (Schenone & 
Suarez, 1978). The worst lesions and scarring are often found over fatty areas, such as 
the thighs, abdomen or buttocks (Wasserman & Siegel, 1977). There may also be 
persistent damage to underlying structures such as nerves (Gross et al., 1990). 
1.1.7.2.2 Systemic form of Loxoscelism 
In addition to the local manifestations, which are identical to those observed in the 
cutaneous form, patients with systemic Loxoscelism have haemolytic anaemia, 
haemoglobinuria, haematuria, jaundice, fever and sensorial involvement, all of which 
generally appear within the first 24 hours. The temperature may reach 42°C and the 
patient may become prostrate, with laboured breathing, and pass dark coloured urine. 
The occurrence of this syndrome has no relationship to age, sex, season, site of bite, 
or size of the local lesion (Schenone & Prats, 1961; Schenone & Suarez, 1978). 
Systemic cases have been documented, although not frequently, in the United States 
and can cause a fatal "total haemolysis" just 2 days after a bite (Dillaha et al., 1964; 
Minton & Olson, 1964; Taylor & Denny, 1966; Litovitz et al., 1999). 
1.1.7.3 Other spiders 
The bites of Tegenaria agrestis (hobo or aggressive house spider), Phidippus 
Gumping spiders) and Cheiracanthium spp. (yellow sac spiders) have occasionally 
been implicated with causing clinical features in North America (Minton, 1972; Vest, 
1987; Vest et al., 1996; Russell, 1996). 
Envenoming by Phidippus species is reported to cause a sharp pinprick and, 
sometimes, the development of a painful, tender area immediately around the bite. 
The symptoms and signs usually abate within 48 hours. 
Envenoming by Cheiracanthium species is associated with a sharp pain, which 
increases during the first 30 to 45 minutes (Russell, 1996) and, since they are 
tenacious biters, they must sometimes be physically removed which explains why 
large numbers ~f spider bites by this species are positively identified. Restlessness and 
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a dull pain over the injured part, often accentuated by movement, are described 
(Russell, 1996) and a reddened weal with a hyperaemic border may develop together 
with small petechiae or purple to red spots under the epidermis caused by 
extravasation of blood near the centre of the weal. The injured area is tender to 
pressure and the skin temperature over the lesion often elevated, although the body 
temperature is usually normal. Inflammation of the lymph glands may develop. Vital 
signs are normal, as are blood findings. Abdominal cramps develop in some patients 
bitten on the lower extremity, and there may be diarrhoea but usually no vomiting. 
Pruritus (itching) is common. 
1.1.7.4 Apis mellifera 
The typical response to a single sting by a honey bee is intense, immediate pain with a 
burning sensation. This usually lasts for a few minutes after which the pain subsides. 
A white weal with a central red spot often forms soon after the sting, then rapidly 
fades to be replaced by a red flare and some local swelling which, by this time, is 
usually warm or hot to the touch. These symptoms subside and generally after a day 
or two all that remains is an itchy spot at the sting site (Schmidt, 1986). 
Over 50 of these stings simultaneously can cause systemic effects due to the relatively 
large dose of venom delivered and about 500 are probably necessary to cause death by 
this direct toxicity, although one death in Arizona was due to only ~ 125 stings 
(Koszalka, 1949; Michener, 1975; Bousquet et al., 1982; 1984; Mejia et al., 1986; 
Franca et al., 1994; Kolecki, 1999). Circulating venom levels of up to 3.8mg/1 have 
been recorded and clinical features can include rhabdomyolysis, nausea and vomiting, 
intravascular haemolysis, disseminated intravascular coagulation, respiratory distress, 
hepatic dysfunction, hypertension, myocardial damage, shock, renal tubular necrosis 
and / or renal failure (Humblet et al., 1982; Mejia et al., 1986; Franca et al., 1994; 
Kolecki, 1999). Typical features normally include evidence of a generalised 
rhabdomyolysis often resulting in myoglobinaemia and myoglobinuria with elevated 
serum levels of muscle enzymes (Franca et al., 1994). Patients often develop renal 
failure and acute renal tubular necrosis with pigment and erythrocytes in the tubules 
and collecting ducts (Humblet et al., 1982; Franca et al., 1994). Intravascular 
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haemolysis is a major feature of most reported cases of multiple bee stings and some 
patients become comatose and die 1-3 days later (Franca et a/., 1994). 
1.2 Latrodectus 
1.2.1 Classification 
The classification of different species of Latrodectus has changed considerably over 
the years depending mainly on the features studied (Kaston, 1970; Bucherl, 1971; 
Bettini & Brignoli, 1978). They are currently classified into the following species in 
the United States; Latrodectus hesperus, La. mactans, La. variolus, La. geometricus 
and La. bishopi (Kaston, 1970). Other species found around the world include; La. 
tredecimguttatus, La. hasselti, La. pal/idus, La. indistinctus, La. menavodi, La. katipo, 
La. curacaviensis, La. corrallinus, La. quartus, La. mirabilis, La. variegatus, La. 
carteri, La. cretace us, La. sagittifer, La. diaguita, La. revivensis, La. hysterix, La. 
cinctus, La. concinnus, La. menavoidi, La. obscurior, La. luzonicus, and La. atritus. 
1.2.2 Distribution 
Spiders of the genus Latrodectus are widely distributed across the World (Figure 1.4) 
and range as far south as New Zealand through to Mongolia in the northern 
hemisphere. 
As noted above, at least five species of Latrodectus occur within the United States 
(US). All are quite large, subglobose theridiid spiders in which the lateral eyes are 
widely separated, a condition virtually exclusive to this genus. Very large females 
sometimes grow to over half an inch in length. Only La. hesperus, La. mactans and 
La. variolus merit the name 'black widows' in as much as the adults of all three are 
mostly jet black and marked with crimson spots. However, when the spiderlings leave 
the egg sac they are whitish and progress through a series of stages in which black 
gradually replaces most of the white, yellow, and red spots and bands. In adult 
females the dorsal markings on the abdomen are frequently lost, leaving it almost all 
black. However, the red hourglass marking is rarely lost on the venter. The males 
retain much of the bright colour pattern of the immature stages and are much smaller 
(Kaston, 1970; Gertsch, 1979). 
The three 'black widows' are very similar and often difficult to separate. The southern 
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black widow, Latrodectus mactans, ranges north to New England and frequently lives 
where its irregular web can be placed under ground detritus near buildings. The 
cephalothorax and legs are usually all black while the abdomen is shiny black with a 
red spot just above the spinnerets and, sometimes, red spots or a band extending 
forward. The red hourglass marking on the venter is usually present and entire. The 
males are black with red and white spotting on the abdomen. 
The northern black widow, Latrodectus vario/us, ranges widely from the eastern US 
south into western Florida and eastern Texas. In Florida it occupies moist areas and 
places its webs in the branches of trees. However its habitats in other parts are more 
varied. Females are much like mactans but typically have a central row of red spots on 
the abdomen while the ventral hourglass is divided into two transverse bands. Males 
are somewhat larger in this sub-species and often have legs marked with paler rings. 
The western black widow, Latrodectus hesperus (Figure 1.5), ranges widely over 
Oklahoma, Kansas, and middle Texas throughout the south-western states. It often 
builds its web near the ground, in animal burrows, under bridges and, frequently, on 
shrubs above the ground or even in trees. Females have a black cephalothorax and 
legs with the upper abdomen typically all black. Occasionally, some paler spots of the 
immature pattern are present. The ventral hourglass is often complete, but somewhat 
variable and occasionally divided. The males are typically much paler than those of 
the other species, with bands and spots on the cephalothorax and abdomen subdued to 
give a general grey appearance. 
The brown widow, Latrodectus geometricus, is widely distributed around the world in 
the tropics and is the dominant species over most of Brazil and the eastern coastal 
portions of South America. Although it now ranges widely as the result of commerce, 
its occurrence in North America is sporadic and limited to southern Florida where it 
lives mainly in or near buildings. The red widow, Latrodectus bishopi, is found only 
in sand-pine scrub in central and south-eastern Florida. The carapace and legs are 
bright orange or reddish and the abdomen is usually brilliantly spotted with red or 
yellow marks on the dorsum which are retained by the adult female. 
1.2.3 Venom Composition 
The major toxic fractions of the venom are variations of a protein, latrotoxin. The 
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Figure 1.5 Adult female black widow spider (Latrodectus hesperus). 
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majority of these components are not toxic to mammals but are potent insect toxins 
(e.g. a, ~ and E-Iatroinsectotoxins. Krasnoperov et ai., 1992). Indeed the only toxin 
said to be active in mammals is a-Iatrotoxin. The proportions of these toxins may 
partially explain the large differences in susceptibility of different animal species to 
the lethal effects of the whole venom (Table 1.1). Other components of the venom 
include the 'spreading factor' hyaluronidase, bradykinin-potentiating peptides and 5-




a-Iatrotoxin is toxic to vertebrates and thought to be responsible for the signs and 
symptoms of human envenoming (Frontalli et ai., 1976). This large toxin (131 kDa) 
constitutes -3% of the venom protein and has been purified by a combination of gel 
filtration and ion-exchange chromatography or by immuno-affinity chromatography 
(Frontalli et ai., 1976; Grasso, 1976; Dalimov et ai., 1988; Krasnoperov et ai., 1992; 
Grishin, 1998; Volynski et ai., 1999). It has been shown that preparations previously 
considered homogeneous also contain a low molecular weight (8 kDa) component 
called latrodectin which expresses no toxicity in either mammals or insects (Grishin et 
ai., 1993; Pescatori & Grasso, 1994; Grishin, 1998). The recent production of a 
functional a-Iatrotoxin molecule from cultured insect cells infected with a 
recombinant baculovirus encoding for the toxin which is free of latrodectin further 
implies that the low molecular weight contaminant has no significant functional role 
(lchtchenko et ai., 1998; Volynski et ai., 1999). 
Nanomolar (nM) concentrations of a-Iatrotoxin can produce a massive release of 
neurotransmitters from synapses of both the central and peripheral nervous systems 
(Frontali et ai., 1976; Tzeng & Siekevitz, 1978; Hurlbut & Ceccarelli, 1979; Grasso et 
ai., 1982; Nicholls et ai., 1982; Scheer et ai., 1984). It has no selectivity for specific 
types of synapses but seems to affect them all (Hurlbut & Ceccarelli, 1979; Scheer et 
ai., 1984). This stimulation by the toxin evokes exocytosis of neurotransmitter-
containing small synaptic vesicles exclusively in frogs (Matteoli et al., 1988), whereas 
in mammals the neuropeptide-containing large dense core vesicles 
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Guinea pig 0.075 
Table 1.1 Toxicity of Latrodectus tredecimguttatus venom on different species 
(Bettini & Brignoli, 1978). 
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are affected equally (Einhorn & Hamilton, 1974; Janicki & Habennann, 1983; 
Watennan & Maggi, 1995). More importantly from the clinical perspective, sensory 
nerve endings which contain large dense core vesicles have also been found to be 
sensitive to the venom or to a-Iatrotoxin both in vivo (Queiroz & Duchen, 1982) and 
in vitro (Watennan & Maggi, 1995). The direct (1M) injection of sub-lethal amounts 
of venom (from Latrodectus tredecimguttatus and from La. hasselti) was shown to 
result in several morphological changes in murine sensory nerve tenninals. Within 30 
minutes some sensory nerve endings became swollen with a progressive degeneration 
of annulospiral endings over time and, after 24 hours, every spindle was devoid of 
sensory nerve tenninals. Degenerated nerve endings were then taken up into the 
sarcoplasm of intrafusal muscle fibres and the regeneration of sensory nerve axons 
was almost complete after one week. Similar features have also been described for 
motor tenninals (Queiroz & Duchen, 1982). 
1.2.4.2 a-Iatrotoxin receptors 
a-latrotoxin has two structurally and pharmacologically distinct classes of high 
affinity (lO-9-10-1<M) receptors. The calcium-dependent receptor (neurexin la) is a 
large (160-220 kOa) cell surface membrane protein existing as multiple isofonns that 
will bind a-Iatrotoxin only in the presence of Ca2+ (Petrenko et al., 1990; 1993; 
Grishin, 1998). It has one transmembrane segment and structurally resembles cell 
adhesion proteins (Ushkaryov et al., 1992). A second high affinity receptor is the 
calcium-independent receptor (CIRL or latrophilin) (Krasnoperov et al., 1996; 
Davletov et al., 1996). CIRL is thought to be the more important because the toxin-
receptor interaction can stimulate neurotransmitter release from neurones in a Ca2+_ 
free media (Misler & Falke, 1987; Capogna et al., 1996). CIRL belongs to a family of 
closely related orphan G protein, protein-coupled receptors homologous to the 
secretin receptor family (Krasnoperov et al., 1997; Lelianova et al., 1997). In this 
family of three closely related homologous proteins, CIRL-l is a brain-enriched high 
affinity a-Iatrotoxin-receptor, whereas CIRL-2 is a ubiquitously expressed low 
affinity receptor of the toxin (Ichtchenko et al., 1999). 
a-Iatrotoxin acts extracellularly by binding to these endogenous membrane receptor 
families. The fonnation of receptor-toxin complexes is followed by cation influx 
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through a-Iatrotoxin-induced channels and by, as yet, only partially identified 
signalling mechanisms that eventually result in massive spontaneous exocytosis 
(Figures 1.6 and 1.7). 
There is ample evidence that a-Iatrotoxin receptors are crucial for the effects of a-
latrotoxin and two different hypotheses have been proposed (Rosenthal & Meldolesi, 
1989; Geppert et al., 1998). According to the first, a-Iatrotoxin needs the receptor just 
to target the membrane at the right location. The toxin then makes pores in the 
plasmalemma, as it does in artificial lipid bilayers (Finkelstein et al., 1976), and 
causes influx of Ca2+ into the cytoplasm, a process known to lead to exocytosis 
(Grasso et al., 1980; Nicholls et al., 1982). The second hypothesis argues that the 
toxin causes substantial neurotransmitter release even in the absence of Ca2+, provided 
other divalent cations are present (Rosenthal et al., 1990). For example, Mg2+ (which 
is unable to elicit a response when applied directly) can apparently replace Ca2+ in 
supporting the toxin's action (Misler & Hurlburt, 1979). This indicates that ion fluxes 
through the latrotoxin-induced channels may not be the main stimulus in the toxin-
evoked release. 
It has been shown recently that a-Iatrotoxin can stimulate insulin secretion from 
pancreatic ~-cel1s in the absence of any ion fluxes (Lang et al., 1998). Moreover, even 
When Ca2+ is present in the medium, it does not need to enter the a-Iatrotoxin-
sensitive cells to stimulate secretion (Capogna et al., 1996; Michelena et al., 1997; 
Davletov et al., 1998). These fmdings suggest that the toxin possesses a signalling 
function instead of, or in addition to, its channel-forming capability (Rahman et al., 
1999). Therefore, the receptor, apart from providing specifically localised binding 
sites, is likely to actively participate in the transduction into the cell of the signal 
elicited by a-Iatrotoxin (Rahman et al., 1999). 
Evidence for this interaction has been demonstrated and indicates that CIRL is a G-
protein coupled receptor (Rahman et al., 1999). The CIRL-G protein complex is very 
stable in the presence ofGDP (guanosine diphosphate) but dissociates when incubated 
with GTP (guanosine triphosphate), suggesting a functional interaction. Also, using a 
a-Iatrotoxin-evoked norepinephrine (noradrenaline) secretion model from rat brain 
synaptosomes, it was found that the amino steroid U73122, which inhibits the 
Coupling of G 'proteins to PLC, blocks the Ca2+ - dependent action of the toxin. 
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Cleavage of phosphatidylinositol-4,5-bisphosphate (PIP2) by PLC produces IP3, a 
second messenger that regulates Ca2+ release from intracellular stores. PLC activity 
towards PIP2 is maximal at micromolar Ca
2
+ concentrations (Kozawa et al., 1987). 
Therefore, this enzyme may constitute the high affinity Ca2+ sensor for exocytosis 
(Rahman et al., 1999). Thapsigargin, which depletes intracellular Ca2+ stores, also 
decreases potently the effect of a.-Iatrotoxin in the presence of extracellular Ca2+ 
(Rahman et al., 1999). 
Conversely in the absence of Ca2+, the toxin-CIRL interaction induces pores in the 
presynaptic membrane which are non-selective and permeable to small fluorescent 
dyes, neurotransmitters and cations (Hurlbut et al., 1994; Davletov et al., 1998; 
Rahman et al., 1999). 
Although a second functional neurexin receptor has recently been identified (~­
neurexin) there is no evidence to-date of the transduction into the cell of a signal 
elicited by a. latrotoxin binding to this class of receptors (neurexin la., ~-neurexin) 
(Sugita et al., 1999). 
Certain cell types (rat adrenal-medulla-tumour cell line, PCI2) contain endogenous a. 
latrotoxin receptors which are insufficient for a complete response using low 
concentrations of a. latrotoxin. Induction of more receptors (via transfection), either as 
neurexins or CIRL-l, dramatically increases their a. latrotoxin response, implying that 
the receptor density drives the a.latrotoxin response (Sugita et al., 1999). Similarly, in 
neurexin la. knockout mice (that do not express neurexin 1 a.), the a. latrotoxin 
response is decreased in the presence of Ca2+, even though the other neurexins and 
CIRL-l are still present (Geppert et al., 1998). This finding also suggests that the 
receptor density is limiting, which may help explain some of the specific 
characteristic symptoms of Latrodectus envenoming (such as pain) due perhaps to 
differences in receptor densities of different types of neurones. Possible variations 
such as these may also help explain why certain mammalian species are more 
susceptible to the lethal effects of the venom (Table 1.1). 
1.2.5 Treatment of Envenoming 
Treatment of latrodectism is principally directed at relieving the severe pain and 
reversing the neUrotoxic action of the venom. 
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A variety of therapies have been advocated, but no large scale controlled studies have 
been performed to determine the optimal treatment (Miller, 1992). As a result, therapy 
in the United States has evolved largely from anecdotal experience with relatively few 
patients. Recommended therapies have included hot baths, the administration of 
calcium gluconate, muscle relaxants, benzodiazipines, narcotic analgesics and 
antivenom (Blair, 1934; Barron, 1960; Maretic, 1983; Timms & Gibbons, 1986; Clark 
et al., 1992; Miller, 1992; Zukowski, 1993). 
Low blood calcium levels are known to be associated with some similar symptoms 
including muscle aches, seizures and spasms as well as tetany (general stiffening and 
spasms of the muscles) and are treated with calcium injections or supplements. 
Intravenous calcium gluconate has, therefore, long been recommended for pain relief 
after envenoming (Maretic, 1983; Timms & Gibbons, 1986). Investigators have had 
inconsistent results in this respect (Russell, 1962; Key, 1981; Clark et al., 1992). For 
instance Key (1981) found calcium gluconate to be effective in only six of 13 patients 
and, since the symptoms found in severe Latrodectus envenoming are known to "wax 
and wane", many patients will demonstrate this clinical pattern and will appear to 
improve regardless of treatment if they are observed for only a limited period after 
envenoming (Maretic, 1983; Clark et al., 1992). 
Muscle relaxants such as methocarbamol (Robaxin) and diazepam (Valium) have 
been used in patients with significant muscle spasm (Russell, 1962; Timms & 
Gibbons, 1986) but one investigator found it to be effective in only one of 10 patients 
(Key, 1981). Several narcotic analgesics have also been used for pain relief with a 
combination of parenteral opioids and benzodiazepines producing the greatest 
improvement (Clark et al., 1992). However, hospital admission for observation and 
pain control with large repeated doses may be required (Clark et al., 1992; Miller, 
1992). 
Antivenom use in the United States is limited usually to patients with signs of severe 
envenoming or with a high risk of developing complications e.g. age under 16 or over 
60 years, respiratory difficulty, marked hypertension, pregnancy, or distress that does 
not respond to other measures (Miller, 1992; Russell, 1996). This limited use reflects 
the high incidence of life-threatening reactions that may be associated with the 
systemic administration of the available product (Clark et al., 1992; Miller, 1992; 
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Zukowski, 1993). Nevertheless, the response to this antivenom is often dramatic, with 
full and lasting relief of symptoms without the need for hospital admission, unless 
reactions to the antivenom occur (Timms & Gibbons, 1986; Clark et al., 1992; Miller, 
1992; Sutherland, 1992; Zukowski, 1993). The use of antivenom has also been 
reported, both in the U.S. and Australia, to be highly effective, even when delayed 
several days (90 and ~120 days respectively) after the bite (Sutherland, 1992; Banham 
et al., 1994; O'Malley et al., 1999). 
1.3 Bees 
1.3.1 Classification and Distribution 
The order Hymenoptera includes bees, wasps, hornets and ants. However, only mass 
attacks by honey bees are capable of injecting toxic quantities of venom and are, 
therefore, of clinical significance in the United States. Honey bees (Apis mellifera) 
originate from Africa and Europe where they have evolved different characteristics to 
survive in their respective tropical and temperate habitats (Winston, 1994). Most of 
the bees in the Americas were imported from Europe and, until the mid-1950s, those 
in South America were also of European origin. While European bees are good honey 
producers in temperate climates, they are less so in the tropics. African honey bees, in 
contrast, had a good reputation for tropical honey production, and were also known to 
exhibit intense defensive behaviour (Winston, 1994). 
In 1956, Brazilian scientists imported some African queens, from South Africa and 
Tanzania, to Sao Paulo, Brazil. The objective was to cross the African and European 
bees to produce a gentle and productive tropical honey bee. However, before these 
hybridisations could be accomplished, 26 swarms escaped and formed the nucleus of 
a feral population (Winston, 1994). The bees spread at a rate of 300-500 km per year, 
and now occupy most of South and Central America and the southern states of the US. 
These Africanised bees are much more aggressive than their European counterparts 
and are capable of sudden large scale attacks induced by only minimal disturbances 
(Collins et al., 1982). Within the southern United States an increasing number of mass 
bee attacks have been reported with the occasional fatality since the arrival of the 
Africanised bee (Kolecki, 1999). In Mexico there have been more than 190 such 
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deaths between 1988 and 1993, with future estimates of60 deaths per year (Guzman-
Novoa & Page, 1994). 
1.3.2 Venom Composition 
Bee venom contains many biologically active components such as melittin, 
phospholipase A2, apamin, mast cell degranulating peptide, hyaluronidase, histamine, 
and dopamine (Habermann, 1972). 
1.3.2.1 Melittin 
Melittin is the major component, comprising 40 - 50 % of the dry weight 
(Habermann, 1972). It is a highly basic 26 amino acid peptide (2,847 Da) with 
strongly hydrophobic and hydrophilic regions and no disulphide bridges. 
1.3.2.2 Phospholipase A2 
Bee venom contains 10-12% phospholipase A2 (PLA2) which forms the major allergen 
of the venom and has a molecular weight of 15,800Da with four disulphide bridges 
(Shipolini et al., 1971; 1974a; 1974b; Schmidt, 1986). 
1.3.2.3 Hyaluronidase 
Hyaluronidase forms a minor constituent (2-3%) of the venom and is a glycoprotein 
with molecular weight of 41,000Da (Kemeny et al., 1984). 
1.3.2.4 Apamin 
Apamin, a minor (-2%) basic peptide component of the venom contains 18 amino 
acids (2,027Da) with 2 disulphide bridges. It is a centrally acting neurotoxin that 
causes uncoordinated movements of the skeletal musculature increasing to spasms, 
jerks and convulsions when injected in mice (Habermann, 1984). 
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1.3.2.5 Mast cell degranulating peptide 
Mast cell degranulating peptide (Peptide 401) is also a minor component (1-2%) of 
the venom consisting of 22 amino acids (2,593Da) with 2 disulphide bridges. This 
highly basic peptide has an isoelectric point above pH 10.5 and causes the 
degranulation of mast cells without their lysis (Banks & Shipolini, 1986). 
1.3.3 Pathophysiology 
The principal effects of bee venom are thought to result from its main components 
melittin and PLA2• Melittin is known to damage cell membrane systems, causing the 
direct lysis of erythrocytes and effects on leukocytes, thrombocytes and other 
pharmacological systems (Habermann, 1972; Hider et al., 1983; Fletcher & Jiang, 
1993). It also causes the depolarisation and contraction of skeletal and heart muscle 
cells and in vivo myonecrosis (Habermann, 1972; Ownby et al., 1997). 
Bee venom PLA2 hydrolyses the 2-acyl bonds of phosphatidylcholines, 
phosphatidylethanolamines, phosphatidylinositols and phosphatidylserines, disrupting 
membrane integrity and releasing lysophospholipids and fatty acids which themselves 
may further damage the membrane. Unlike melittin, the purified enzyme has no direct 
effect on washed erythrocytes but, when combined with melittin, there is a synergistic 
effect, and erythrocytes are lysed under conditions in which neither alone would cause 
lysis (Vogt et al., 1970; Habermann, 1971). 
It seems likely that most of the toxic effects seen after a mass bee attack are due to the 
general membrane damaging effects of the melittin and PLA2 which cause the 
myotoxic features (Azevedo-Marques et aI., 1992; Ownby et al., 1997). 
1.4 Antibodies 
Protein antigens encountering the immune system are processed by antigen-presenting 
cells (e.g. macrophages, dendritic cells, Langerhans' cells) which then express 
fragments of the antigen on their surface together with MHC (Major 
Histocompatibility Complex) II molecules. Specific T -helper cells recognise the 
antigen fragment presented with the MHC II molecule via their specific surface 
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receptors and facilitate, via the release of cytokines, B-cells which have also 
recognised the antigen (either free or via antigen presenting cells) with their own 
specific surface receptors (a specific idiotype of immunoglobulin). The specific B-cell 
clones are then stimulated to proliferate and divide into antibody-fonning cells 
(plasma cells) which secrete large quantities of the specific antibodies. A few B-cell 
clones differentiate into memory cells which are utilised in any secondary exposure to 
the antigen and are responsible for the rapid production of large quantities of antibody 
seen in the secondary response. 
1.4.1 Summary of Antibody Structure 
Antibody molecules all have a basic four polypeptide chain structure, consisting of 
two identical light and two identical heavy chains, stabilised and cross-linked by intra-
chain disulphide bonds. There are five major types of immunoglobulin heavy chains 
(1, J.1, a, 0, E) and the type detennines the class of the antibody (e.g. IgG, IgM, IgA, 
IgD and 19B, respectively). IgG and IgA are further divided into subclasses. For 
example, in man there are four IgG subclasses compared to two in sheep. Light chains 
are of two main types (tc or A) and either type may associate with any of the heavy 
chains. 
Antibody domains (globular regions) consist of 3 or 4 polypeptide loops stabilised by 
a ~-pleated sheet and an intra-chain disulphide bond. Light chains have two domains 
and heavy chains four or five. The hinge region resides between the Fc and Fab and 
contains the inter-heavy chain disulphide bonds and confers segmental flexibility on 
the antibody molecule. The highest degree of amino acid variability between different 
antibody molecules of the same class is found concentrated within the N-tenninal 
domains of the light and heavy chain; hence called the variable (V) region. The V 
regions of one light and one heavy chain fonn an antigen binding site. The remaining 
domains are relatively invariant, within any particular class of antibody, and so are 
called the constant (C) region. 
IgG is the major serum immunoglobulin and constitutes the main antibody type in the 
secondary immune response to most antigens. In humans it accounts for 70-75% of 
the total immunoglobulin pool and has a molecular weight of -146,000 and a 
sedimentation coeficient of 7S. The IgG class is distributed between the intra- and 
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extravascular pools and is the exclusive anti-toxin class. Sheep IgG is unusual in that 
it fails to bind staphylococcal protein A. 
1.4.2 Summary of Antibody Function 
Antibodies are bifunctional molecules. One function is to bind to specific epitopes on 
the surface of micro-organisms or of macromolecules and the second is to interact 
with effector systems to facilitate the destruction of the microbe or its removal. Some 
antibody functions can be mediated just by binding to the antigen (e.g. toxin 
neutralisation or preventing viral penetration of cells). However, most antibody 
functions require binding to its Fc region by various cells and / or the first component 
of the classical complement system. Thus the binding interaction between the Fab of 
the antibody and the antigen causes a conformational change in the Fc region which 
allows the Fc to interact with cells of the immune system, phagocytes and Clq of the 
classical complement pathway. The different antibody classes and subclasses interact 
with different cells, and so have slightly different functions (see Table 1.2). 
The complement system is a complex group of serum proteins which mediate 
inflammatory reactions. Having bound to antigen, IgM, IgGl and IgG3 can activate 
the complement cascade while IgG2 appears to be less effective and IgG4, IgA, IgD 
and IgE are ineffective in this respect. 
The immunoglobulins display a complex pattern of interactions with various cell 
types which display Fc receptors (FcR). Different immunoglobulins (IgG, IgM, IgE, 
and IgA) bind to different Fc receptors: FcyR, FCf.lR, FCER, FcaR, respectively, with 
FcyR being further subdivided into FcyRI, FcyRII, and FcyR1o• The FcyRI is expressed 
on monocytes and macrophages but not on lymphocytes; the FcyRII is expressed on 
monocytes, granulocytes, platelets, and B lymphocytes but not on T lymphocytes; the 
FcyR10 is expressed on a variety of non-lymphoid cells and a subset of T lymphocytes 
(the so-called Ty cells) but not on B lymphocytes. 
1.S Immunotherapy 
1.5.1 History 
The protective effect of immunising an animal with small amounts of venom was first 
described by Sewall, in 1887, who repeatedly injected pygmy rattlesnake venom into 
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IgG 19A IgM IgD IgE 
Complement fixation: 
Classical ++ - +++ - -
Alternative - ± - - -
Cross placenta ++ - - - -
Fix to homologous mast 
cells and basophils - - - - ++ 
Binding macrophages and 
polymorphs ++ ± - - ± 
Table 1.2 Biological properties of major immunoglobulin classes in the human. 
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a pigeon and showed its subsequent ability to survive the injection of six lethal doses 
of the venom - an example of active immunisation. Roux and Yersin (1888) 
demonstrated the passive transfer of immunity by protecting non-immune animals 
against diphtheria following the transfer of blood from an animal immunised with 
diphthera toxin. These findings were confirmed by Von Behring and Kitasato (1890) 
against diphtheria and tetanus toxins as well as by Phisalix and Bertrand (1894) and 
Calmette (1894) against the European viper (Vipera aspis) and Vietnamese cobra 
venoms respectively. The first commercial antivenom was developed by Calmette to 
treat envenoming by the Indian cobra. 
The first antivenoms consisted of crude hyperimmune horse serum and some such 
products still exist today. However, most current antivenoms consist of purified 
antibodies or antibody fragments. Thus the dangers associated with the systemic 
administration of unrefined equine serum were quickly recognised. Most patients 
developed serum sickness after about 8 days while a few, who had been exposed 
previously to horse proteins, experienced acute and sometimes fatal early anaphylaxis. 
The incidence of deleterious effects was reduced by the use of an ammonium SUlphate 
precipitated immunoglobulin fraction of the serum as summarised by Landon et al., 
(1995). Another major advance followed the work of Pope (1938; 1939a; 1939b), in 
which pepsin digestion was introduced to prepare F(ab')2 before the final salt 
precipitation step. This improved both the purity and the activity of the final product. 
These processes remained unchanged until the recent incorporation of ion-exchange 
(Grandgeorge et al., 1996) and affinity chromatography (Karlson-Stiber et al., 1997) 
steps. 
1.5.2 Side Effects 
Adverse reactions occur commonly in patients who are receiving foreign proteins and 
even homologous proteins when given intravenously. Such reactions are usually mild 
and easily controlled by decreasing the rate of administration of the solution 
(Kirkpatrick, 1991). They may be due to contaminants in the solution (such as 
pyrogens) or to immunological mechanisms and it is usual to divide them into either 
early (anaphylactic or anaphylactoid) or late (serum sickness) responses. 
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1.5 .2.1 Early 
Anaphylaxis is an immunological term to describe a type I hypersensitivity reaction 
mediated by specific IgE. Briefly an antivenom component interacts with pre-formed 
specific IgE fixed to mast cells and basophils, triggering the release of histamine and 
other mediators. These reactions develop rapidly and may be associated with anything 
from just a mild urticarial reaction to severe and life-threatening anaphylactic shock. 
The exact cause of immediate anaphylactoid (anaphylaxis-like) reactions remains 
elusive. However, numerous studies have been performed to elucidate the cause of 
human intravenous IgG reactions. From this it appears likely that reactions to human 
IgG may be due to the release of inflammatory mediators caused by the activation of 
phagocytic cells predominantly in the liver, through the interaction of IgG dimers or 
aggregates with Fc receptors (Bleeker et al., 1987; 1989; 2000; Lobatto et aI., 1987; 
Jenei et al., 1991; Sylvestre et al., 1996). Aggregates may also activate the 
complement system which may contribute to the reaction (Waldesbuhl et al., 1970). 
Commercial antivenoms have also been shown to have a complement activating effect 
in vitro that varies substantially between manufacturers, and probably reflects 
different degrees of purity ranging from whole antiserum to pure F(ab')2 (Sutherland, 
1977). 
Pyrogen (or endotoxin) contamination may also result in side effects although, with 
modem production facilities and testing, this is becoming a thing of the past. 
1.5.2.2 Late 
Serum sickness is a type III hypersensitivity reaction where specific antibodies (lgG) 
are produced by the recipient after about a week and combine with the foreign protein 
to form small immune complexes in the circulation. Normally, immune complexes are 
removed from the circulation via the reticulo-endothelial (mononuclear phagocyte) 
system, particularly in the liver (by Kupffer cells), spleen, and lungs. However, if they 
are formed in large quantities, they are also deposited in various other tissues. The 
deposited immune complexes then bind and activate complement and the C3a and 
C5a fragments so generated bind to basophils in the blood and cause their 
degranulation. Immune complexes may also interact directly with basophils and 
platelets (via their immunoglobulin Fc regions) and cause their degranulation. Some 
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of the released mediators, in particular histamine and 5-hydroxytryptamine, cause 
retraction of endothelial cells and so increase the permeability of the blood vessels 
leading to the deposition of still more immune complexes. The activated platelets 
aggregate and initiate the formation of small clots on the collagen of the exposed 
basement membrane beneath the endothelial cells. Other mediators attract neutrophils 
which then attempt to phagocytose the deposited complexes. However, since the 
tissue-bound complexes cannot be easily engulfed, the macrophages release their 
lysosomal contents causing local damage (Klein, 1990). This is associated with an 
abrupt fall in total complement levels and the clinical signs of serum sickness (e.g. 
fever, glomerulonephritis, pain in the joints, erythema, oedema and urticaria). 
1.5.2.3 Merck Antivenom 
The only spider antivenom available in the United States is specific for the black 
widow spider (Antivenin Latrodectus mactans, Merck & Co., Inc.) and consists of 
unrefined horse serum. As a result, its administration carries a high risk of causing 
hypersensitivity reactions such as anaphylaxis and / or serum sickness (Kobernick, 
1984; Timms & Gibbons, 1986; Clark et al., 1992; Zukowski, 1993). These reactions 
can be severe and even fatal and pose a severe therapeutic dilemma (Clark et al., 
1992). Thus although the antivenom is highly effective, the mortality rate from black 
widow spider bites is low «5%) with the majority of deaths in children and the 
elderly (Miller, 1992; Zukowski, 1993). As a result this antivenom is recommended 
only for patients with severe envenoming that fall into one of the following 
categories; age under 16 or over 60 years; patients experiencing respiratory difficulty 
or marked hypertension; pregnant woman and those with severe distress that does not 
respond to other measures (Miller, 1992; Russell, 1996). 
By comparison, highly purified ovine antibody fragments directed specifically against 
digoxin have an excellent safety record and an incidence of adverse reactions of less 
than 1 % (Kirkpatrick, 1991). This clearly demonstrates that a safe antibody based 
product is needed and could be developed to treat spider envenoming in North 
America. 
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1.5.3 Purification of Poly clonal Antibodies 
Although originally crude antisera were used for therapy, most antivenoms are now 
purified by a process involving one or more steps to reduce the incidence of adverse 
reactions. After removal of the red and other cells by centrifugation, one approach is 
to first digest the antiserum with pepsin followed by thermocoagulation and removal 
of the precipitated material by centrifugation or filtration. Finally the majority of 
remaining contaminants are removed when the antibody fragments are precipitated 
with ammonium sulphate (Pope, 1939a; 1939b; Harms, 1948 (Figure 1.8)). 
Alternatively the y-globulins are precipitated first with either ammonium or sodium 
sulphate, to yield a y-globulin rich fraction which may be used as it is or then 
enzymatically cleaved with pepsin (or papain) to produce smaller active fragments 
(Figure 1.9). 
Extra steps such as anion-exchange and affinity chromatography have been 
incorporated recently into certain manufacturing processes to remove contaminating 
proteins and increase the potency of the final product (Grandgeorge et al., 1996; Raw 
et al., 1996; Karlson-Stiber et al., 1997; Chippaux & Goyffon, 1998). 
1.5.3.1 Fractionation of immunoglobulins 
Mineral salts such as ammonium and sodium sulphate are widely used for the 
purification of immunoglobulins, causing their precipitation as a result of 
'dehydration' of the protein by the salt. Polyethylene glycol (PEG) also selectively 
precipitates proteins in proportion to their molecular size and concentration. 
Conversely caprylic acid precipitates most of the plasma proteins except the 
immunoglobulins (Steinbuch & Audran, 1969; McKinney & Parkinson, 1987). The 
precipitation of unwanted proteins has a major advantage for large scale production, 
when continuous flow centrifuges are used. Thus these machines are not designed to 
retain the precipitate and, as a result, large losses are often found with ammonium and 
sodium sulphate precipitates (Dos Santos et al., 1989). 
1.5.3.2 Enzymatic Cleavage 
1.5.3.2.1 Pepsin 
Pepsin A (EC 3.4.23.1) is the predominant aspartic endopeptidase found in the gastric 
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Figure 1.8 Some commercial antivenom production processes. 
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JUIce of vertebrates. Commercial grade preparations can also contain gastricsin 
(pepsin C, EC 3.4.23.3) and a minor component called pig gelatinase (pepsin B, EC 
3.4.23.2) which have more restricted specificities and either a pronounced or little 
activity against haemoglobin respectively. Un-phosphorylated pepsin A is also known 
as pepsin D. 
Pepsin A is produced in the form of an inactive precursor (zymogen) called 
pepsinogen with a MW of 40,000Da, by the parietal (chief) cells of the stomach. A 
reduction of the pH below 5 causes a conformational change in the molecule and an 
autocatalytic process with the cleavage of a 44aa highly basic pro-segment to form the 
active pepsin with a MW of 35,000Da and isoelectric point of 2.2 which is capable of 
hydrolysing peptide bonds (Jones et al., 1995; Jonsson, 1972). 
The aspartic proteinases have a typical bilobal structure composed predominantly of 
~-sheets separated by a deep cleft that serves as an extended binding site (Figure 
1.10). This may accommodate at least seven amino acid residues. When all the 
binding sites are occupied, a conformational change occurs which, in an unknown 
way, enhances catalytic activity. In pepsin the aspartic acid residues found at positions 
32 and 215 lie in close proximity in this cleft and are involved in the catalytic process. 
Two antiparallel ~-strands form a flexible loop, L 71-082, which is located at the 
entrance to the active site and commonly known as the flap. The flap projects over the 
cleft forming a channel into which substrate binds. The role of a threonine residue on 
this flap, at position 77, has also been shown to provide an essential hydrogen bond 
that contributes to proper substrate alignment and, indirectly, to a catalytically 
favourable geometry of the transition state (Sielecki et al., 1990; Okoniewska et al., 
1999). The enzyme is considered rather non-specific, in that no clear cut rules for its 
specificities have been found. 
Although the enzyme shows a preference for hydrophobic (e.g. Ala, Val, Leu, He) or 
aromatic (e.g. Phe, Tyr, Trp) amino acids at the PI and Pl 1 positions, the residues 
found at up to 3 or 4 amino acids from the cleavage point also play an important role 
in the enzyme's specificity (Figure 1.11). The conformational shape of the substrate 
(e.g. haemoglobin or albumin) also plays a significant role, as demonstrated by 
Schlamowitz and Peterson (1959). 
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Figure 1.10 Schematic illustration of the folding of the peptide chain of the aspartic 
proteinases (Foltmann, 1981). The arrows indicate parallel or anti-parallel ~­
structures, the cylinders indicate a -helices, N-terminus and C-terminus are marked by 
Nand C respectively. The model is opened along the cleft, in the real model Asp 32 
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Figure 1.11 Subsite preferences and dislikes for pig pepsin (Powers et ai., 1977). The sample used for this calculation consisted of peptides 
comprising 6910 bonds of which 1020 were cleaved by pig pepsin. The amino acid residues on the top occupy positions relative to the cleavage 




Papain (papaya peptidase I, EC 3.4.22.2) is a cysteine endopeptidase which 
hydrolyses proteins with a broad specificity for peptide bonds and a preference for a 
residue bearing a large hydrophobic side chain at the P2 position. However, it does 
not accept Val at PI'. Papain is a major protein constituent of the latex and the melon-
like green fruit of the small softwood tree Carica papaya. It has a molecular weight of 
23,700 Da and an isoelectric point of 8.75. Papain was the first recognised member of 
this class of proteolytic enzymes that need a free sulfhydryl group for activity. Other 
enzymes belonging to this group are chymopapain (also isolated from papaya latex), 
ficin from the fig tree, and bromelain from pineapples. The enzymes from animal 
tissue, called cathepsins, belong to this group, as well as clostridio-peptidase B and 
streptococcal proteinase from bacteria. These enzymes usually need an activator to 
release the blocked SH group. The most usual activators are cysteine, cyanide, or 
glutathione (Drenth et aZ., 1971). 
1.5.3.2.3 Trypsin 
Trypsin (EC 3.4.21.4) is a serine endopeptidase which preferentially cleaves 
substrates containing Arg or Lys. It is produced as an inactive precursor called 
trypsinogen in the pancreas and cleaved initially by a specific enteropeptidase secreted 
in the duodenum to produce a small amount of active trypsin which can then activate 
more trypsinogen. 
1.5.3.3 Enzymatic digestion of immunoglobulins 
Treatment of immunoglobulins with proteolytic enzymes found practical use over 50 
years ago when Pope (1939) employed pepsin to remove the Fc of horse anti-tetanus 
and anti-diphtheria antibodies. Proteolytic enzymes were subsequently used to 
determine the structure of antibodies, by Porter (1959). He described the partial 
digestion of rabbit gamma globulin by papain to yield three fragments, two antibody 
binding fragments (Fab) and a slightly larger fragment (Fc) that had much of the 
antigenic specificity of the original molecule. Other studies using increasing 
concentrations of the enzyme demonstrated the further digestion of part of the rabbit 
gamma globulin molecule into small dialysable fragments representing 42% of the 
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total protein, but with only a 25% decrease in specific binding capacity of the 
remaining fragments (Nisonoff & Woernley, 1959). 
Enzymes used for the digestion of antibodies today include pepsin, trypsin, bromelain 
and ficin (Mariani et al., 1991; Zou et al., 1995). However, only pepsin and papain are 
used to digest polyclonal antibodies in the commercial production of antivenoms. 
Despite the generally over-simplified view of antibody digestion, there are subtle 
differences in the susceptibility of different classes and sub-classes of antibody to 
digestion by various enzymes (Turner et al., 1970). The antibodies from different 
species can also demonstrate a considerable variation in their relative susceptibility to 
enzymes. For example, the digestion of rabbit antibodies by pepsin at pH 4.5-5.0 
(Nisonoff et al., 1960), even after 48hr, produces an intact F(ab')2 fragment, without 
appreciable loss of antibody combining activity. However, at pH 2.5, digestion 
proceeds via the formation of an intermediate Fab' fragment until all parts of the 
molecule are reduced to small peptides without any binding activity (Haber & Stone, 
1967). Davies et al., (1978) have shown that sheep IgG, by comparison, is only slowly 
digested at pH 4.7 and even after 48hr at 37°C some residual intact IgG remains. 
Despite this partial digestion, both subclasses of ovine IgG (IgG 1 and IgG2) were 
susceptible to proteolytic cleavage producing F(ab')2 and small fragments of Fc 
(Davies et al., 1978). 
1.5.4 Antivenom 
1.5.4.1 The ideal antivenom 
The ideal antivenom should be rapidly distributed to the tissues where the venom may 
be present, including its site of introduction, and must be retained sufficiently long to 
continue to neutralise any venom that is being released slowly from the bite site 
(Cardoso et al., 1990). It should have a high avidity for the toxic components of the 
venom and, therefore, be effective at preventing morbidity or mortality. It should also 
not produce any side effects. Its stability should reflect the likely storage conditions in 
the field and it should be of a cost affordable by the people or country that it is 
destined for. 
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1.5.4.2 Types and availability of anti venom 
All commercial antivenoms are produced by immunising the recipient animal(s) with 
the specific venom or venoms and collecting the antisera. This may then be refined to 
IgO or F(ab')2 fragments to reduce the amount of foreign protein given per treatment 
and, thereby, the incidence of side effects. Normally horses are used due to their large 
size although other species are also used occasionally. Table 1.3 lists the 
commercially available spider antivenoms. 
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Product Name I Type Venoms Covered Manufacturer 
Antivenin (Latrodectus mactans), Latrodectus mactans Merck & Co., Inc., USA 
whole serum (equine) 
Red-backed spider antivenom, Latrodectus hasselti Commonwealth Serum 
F(ab')2 (equine) Laboratories (CSL), Australia 
Spider antivenom, F(ab')2 Latrodectus indistinctus The South African Institute for 
(equine) Medical Research, South Africa 
Anti-Latrodectus mactans Latrodectus tredecimguttatus, Institute ofImmunology, Croatia 
tredecimguttatus serum, F(ab')2 (Latrodectus hasselli, 
(equine) Latrodectus indistinclus) 
Soro-antiloxoscelico, whole Loxosceles reclusa Instituto Butantan, Brazil 
serum (equine) 
Suero-antiarachnidico, F( ab')2 Loxosceles sp. Instituto Naeional de Salud, Peru 
(equine) 
Soro-antiarachnidico polyvalente, Loxosceles sp., Instituto Butantan, Brazil 
whole serum (equine) Phoneutria sp., 
Tityus bahiensis, 
Tityus serrulatus 
Funnel-web spider antivenom, Atrax robustus, Commonwealth Serum 
IgO (lapine) Atraxsp. Laboratories (CSL), Australia 
Hadronyche sp. 
Table 1.3 Commercially available spider antivenoms (Theakston & Warrell, 
1991; Meier, 1995). 
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CHAPTER 2: 
MATERIALS AND GENERAL METHODS 
2.1 Materials 
2.1.1 Antivenoms and Immunochemicals 
Black widow spider antivenom (Latrodectus mactans) was purchased from Merck & 
Co., Inc. (West Point, USA). Normal sheep and horse serum and donkey anti-sheep 
IgG serum were obtained from MicroPharm Ltd (West Wales, UK). 
Peroxidase-conjugated affinity purified rabbit anti-sheep F(ab')2 was purchased from 
Jackson Immuno Research Laboratories Inc. (Luton, UK). 
2.1.2 Venoms 
Frozen spider venoms from La. hesperus, La. mactans, Loxosceles reclusa and Lo. 
deserta were purchased from Spider Pharm Inc. (Feasterville, USA). These venoms 
were obtained by the electrical stimulation of CO2 anaesthetised spiders. Suitable 
precautions were taken to prevent venom contamination with gastric secretions by 
inserting a suction tube into the spider's mouth while collecting venom from the fang 
tips using a capillary pipette. La. tredecimguttatus freeze dried venom gland extracts 
and purified venom components were purchased from Latoxan (Rosans, France) and 
La. hasselti venom from Venom Supplies Pty. Ltd. (Tanunda, South Australia). 
Alpha latrotoxin and other venom components were purified according to the method 
of Krasnoperov et al., (1992). Freeze-dried Apis melli/era melli/era venom and its 
purified venom components were obtained from Latoxan (Rosans, France) and 
Africanised bee venom was obtained from Southwest Venoms (Tucson, USA). 
2.1.3 General Chemicals and Materials 
CNBr-activated Sepharose 4B and Q Sepharose Fast Flow were purchased from 
Pharmacia (Uppsala, Sweden); Ultra Pure Protogel (30% acrylamide / 0.8% bis-
acrylamide w/v, solution) from National Diagnostics Ltd (Atlanta, USA); flat-bottom 
polystyrene Nunc Microwell plates from Life Technologies Ltd (Paisley, UK); and 
ultrafilters and filters from Sartorius (Goettingen, Germany). 
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All other general chemicals and solvents were of AnalaR or similar grade and 
supplied by BDH / Merck (Poole, UK) or Sigma (Poole, UK) unless otherwise stated. 
2.2 List of General Instruments 
ELISA plate washer; Flow Laboratories (Lugano, Switzerland). 
ELISA plate reader; Titertek Multiscan PLUS (MKII), Flow Laboratories (Lugano, 
Switzerland). 
Multipipette; Life Sciences International (Basingstoke, UK). 
Incubator; Genlab Ltd (Widnes, UK). 
Water bath; Grant SUBI4 (Cambridge, UK). 
Centrifuge; Mistra13000 (Crawley, England). 
Spectrophotometer; Jenway 6105 U.V.NIS (Felsted, England). 
Electrophoresis system; Mini-protein II dual slab cell, Biorad (California, USA). 
FPLC; comprising two P-500 pumps, LCC-501 PLUS control unit, HRIO flow cell, 
motor valve MV-7, mixer, UV-l optical/control units, REC 2, Pharmacia (Uppsala, 
Sweden). 
Fraction collector; FRAC-IOO, Pharmacia (Uppsala, Sweden). 
Micro balance; BPII0S, Sartorius (Goettingen, Germany). 
PH meter; Jenway 3200 (Felsted, England). 
Nerve muscle equipment; Mac1ab 4e, Quad Bridge Amp, Isometric force transducers, 
Performa 6300 Power PC, ADInstruments (Hastings, UK). Two channel dual 
impedance stimulator, 60mL tissue baths, tissue holder electrodes, Harvard Apparatus 
Ltd (Edenbridge, UK). 
2.3 General Methods 
2.3.1 Protein Concentration 
2.3.1.1 Optical density (OD) at 280nm 
A spectrophotometer set at 280nm was first blanked or zeroed against the appropriate 
buffer in a I cm path length silica (quartz) cuvette and then the sample at an 
appropriate dilution measured (ideally reading at - 1.0). Extinction coefficients (lg/L) 
of 1.5 for ovine IgG (Curd et al., 1971) and 1.4 for ovine Fab (Allen, 1996) were used 
throughout. 
44 
2.3.1.2 Bicinchoninic acid (BCA) assay 
The macromolecular structure of a protein, the number of peptide bonds and the 
presence of four amino acids (cysteine, cystine, tryptophan and tyrosine) are reported 
to be responsible for the colour formation with the BCA assay. 
Proteins in an alkaline medium reduce copper II to copper I (the biuret reaction) 
which then reacts with BCA to form an intense purple colour at 562nm. BCA forms 
alkaline metal salts which are soluble in water due to the polar carboxylic acid groups. 
The purple reaction product, formed by the interaction of two molecules of BCA with 
one cuprous ion, is also water-soluble enabling the spectrophotometric measurement 
of an aqueous protein solution. Protein to protein variation is said to be less with BCA 
than with OD at 280nm resulting in a more accurate quantitation of impure solutions 
or of those with an unknown extinction coefficient. 
Wells of a microtitre plate were filled with 200J.l.L of BCA working reagent which is a 
50: 1 mix of BCA reagent A (containing sodium carbonate, sodium bicarbonate, 
bicinchonic acid and sodium tartrate in 0.2M sodium hydroxide) and B (containing 
4% cupric sulphate, Pierce Chemical Company) and 10J.l.L protein samples added to 
each well. Both a standard curve (20-2,OOOJ.l.glmL), using bovine serum albumin 
(BSA) standard, and unknown samples were assayed in duplicate on the same plate 
which was mixed by shaking for 30 seconds, then incubated for Ihr at 37°C and the 
absorbance measured at 562nm. The protein concentration of unknowns was read off 
from the standard curve (Figure 2.1). 
2.3.2 Antisera Production 
Antisera were raised by immunising half-breed Welsh ewes every 28 days with 
immunogen dissolved in phosphate buffered saline (1.3mLlsheep) and mixed 
extensively with Brij 35 (0.2mL/sheep) and adjuvant (3.25mL/sheep) to form a stable 
water-in-oil emulsion. Freund's complete adjuvant was used for the primary 
immunisation, and Freund's incomplete adjuvant for all reimmunisations. The sheep 
were immunised in six sites, namely intramuscularly in each forelimb and hindlimb 
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Figure 2.1 BCA protein assay standard curve 
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Ten mL blood samples were collected from each sheep via the external jugular vein 
two weeks after each immunisation and, once adequate antibody levels had been 
achieved, 10mL 1 kg body weight of blood was collected at the same intervals. The 
blood was then rolled slowly for 2hr at room temperature to enhance clotting, 
centrifuged and the serum aspirated and stored frozen (-20°C) until used. 
2.3.3 Fast Protein Liquid Chromatography (FPLC) 
Gel filtration columns consisted of a cross linked agarose medium (Superose 12 or 
Superose 6 HR 10/30, volume 25mL). Superose 12 and 6 columns had a range of pore 
sizes suitable for the separation of proteins with molecular weights between 1 and 300 
kDa and between 5 and 5,000 kDa respectively. Samples were diluted in running 
buffer (Tris, 0.05M, pH8.0, NaCI 0.2M) and centrifuged or filtered to remove any 
insoluble material. A 50JlL sample loop attached to a MV -7 motor valve was used to 
apply the sample to the column and the appropriate sensitivity levels set for measuring 
the eluted proteins (UV-1 at O.1AU, chart recorder REC2 at 10mV) at 280nm through 
a HR10 flow cell. A constant flow rate of 0.5mL/min was provided by a P-500 pump 
and samples were run for a minimum of 1hr. Peak detection was set at 5% above the 
baseline and the integrator on the LCC-501 PLUS control unit used to calculate both 
the peak retention times and the percentage area under the peak. 
Known molecular weight standards (aprotinin 6,500Da, cytochrome C 12,400Da, 
carbonic anhydrase 29kDa, bovine serum albumin 66kDa, alcohol dehydrogenase 
150kDa, ~-amylase 200kDa, apoferritin 443kDa, thyroglobulin 669kDa) and blue 
dextran (2,OOOkDa, used to calculate the void volume) were run under identical 
conditions and their retention times used to plot a molecular weight calibration curve 
with the elution volume (V e) expressed in terms of the void volume (Vo) which was 
used to estimate unknown molecular weights (Figure 2.2). 
2.3.4 Sodium Dodecyl Sulphate Polyacrylamide Gel Electrophoresis (SDS-PAGE) 
Sodium dodecyl sulphate is an anionic detergent which binds strongly to proteins, 
causing their denaturation. In the presence of excess SDS, about l.4g of the detergent 
binds to each gram of protein, giving the protein a constant negative charge per unit 
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Figure 2.2 Superose 12 size exclusion chromatography standard curve 
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electrophoresis and, owing to the molecular sieving properties of the gel, the mobility 
of each is proportional to its molecular weight. 
The stacking gel serves to concentrate the protein sample into a sharp band before it 
enters the main separating gel. This is achieved by utilising differences in ionic 
strength and pH between the electrophoresis buffer and the stacking gel and involves a 
phenomenon known as isotachophoresis. The stacking gel has a very large pore size, 
which allows the proteins to move freely and concentrate, or stack, under the effect of 
the electric field. The band sharpening effect relies on the fact that negatively charged 
glycinate ions (in the electrophoresis buffer) have a lower electrophoretic mobility 
than the protein -SDS complexes which, in turn, have a lower mobility than the 
chloride ions of the loading buffer and the stacking gel. 
SDS-PAGE gels were prepared to characterise the various components of the venom 
or anti venom using the buffer system described by Laemmli (1970). They were 
prepared between two glass plates which had been thoroughly cleaned using distilled 
water and acetone. The plates were separated using Teflon spacers with the base of the 
gel sealed using a rubber seal onto which the glass plates were pressed and the 
running gel (Table 2.1) poured between the plates. The gel was then covered by an 
overlay solution (acetone) which ensured even setting at the acrylamide/acetone 
interface. Once set, the overlay solution was washed off with distilled water and the 
stacking gel (composition also shown in Table 2.1) poured and a Teflon comb inserted 
at the top to form the wells. Once set, the comb was removed and the sample wells 
and upper and lower buffer chambers filled with running buffer (Tris 25mM, glycine 
0.192M, SDS 0.1 % w/v, pH 8.3) before use. 
The samples were diluted at least 1:4 with sample buffer containing 62.5mM Tris-HCI 
(PH 6.8), 2% (w/v) SDS, 10% glycerol and 0.005% (w/v) bromophenol blue for non-
reducing conditions. Reducing buffer was identical but also contained 5% 2-
mercaptoethanol and the samples were heated at 95°C for 4 min. The molecular 
weights of unknown proteins were calculated by running the MW standards myosin 
(205kDa), p-galactosidase (116kDa), phosphorylase b (97kDa), fructose-6-phosphate 
kinase (84kDa), albumin (66kDa), glutamic dehydrogenase (55kDa), ovalbumin 
(45kDa), and glyceraldehyde-3-phosphate dehydrogenase (36kDa) on the same gel 
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Separating Gel 
12% 7.5% Stacking Gel 
Water 3.35mL 4.85mL 6.1mL 
1.5M Tris-HCl, pH 8.8 2.5mL 2.5mL 
O.5M Tris-HCI, pH 6.8 2.5mL 
10% (w/v) SDS stock 100~L 100~L 100~L 
AcrylamidelBis (30 / 0.8% w/v) 4.OmL 2.5mL 1.3mL 
10% ammonium persulfate 50~L 50~L 50~L 
TEMED 5~L 5~L lO~L 
Table 2.1 Constituents of SDS-PAGE gels. 
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and plotting a calibration curve of the RF (distance protein has migrated from origin / 
distance from origin to tracking dye) against MW (Figure 2.3). 
Gels were run at a constant voltage of 150V and then visualised by staining 
(Coomassie brilliant blue G 0.05% w/v in de stain) for 1 hr before being de stained 
(water/acetic acid/methanol mixture 5: 1 :4), prior to drying. 
2.3.5 Diafiltration. 
Small volumes of material were diafiltered or concentrated using 2mL centrifuge 
concentrator units with polyethersulfone membranes (Vivaspin) according to the 
manufacturer's instructions in a swing-out bucket type centrifuge and repeatedly 
washed as required. Larger volumes were diafiltered using Sartocon-Micro cross flow 
ultrafiltration units with either 30 or 50kDa MWCO polyethersulfone membranes 
(Sartorius, Goettingen, Germany). Fluid was pumped around the ultrafiltration unit as 
shown in Figure 2.4 and membranes primed with at least 50mL buffer before being 
used. Material to be ultrafiltered was initially concentrated to ~ 100mL and regularly 
topped up with fresh buffer as the volume decreased until it had been washed with 10 
volumes or lL of buffer. Ideally fresh buffer should continually be added at the same 
rate as the filtrate waste is produced in order to increase the efficiency of the 
diafiltration. Any residual material left trapped in the tubing and ultrafiltration unit at 
the end was flushed out with a small volume of buffer and added to the product. The 
membrane was regenerated between use by thoroughly washing the system with 
distilled water and then with 1M NaOH for 2 hr. 
2.3.6 Enzyme Linked Immunosorbant Assay (ELISA) 
Serum antibody titres directed specifically against purified alpha latrotoxin or whole 
venom, were determined by ELISA according to the method of Sjostrom et al., 
. (1996). Polystyrene 96-well micro-titre plates were coated with a solution of venom 
(2J.1.g/mL in sodium carbonatelbicarbonate buffer O.lM, pH 9.6) or a latrotoxin 
(500ng/mL) by incubating 100J.l.L per well for 2 hours at 37°C. Coated plates were 
then washed three times with 300J.l.L of ELISA washing buffer per well (NaCI 
137mM, N~HP04 8.lmM, KCI 2.68mM, NaH2P04·2H20 1.28mM, Thimerosal 
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Figure 2.4 Diafiltration using a cross flow ultrafiltration unit. 
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37°e and finally washed to remove any unbound antigen. The plates were then 
incubated with 1 OO~L of doubling dilutions of the immune serum diluted with ELISA 
washing buffer. A reference antiserum (from a pool of sera with an established titre) 
and normal sheep serum (NSS) were included on each plate as controls. All dilution 
curves were performed in duplicate. Plates were subsequently incubated at 37°e for 1 
hr, washed three times and then incubated with 100~L of donkey anti-sheep 
immunoglobulin (1 :500 dilution in ELISA washing buffer) to which had been 
conjugated horse radish peroxidase (HRP). Colour development was achieved at room 
temperature using 100~L of o-phenylenediamine dihydrochloride (OPD, O.lmg/mL in 
citrate buffer, 0.07M, pH 5.0) with hydrogen peroxide (0.02%) and stopped after 15 
minutes with 50J.1L of 3M sulphuric acid. The optical density (492nm) was read using 
a Titertek Multiscan PLUS (MKII) plate reader and the mean of the duplicates 
calculated. Titres were determined at 50% of the background NSS corrected 
absorbance (Figure 2.5) and values corrected for between assay variation using the 
reference antiserum. 
2.3.7 Small Scale Affinity Purification. 
Cyanogen-bromide activated Sepharose 4B columns (lg) were prepared according to 
the manufacturer's instructions using venom or toxin as the ligand at a concentration 
of 5mg/g of dry gel. Loading and eluting conditions were optimised and conditions 
providing the highest levels of specific antibody and the lowest levels of nonspecific 
binding were chosen. Antiserum samples (500~L) were diluted in 0.9% saline / 2% 
acetonitrile (6mL), mixed end-over-end overnight with the gel at 4°C, washed (saline / 
2% acetonitrile), and eluted (100mM glycine, pH 2.5). Specific antibody 
concentrations were determined based on their optical density at 280nm, using an 
extinction coefficient of 1.5 for ovine IgG. Non-specific binding was determined by 
running NSS and levels of specific antibody were corrected by subtracting the value 
due to non-specific binding. 
2.3.8 Venom Phospholipase Assay. 
Venom phospholipase A2 (Ee 3.1.1.4) activity was assessed by measuring free fatty 
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Figure 2.5 La. hesperus venom specific antiserum dilution curves by ELISA. 
Antiserum samples were; standard (0), week30 (2mg) La.hesperus ( ... ), week58 
(O.lmg) La. hesperus ('~), week58 (O.lmg) La.hasselti (+), NSS (*). 
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cresol red as a pH indicator (deAraujo & Radvanyi, 1987). 
To ImL of the freshly prepared lipid suspension (1.2g phosphatidyl-choline dissolved 
in ImL methanol made up to lOmL with assay buffer), was added 25mL of assay 
buffer (100mM NaCI, 100mM KCI, lOmM CaCI2, pH 8.6) followed by O.3mL of 
Triton-X-I00. The solution was mixed thoroughly until it became clear and the pH 
adjusted to 8.5. One mL of the indicator solution (lOmg cresol red in lOmL of assay 
buffer) was added and the resultant solution made up to a final volume of 30mL with 
assay buffer, producing a red coloured substrate solution. This solution was protected 
from light as the indicator solution is light sensitive. Next, 100/-1L of assay buffer was 
added to 2.8mL of the substrate solution in a plastic cuvette and the optical density 
(573nm) measured. To this was added 100/-1L of venom solution (10/-1g/mL in assay 
buffer) and a stop-watch started. To a second cuvette containing 2.8mL of substrate 
solution and 100/-1L of assay buffer was added a further 100/-1L of assay buffer as a 
control, which was run concurrently with the assay cuvette. Readings were taken 
every minute for 25 minutes and expressed as percentage hydrolysis of the substrate, 
taking the second cuvette as a zero standard (0% hydrolysis). 
Effects of various concentrations of venom were measured and the optimum 
concentration was used to assess antivenom neutralisation. Venom (1 OmglL) was 
premixed with antivenom for 30 min at 37°C prior to substrate addition and the 
optical density at 573nm measured after 10 min. 
2.3.9 Nerve-Diaphragm Assay 
The two phrenic nerves are made up from branches of the 3ni, 4th and 5th cervical 
(neck) nerve roots and descend through the neck and thorax to innovate the 
diaphragm. 
Left phrenic nerve-hemidiaphragm preparations were isolated from 20-35g male, out-
bred white mice (Kitchen, 1984; Bulbring, 1946). 
Mice were killed by cervical dislocation (avoiding over stretching the mice as this 
may damage the diaphragm and break the nerves) and placed under a lamp/extractor 
hood on an ice block wrapped with a paper towel. Krebs buffer (NaCI 118mM, 
NaHC03 25mM, NaH2P04.H20 1.0mM, KCI 4.8mM, CaCI2.2H20 1.9mM, 
MgS04.7H20 1.2mM, D-glucose 11.1mM) was placed on a separate ice block and 
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gassed with 95% O2 / 5% CO2, The skin covering the upper part of the abdomen and 
thorax was removed to reveal the muscle layers covering the chest which were 
removed in turn to expose the rib cage. An incision was made along the midline half 
way between the xiphisternum and the neck and a quick examination performed to 
ensure that the phrenic nerves were not adhering to the chest wall. The cavity and 
diaphragm was then irrigated with cold gassed Krebs solution at regular intervals. 
Lateral cuts were made on either side of the midline incision, parallel to the ribs, and 
the overlying section of rib cage carefully removed to leave just one or two ribs 
attached to the diaphragm on the animal's left side. The left phrenic nerve was 
carefully trimmed of connective tissue / fat and a short length of thread tied around it 
as far from the diaphragm as possible and the nerve cut leaving the thread attached to 
the nerve and diaphragm. The wall of the abdomen was then cut to free the rib cage. 
Holding the xiphisternum with forceps the diaphragm was cut straight down through 
the xiphisternum to the spine, taking care not to cut or stretch the phrenic nerve. The 
diaphragm was then cut laterally from its attachment to the body wall so freeing the 
preparation from the animal, placed in a petri dish containing gassed Krebs and 
trimmed to a suitable size to fit in the tissue holder. Using a needle, a piece of thread 
was attached to the tip of the tendon at the apex of the diaphragm preparation for 
attachment to the transducer. 
The recording equipment was calibrated by applying a 5g calibration weight (Ohaus) 
to each transducer. The rib was attached to the mounting bar of the tissue holder 
(Harvard Apparatus Ltd) and the nerve pulled gently across the sliding jaw-hook 
electrode and secured in place. The mounted preparation was then transferred to an 
organ bath and connected to the transducer (see Figure 2.6). 
Each tissue preparation was bathed in either 40 or 60mL Krebs buffer maintained at 
32°C, and supplied with 95% O2 + 5% CO2, Indirect stimulation (via the nerve) was 
applied at supramaximal voltage (~3V, 0.2Hz, 0.2ms) and muscle contractions 
recorded using an isometric transducer linked to a bridge amplifier and MacLab chart 
recorder (200samples/sec, DC high pass, 200Hz low pass, ImV range). Indirect 
stimulation was continued for at least 30min until a consistent twitch response was 
produced after which venom was added (to), and washed out once after 30min (t30) and 
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percentage of the contractions just before venom addition. Only tissue preparations 
with muscle contractions producing greater than Ig of tension were used. The 
myotoxic effects of the venom were assessed by applying a short burst of direct 
(muscle) stimulation (0.2Hz, Ims, -lOOV) before venom addition and at 30min 
intervals thereafter. 
The ability of antivenom to neutralise the effects of the venom was assessed by 
premixing a fixed venom concentration with antivenom and incubating at 37°C for 30 
min before addition to the hemidiaphragm preparation (to) followed by an identical 
dose cycle as outlined above. 
2.3.10 Venom Lethality in Mice and Antivenom Efficacy 
Where possible all solutions were sterile filtered (0.2J.!m) prior to use. The LDso of the 
venom (the amount that causes the death of 50% of the animals) was assessed by 
intravenous (Lv.) injection of various doses of venom in O.2mL of physiological saline 
into the tail vein of 18-20g male out-bred white (TFW) mice (Theakston & Reid, 
1983). Animals were placed under a heat lamp to dilate the tail vein and, thereby, aid 
injection. Five mice were used for each venom dose and the LDso was calculated from 
the number of deaths within 24hr by pro bit analysis. Animals were regularly checked 
during the 24hr period and dead animals removed. Any animals in severe distress and 
likely to die before the full 24hr period were humanely killed according to Home 
Office guidelines. 
To assess antivenom potency, various amounts of antivenom were mixed with two or 
five times the LDso of venom; the mixture was then incubated at 37°C for 30 min and 
injected intravenously into mice. Five mice were used at each antivenom dose. The 
ED so or median effective dose of the antivenom (the amount that prevents 50% of the 
mice from dying) was calculated from the number of deaths within 24 hr after 
injection of the venomlantivenom mixture using probit analysis (Laing et al., 1992). 
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CHAPTER 3: 
PRODUCTION OF ANTISERA FROM WHICH TO 
MANUFACTURE ANTIVENOMS 
- USING AFRICANISED BEE VENOM AS AN EXAMPLE 
3.1 Introduction 
The development of a platform technology with which to manufacture a range of 
antivenoms involves two distinct stages 
(1) Production of a suitable pool of antisera, processing using a conventional 
method and its assessment. 
(2) Development of a new improved method of manufacturing antivenom from 
the antisera pool. 
This chapter deals with (1) and chapter 4 with (2). 
3.1.1 Production and Assessment of Antiserum 
Before beginning to produce a new pool of antisera there must be adequate supplies of 
high quality venom - for immunisation and for use in assessment techniques. An 
appropriate species must be selected that produces adequate volumes of antisera such 
as the horse, goat or sheep, and their immunisation schedule optimised to produce the 
maximum amount of specific antibodies. Appropriate assessment techniques must 
also be selected and should include a bioassay to measure the neutralisation of 
toxicity. 
Because of problems in obtaining large quantities of high quality spider venom and its 
high cost, it was decided to develop a new platform technology using antisera raised 
against an easily available venom. This chapter describes the production of large 
quantities of antisera to bee venom for use in the next stage. Bee venom was chosen 
as a model because it is easily collected in large quantities and is, therefore, widely 
available at low cost. In addition, there are concerns in the US about increasing 
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numbers of mass bee attacks for which there is no specific antivenom available. Thus 
a safe, effective treatment is required urgently as only normal supportive intensive 
care treatment of the clinical features as they occur is currently available (Franca et 
al., 1994; Schumacher & Egen, 1995; Schumacher et al., 1996). Treatments include 
haemofiltration or haemodialysis, exchange transfusions or plasmaphoresis, 
antihistamines, corticosteroids, calcium gluconate and bicarbonate with mannitol 
(Franca et al., 1994; Schumacher & Egen, 1995). 
The pre-clinical development and assessment of a model antiserum specific for A. 
melli/era venom is described here that was subsequently used in the next chapter to 
develop a new procedure for processing antivenoms. 
3.2 Methods 
3.2.1 Venom 
Freeze dried Apis melli/era melli/era venom and its purified venom components were 
obtained from Latoxan (Rosans, France) and Africanised bee venom was obtained 
from Southwest Venoms (Tucson, USA). 
3.2.2 Venom Analysis by Electrophoresis 
A conventional SDS·P AGE technique was performed as described in Chapter 2. 
Propionic acid • urea polyacrylamide (22%) gel electrophoresis was performed 
according to the method of Chettibi and Lawrence (1989). Gels were prepared by 
mixing 15 mL of Protogel (30% acrylamide, 0.8% bis-acrylamide, w/v) with O.4ml 
propionic acid and 7.2g urea. Once dissolved, 133J.lL of freshly prepared 10% 
ammonium persulphate and 16J.lL of TEMED were added, quickly mixed and poured 
to form two mini gels. Running buffer consisted of 2% acetic acid in distilled water 
and sample buffer contained 30% sucrose, 2% acetic acid, and 0.01 % neutral red dye. 
Samples were dissolved in distilled water, diluted with an equal volume of sample 
buffer and run at 10mAlgei with the anode connected to the top of the gel. Gels were 
stained with 0.1% Coomassie blue in methanol : water : acetic acid (50:50:7) and 
destained in methanol: water: acetic acid (5:100:7). 
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3.2.3 Venom Phospholipase A2 Assay 
Venom phospholipase A2 (EC 3.1.1.4) activity was assessed by measuring free fatty 
acid release from a phospholipid substrate (phosphatidylcholine, egg yolk type) using 
Cresol red as a pH indicator (deAraujo & Radvanyi, 1987), as described in Chapter 2. 
3.2.4 Nerve-Diaphragm Assay 
Mouse left phrenic nerve-hemidiaphragm preparations were isolated, set up and run as 
described in Chapter 2. 
3.2.5 Electron Microscopy 
Following a period of stimulation of 3.5 hr in the above assay, control and venom 
treated (2Omg/L) diaphragm preparations were fixed and mounted using standard 
methods for transmission electron microscopy. Tissue was bathed in formaldehyde 
overnight and a series of increasing ethanol concentrations used to totally dehydrate the 
sample, followed by staining with osmium tetroxide, baking in resin and post sectioning 
staining with uranium. Numerous sections were made from each preparation and 
photographs taken which were representative of the entire tissue. 
3.2.6 In vivo Toxicity 
Mouse LDso was assessed by intravenous (i.v.) injection of the venom as described in 
Chapter 2 and calculated from the number of deaths within 24 hr. 
3.2.7 Antisera Production 
Antisera were raised by immunising half-breed Welsh ewes every 28 days (see Table 
3.1) withA. m. mellifera venom dissolved in phosphate buffered saline as described in 
Chapter 2. 
3.2.8 Sodium Sulphate Precipitation 
Serum (at room temperature) was pooled, filtered through a glass wool plug and 
mixed with an equal volume of sodium sulphate (36% in water at 37°C) for 15 min at 
room temperature to precipitate the immunoglobulins. The mixture was then 
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IMMUNOGEN DOSE (mg) PER 
SHEEP 
IMMUNISATION I WEEKS POST LOW MEDIUM HIGH 
SAMPLE I BLEED PRIMARY DOSE DOSE DOSE 
IMMUNISATION GROUP GROUP GROUP 
Primary Immunisation 0 0.25 0.5 0.5 
Re-Immunisation 4 0.25 1.0 1.0 
Sample 6 
Re-Immunisation 8 0.25 1.0 2.0 
Sample 10 
Re-Immunisation 12 0.25 1.0 4.0 
Sample 14 
Re-Immunisation 16 0.25 1.0 4.0 
Sample 18 
Re-Immunisation 20 0.25 1.0 4.0 
Sample 22 
Re-Immunisation 24 0.25 1.0 4.0 
Sample 26 
Re-Immunisation 28 0.25 1.0 4.0 
Bleed + Aliquot 30 
Re-Immunisation 32 0.25 1.0 4.0 
Bleed + Aliquot 34 
Re-Immunisation 36 0.25 1.0 4.0 
Bleed + Aliquot 38 
Re-Immunisation 40 0.25 1.0 4.0 
Table 3.1 Apis m.mellifera venom immunisation schedule. 
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centrifuged at 2,750g for 1 hr at - 25°C, the supernatant containing the albumin and 
other small molecular weight serum proteins discarded and the precipitate washed by 
resuspending with 18% sodium sulphate and re-centrifuging. This washing was 
repeated and the final precipitate was redissolved in saline to give a final volume 
approximately equivalent to that of the original serum. The resultant solution was 
dialysed against at least 20 volumes of saline at 4°C for 48hr, the volume of the 
dialysed material recorded and any remaining precipitate removed by centrifugation 
or filtration. Optical density (280nm) was measured to determine the IgG 
concentration using an extinction coefficient of 1.5 (lg/L solution, path length 1cm). 
3.2.9 Papain Digestion 
An established papain digestion method was used (Smith et al., 1992) in which IgG 
(typically between 15-40gIL) was adjusted to pH 7.0 using either hydrochloric acid or 
sodium hydroxide and 0.8mg Iml EDT A added, mixed, and allowed to equilibrate in a 
water bath at 37°C for 30 min. Papain (16% of the total IgG weight, Merck 30,000 
grade) was added, mixed gently and, once dissolved, activated by the addition of L-
cysteine HCI (1.6mg/mL) with gentle mixing for 1 hr at 37°C. After standing at this 
temperature for a further 23 hr, the reaction was stopped by the addition of 
iodoacetamide (2.8mg/mL) and mixed for 15 min at 37°C. The digest was then 
dialysed against at least 20 volumes of saline at 4°C for 48hr, and centrifuged at 
2,750g for 1 hr to pellet the precipitate. The Fab supernatant was decanted off, filtered 
and the concentration determined by optical density at 280nm using an extinction 
coefficient of 1.4 for ovine Fab. Final Fab concentrations were typically between 20-
30 gIL. The Fab was then stored at 4°C or at -20°C for long term storage. 
3.2.10 Enzyme Linked Immunosorbant Assay (ELISA) 
Serum antibody titres directed specifically against purified melittin or whole venom 
were determined by ELISA according to the method of Sjostrom et al., (1996) (see 
Chapter 2). Titres were determined at 50% of maximum absorbance after correction 
for the background NSS absorbance (Figure 3.1) and values corrected for between 
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Figure 3.1 Melittin specific antiserum dilution curves by ELISA. Antiserum 
samples were: standard (+), week 38 high (II), medium (.) and low (T) 
immunisation dose groups. NSS (*). 
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3.2.11 Small Scale Affinity Purification 
Venom or melittin were covalently conjugated to cyanogen-bromide activated 
Sepharose 4B gel according to the manufacturer's instructions. Briefly 19 of CNBr-
activated Sepharose 4B was re-swollen on a sintered glass filter for IS min and 
washed with 1mM HCI, followed by Sml of coupling buffer (O.lM sodium hydrogen 
carbonate, O.5M sodium chloride, pH 8.3). The washed gel was quickly placed in a 
chromatography column containing Smg of the protein to be coupled, dissolved in 
6mL of coupling buffer, and mixed end over end at 4°C overnight. Unbound material 
was collected and its OD (280nm) used to assess the amount bound by difference. 
Any remaining active groups were blocked with 6ml of blocking reagent (1M 
ethanolamine, pH 8.0) and mixed overnight at 4°C. The blocking agent was drained 
off and the column washed with 12mL coupling buffer followed by 12mL acetate 
buffer (O.lM sodium acetate, O.5M sodium chloride, pH4.0) followed by coupling 
buffer and the wash step repeated once more. 
Loading and eluting conditions were optimised and conditions providing the highest 
levels of specific antibody and the lowest levels of nonspecific binding were chosen. 
Non-specific binding was found to be reduced by the inclusion of 2% acetonitrile in 
the wash buffer without affecting specific binding. Antiserum samples (SOOJ,tL) were 
diluted in 0.9% saline / 2% acetonitrile (6mL), mixed end-over-end overnight with the 
gel at 4°C, washed (saline / 2% acetonitrile), and the columns eluted with 100mM 
glycine, pH 2.5. Specific antibody concentrations were determined based on their 
optical density at 280nm, using an extinction coefficient of 1.S for ovine IgG. Non-
specific binding was determined by running NSS and levels of specific antibody were 
corrected by subtracting the value due to non-specific binding. 
3.2.12 Venom Phospholipase A2 Neutralisation. 
Venom (lOmg/L) was premixed with antivenom for 30 min at 37°C prior to substrate 
addition and the optical density at S73nm measured after 10 min. 
66 
3.2.13 Neutralisation of In Vivo Toxicity. 
Mouse ED so was assessed by intravenous (Lv.) injection as described in chapter 2 
using a Fab-based anti venom prepared from a pool of antisera raised using the high 
immunisation dose against five times the LDso. 
3.3 Results 
3.3.1 Venom Analysis 
A conventional SDS-PAGE analysis (Figure 3.2) clearly separated the phospholipase A2 
(~19,000Da) and melittin (2,847Da) components of the venom, but could not separate 
the melittin from the other low molecular weight components such as mast cell 
degranulating peptide (2,593Da) and apamin (2,027Da). 
Using an acid urea gel system which separates proteins by a combination of their native 
charge at low pH and size, the venom was clearly separated into its individual 
components and these were identified by running the purified major components: 
melittin, phospholipase A2, mast cell degranulating peptide (at the electrophoresis front) 
and apamin (Figure 3.3). No differences between the European or Africanised bee 
venoms could be detected. 
3.3.2 PLA2 Activity 
A. m. mellifora venom concentrations of 10mg/L produced a rapid decrease in OD 
representing ~ 90 % hydrolysis of the phosphatidylcholine substrate after 10 min 
compared to a slower rate of hydrolysis produced by 7 mg/L (Figure 3.4). Minimal 
hydrolysis was produced by 0.7mg/L and no enzymatic activity could be detected in 
10mg/L of melittin, indicating that there was no major enzymatic contamination of this 
material. A snake (Crotalus scutulatus scutulatus) venom known to have high levels of 
PLA2 activity was run as a comparison and shown to have slightly less activity than the 
bee venom. 
3.3.3 Toxicity as Shown Using a Nerve-Diaphragm Assay 
After their addition to the phrenic nerve diaphragm preparation an initial tonic 
contraction was produced both by the whole venom and by the purified melittin, 
followed by a progressive decrease in muscle contractions. 
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Figure 3.2 SDS-PAGE (15%) analysis of A. m. mellifera venom and melittin. 
Molecular weight markers (1, 6), 28~g melittin-reduced (2, 3), 14~g venom-reduced 
(4, 5), 28~g melittin non-reduced (7, 8), 14~g venom non-reduced (9, 10). 
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Figure 3.3 Venom composition by acid-urea polyacrylamide gel electrophoresis. 
Whole bee venom (30J..lg or 15J..lg) from either European A. m. melli/era (lanes I and 2 
respectively) or Africanised bees (lanes 3 and 4) and 5J..lg of each of the purified 
components; melittin (lane 5), phospholipase A2 (lane 6), mast cell degranulating 
(MCD) peptide (lane 7) and apamin (lane 8). 
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Figure 3.4 Phospholipase A2 activity measured by the hydrolysis of 
phosphatidylcholine. A. m. mellifora venom 1O~, 7 C.), and 0.7 CY) mgIL. Melittin 
10mgIL (.). Crotalus scutulatus scutulatus venom 10mgIL (0). 
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3.3.3.1 Venom 
The decrease in muscle contraction showed a similar time course whether the 
preparation was stimulated indirectly via the nerve or directly via the muscle with a 
range of venom concentrations (2-20 mg/L, see Figure 3.5 and 3.6). This indicates a 
direct myotoxic effect and no specific neurotoxic activity could be demonstrated. The 
progression of the toxicity appeared unaffected by two washes of the tissue with Krebs 
buffer and, using a venom concentration of 20mg/L, muscle contractions had virtually 
stopped before the end of the experiment. 
3.3.3.2 Melittin 
Melittin also had an inhibitory effect on muscle contractions that followed a similar time 
course whether stimulated via the nerve or muscle, indicating a direct myotoxic effect 
(Figure 3.7). A 5mg/L concentration ofmelittin only produced up to 65.6% ±2.9 (SEM, 
n=4) inhibition of direct stimulation compared to 91.4% ±3.1 (SEM, n=4) by an equal 
concentration of whole venom. 
3.3.4 Electron Microscopy 
Electron microscopy of muscle fibres from a control diaphragm showed a normal 
characteristic banding pattern (Figure 3.8a), due to the presence of parallel myofibrils 
interspersed with mitochondria, sarcoplasmic reticulum and triads, indicating that the 
tissue was unaffected by the procedure. By contrast, muscle fibres from the venom 
treated (20mg/L) diaphragm showed complete disorganisation of the normal architecture 
with clumping of myofibrils and disruption of the sarcoplasmic reticulum and triads 
(Figure 3.8b). These features were found across all the tissue sections analysed. This 
venom concentration also produced a parallel loss of functional activity of the tissue. 
3.3.5 In vivo Toxicity 
The A. m. mellifora venom had an LDso of 3.1 mg/kg (59.7J..lg/mouse, 95% confidence 
limits from probit analysis 53.2 - 81.6) and mice receiving high venom concentrations 
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Figure 3.5 Effects of A. melli/era venom on the phrenic nerve diaphragm 
preparation. Nerve (a), and direct (b) stimulation, using venom concentrations of 0 (+), 
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Figure 3.6 Time taken for A. melli/era venom to cause 70% inhibition of nerve 
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Figure 3.7 Effects of melittin on the phrenic nerve diaphragm preparation. Nerve 
(a), and direct (b) stimulation, using melittin concentrations of 0 (+), 3 (II) and SmgIL 




Figure 3.8 Electron micrograph of control (a) and venom treated (b) diaphragm. 
The former shows paralleJ myofibrils and characteristic banding patterns (IabeJJed A, 
I, and Z) interspersed with mitochondria (m), sarcop.lasmic reticulum (empty arrow) 
and triads (arrowheads). Venom treatment resulted ill areas of complete disruption 
with clumped myofibrils (C). ScaJe bar = 6.6I1m. 
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3.3.6 Specific Antibody Levels 
3.3.6.1 ELISA 
ELISA titres of up to ] :300,000 and 1 :75,000 were produced against whole venom and 
melittin respectively, when immunising with the largest dose schedule (viz up to 
4mg/sheep every 28 days). The highest dose consistently produced higher antibody 
titres than the medium and low dose groups (Figure 3.9). Antibody titres appeared 
directly related to the dose of immunogen except for those against melittin, when the 
medium dose group displayed similar or lower titres than the low dose group. 
3.3.6.2 Small scale affinity chromatography 
A typical elution profile from an A. m. mellifera venom small scale affinity 
chromatography column is shown in Figure 3.10, with most of the material eluted in the 
41h and 51h fractions . Consistent with the ELISA titres, the high immtmisation dose 
produced the highest levels of specific antibodies with up to 8.8 and 4.5 gIL (after 
subtracting the non-specific binding) against whole venom and melittin respectively 
(Figure 3.11). Conversely the lowest specific antibody levels were produced using the 
lowest immunisation dose schedule (viz up to 0.25mg/sheep every 28days). A slow 
progressive increase in the antibody response to melittin was noted without any sign of 
reaching a plateau after more than a year. 
3.3.7 SDS-PAGE Analysis ofIgG and Fab 
The fractionated IgG showed just one major band and contained only minor traces of 
albumin (Figure 3.12). Fab prepared using conventional papain digestion had no visible 
intact IgG and principally consisted of a band of ~46,000Da. 
3.3.8 Neutralisation of Venom Phospholipase A2 Activity 
Neutralisation of phospholipase A2 activity was most pronounced using the high and 
medium immunisation dose group anti venoms, with 400mg/L of these JgG or Fab 
preparations able to fully neutralise 10mg/L of venom phospholipase A2 activity (Figure 
3.13). From this data (50% neutralisation) it was calculated that ~14mg ofIgG or 16mg 
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Figure 3.9 Specific antibody levels determined by ELISA, directed against 
A.m.mellifera venom (a) and against melittin (b). High ~, medium (.6.) and low (~) 
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Figure 3.11 Specific antibody levels, detennined by small scale affinity 
chromatography, directed against whole A. m. melli/era venom (a) and against melittin 
(b). High (11), mediwn (.) and low (Y) immunisation dose groups. 
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Figure 3.12 SOS-PAGE (10%) analysis of IgG and Fab purities. Molecular weight 
markers (1), normal sheep serum (2), week 30 low dose IgO (3) or Fab (7), week 30 
medium dose IgG (4) or Fab (8), week 30 high dose IgG (5) or Fab (9), normal sheep 
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Figure 3.13 Neutralisation of A. melli/era venom phospholipase A2 activity using 
anti-A. melli/era IgG (a) or Fab ~), ,Prepared from serum produced by the high (+), 
medium C") and low (A) immurusatIon dose groups or normal sheep serum (_). 
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3.3.9 Venom Toxicity Neutralisation as Shown Using a Nerve-Diaphragm Assay 
Increasing total Fab antivenom concentrations had a progressive neutralising effect but 
even a high concentration (800mg/L) could not completely neutralise the venom's 
toxicity (Figure 3.14). 
3.3.10 Melittin Toxicity Neutralisation as Shown Using a Nerve Diaphragm Assay 
Increasing total Fab antivenom concentrations had a progressive neutralising effect but 
even a high concentration (l600mg/L) could not completely neutralise melittin's 
toxicity (Figure 3.15). The tonic contraction was, however, fully neutralised with these 
high antivenom concentrations (Figure 3.16). 
3.3.11 In vivo Toxicity Neutralisation 
The EDso for the antivenom preparation (total Fab) was 258 mglkg (4.9mg/mouse, 95% 
confidence limits from probit analysis = 4.3 - 5.3) against five times the LDso. From this 
data it can be calculated that -20.5mg of antivenom is required to neutralise each mg of 
venom. 
3.4 Discussion 
Bee venom was chosen as a model because it is easily collected in large quantities and 
is, therefore, widely available at a low cost. Also, the frequency of mass bee attacks 
has dramatically increased in the Americas following the introduction and spread of 
the aggressive Africanised 'killer' bee. As yet no specific therapy is available for 
these toxic effects (Franca et al., 1994; Schumacher et al., 1996), which led us to 
develop an ovine antisera which could be refined to produce a potential new 
antivenom treatment. 
Venom from European and Africanised bees appeared identical when resolved by 
electrophoresis systems utilising differences in both the charge and size of the 
components. Based on this finding and their similar toxic properties and cross 
reactivity (Schumacher et aZ., 1990; 1996; 1989; Nelson et al., 1990), it is probable 
that an antivenom raised against the European bee venom will be equally effective at 
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Figure 3.14 Neutralisation of venom toxicity as evidenced using nerve (a) or directly 
(b) stimulated diaphragm preparations, bathed in Smg/L venom only ~, or plus 
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Figure 3.15 Neutralisation of melittin toxicity as evidenced using nerve (a) or 
directly (b) stimulated diaphragm preparations, bathed in Smg/L melittin only ( .. ), or 
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Figure 3.16 The tonic contraction induced by melittin and its neutralisation. 
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The LDso of A. m. mellifera venom in this study was similar to that previously 
reported for both European and Africanised bee venoms (Schumacher et al., 1989; 
1990; 1996). The dramatic manifestations and rapid lethal effects produced by high 
venom concentrations in mice are probably due to apamin which acts on the central 
nervous system (Habermann, 1972; 1984; Vincent et al., 1975; Spoerri et al., 1975; 
van-Rietschoten et al., 1975). 
A powerful PLA2 activity was found in the venom with a potency similar to that found 
in snake venoms. 
The effects of the venom on the phrenic nerve diaphragm preparation were of a 
predominantly myotoxic type, as evidenced by both ultrastructural and functional 
changes. It produced an immediate tonic contraction, similar to the cardiotoxins (Lin 
et al., 1975), which appears to be produced by the melittin. Although melittin 
produced a myotoxic effect on this isolated tissue preparation, an equal concentration 
of whole venom was significantly more toxic, suggesting a synergistic interaction 
between melittin and PLA2• 
In our laboratory total IgG levels of 28gIL were found in pooled antisera from sheep 
and others have reported levels in normal sheep serum greater than 26g/L (Strain et 
al., 1984). These high levels of IgG may explain why sheep often produce relatively 
high levels of specific antibodies (e.g. 7 - 15g1L) to an immunogen (Smith et al., 
1992). The size of sheep also helps ensure their suitability for scaling up to produce 
antivenoms commercially, as each sheep will yield,.., 4L of antiserum per year (Meyer 
et al., 1997; Karlson-Stiber et al., 1997). Although horses are much larger and will 
produce ,.., 8 times this volume, they are considerably more expensive to buy and 
maintain. Sheep were, therefore, used as the species of choice in this study. Levels of 
venom-specific antibodies were found to be consistently greater using the highest 
immunogen dose (4mg/sheep). 
The present results indicate that early in the immunisation schedule most of the 
specific antibodies were directed against venom components other than melittin. 
Phospholipase A2 is one of the most immunogenic components of bee venom and may 
contribute to the generalised toxicity of envenomation by a synergistic interaction 
with melittin (Schumacher & Egen, 1995; Vogt et a/., 1970; Mollay & Kreil, 1973; 
Ownby et al., 1997; Schumacher et al., 1996; King et al., 1976). The antivenoms 
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raised by immunising with 1 or 4mg of venom fully neutralised this important 
enzymatic activity. Melittin is also important, with its insertion into cell membranes 
being thought to cause disruption of the surrounding phospholipid bilayer which 
allows phospholipase A2 to gain access to its phospholipid substrate (Banks & 
Shipolini, 1986). However, melittin is said to be poorly immunogenic probably 
because of its small size (26 amino acids with a molecular weight of 2,800 Da) and 
strongly hydrophobic regions (Schumacher & Egen, 1995; Schumacher et al., 1996; 
King et al., 1976). It forms the major venom component and, fortunately, up to 4.5 g / 
L of specific antibodies to this peptide could be generated in the high dose group of 
sheep provided the period of immunisation was sufficiently prolonged. This led to the 
selection of the 4mg per sheep dose as the optimum immunisation schedule. 
A conventional procedure for producing Fab-based antivenoms using a sodium 
sulphate precipitation step followed by papain digestion was performed and the 
resultant preparations tested. Similar proportions of PLA2 neutralisation were found 
using either IgG or Fab preparations derived using the various immunisation 
schedules, although the IgG appeared to be slightly more active on a weight for 
weight basis than the Fab, indicating a loss of some of the activity as a result of the 
digestion procedure. 
Antivenom was capable of neutralising most of the toxicity on the phrenic nerve 
diaphragm preparation produced by venom or melittin, as well as the initial tonic 
contraction. However, it was incapable of producing 100% neutralisation at the doses 
tested, which may be due to the large proportion of melittin found in the venom, 
together with its low molecular weight and, therefore, high molar concentration 
(5mg/L = 1. 76J.1M). 
The anti venom was capable of neutralising the venom in vivo when assessed using the 
standard mouse EDso test and it was calculated that -20.5mg of antivenom was 
required to neutralise each mg of venom. The EDso results indicate, indirectly, that the 
antivenom is also effective against apamin. 
The vast majority of bee sting reactions involve just a single sting and are severe only 
in the 0.15 - 4.0% of people with true systemic hypersensitivity to hymenoptera 
venoms (Schmidt, 1986). These 'allergic' type individuals are at a high risk of 
developing life threatening IgE-mediated or anaphylactoid reactions, which must be 
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treated conventionally (e.g. antihistamines, steroids, alphalbeta agonists, 
bronchodilators and adrenaline) (Ewan, 1998). In the US some 40 deaths per year 
result from such a reaction which usually occurs within Ihr (Schmidt, 1986). Such 
subjects will not benefit from the availability of an antivenom whose use will be 
limited to those stung by 50 or more bees and who often develop features of systemic 
toxicity many hours latter, with the majority of deaths after 22 hr or more (Franca et 
al., 1994; Kolecki, 1999). This suggests that the use of antivenom may still be 
beneficial even if delayed for several hours. This is supported by the benefits that may 
arise by receiving antivenom several days after snake envenoming (Meyer et al., 
1997; Warrell, 1995). 
Clinical studies are now essential to assess the effectiveness of an anti venom 
produced from this material to neutralise the high systemic levels of venom found 
after mass bee attacks and, thereby, alleviate the clinical manifestations and improve 
the prognosis. Unlike with snake bites where the amount of venom injected may vary 
greatly (e.g. 0-1.5g) and is unknown (Bdolah, 1979), the ability to assess the amount 
of bee venom injected after a mass attack by counting the number of stings should, 
theoretically, be of help in evaluating whether (a) antivenom is required (e.g. >50 
stings), and (b) the quantity of antivenom required. Again clinical trials will be 
necessary to assess this. 
In conclusion, this study has demonstrated that a specific A. melli/era anti venom can 
be raised in sheep that will neutralise the toxic components of the venom, and protect 
mice. Large quantities of antisera were successfully produced for use in the 




A SIMPLE NEW PROCESS FOR PURIFYING ANTmODY 
FRAGMENTS (F(ab')2) IN HIGH YIELD FROM SERUM. 
4.1 Introduction 
For more than 50 years proteolytic enzymes have been used in the refinement of 
antitoxins, and were a key factor in the subsequent elucidation of immunoglobulin 
structure (Imray, 1902; Parfentjev, 1936; 1938; Pope, 1939; Porter, 1959). Today, 
enzyme cleaved antibodies are widely used throughout the world for the treatment of, 
for example, victims of snake envenoming. 
The commercial production of polyclonal antibody fragments for therapeutic use often 
involves numerous steps such as ammonium or sodium sulphate precipitation, enzyme 
digestion, diafiltration, thermocoagulation and, more recently, ion-exchange and / or 
affinity chromatography (Harms, 1948; Schultze et al., 1965; Kirkpatrick, 1991; 
Grandgeorge et al., 1996; Karlson-Stiber et al., 1997). Such procedures can result in 
an effective and safe, but expensive product (Kirkpatrick, 1991; Karlson-Stiber et al., 
1997; Theakston & Warrell, 2000). The latter is unfortunate, especially with regard to 
antivenoms, for which the greatest demands are from the poorest regions of the world. 
Thus, in many regions anti venoms are either not available or are relatively impure and 
cause a high (10-76%) incidence of side effects (Karlson-Stiber & Persson, 1994; 
Wilde et al., 1996; Meyer et al., 1997; Moran et al., 1998; Theakston & Warrell, 
2000). These side effects are generally attributed to contaminants including serum 
proteins, Fc or aggregates (Porter, 1957; Hristova, 1968; 1970; Waldesbuhl et al., 
1970; Sutherland, 1977; Malasit et al., 1986). 
The aspartic proteinase pepsin, purified from the gastric mucosa of pigs, is used 
extensively by commercial producers of antibody-based therapeutic products. Its use 
has to be optimised since, for example, it will hydrolyse rabbit IgG at pH 2.5 to small 
peptides without any binding activity while, at a pH of 4.5-5.0, the IgG is digested to 
F(ab')2 and small fragments of Fc (Nisonoff et al., 1960; Haber & Stone, 1967). 
Davies and his colleagues (1978) found that the production of F( ab')2 by digesting 
89 
sheep IgO at pH 4.7 required a high pepsin concentration, was slow and left some 
residual intact IgO even after 48 h at 37°C. 
The plant enzyme papain has been used to produce some recent antitoxins. Papain 
cleaves an antibody molecule at - neutral pH to give two molecules ofFab and one of 
Fc, each with a similar molecular weight. Fc contaminants then have to be removed 
using further steps such as ion-exchange chromatography (Meyer et al., 1997; 
Karlson-Stiber et al., 1997; Ariaratnam et al., 1999). Unfortunately such ion-exchange 
methods are limited by the wide isoelectric range of polyclonal antibody fragments, 
with a resultant trade-off between purity and yield (Hristova, 1968; 1970; Saetang et 
ai., 1997). Papain, unlike pepsin, is also a known allergen in man (Quarre et al., 1995; 
Baur et ai., 1995). 
The initial salt precipitation of the globulin fraction from serum is time consuming, 
difficult to perform on a large scale under sterile conditions, and may be associated 
with large losses and / or aggregate formation (Schultze et ai., 1965; Friesen, 1987). 
Various direct serum digestion methods have been devised. For example Parfentjev 
(1936; 1938), managed to directly digest equine antisera and remove the unwanted 
components by a combination of diafiltration, ammonium SUlphate precipitation, 
dialysis and tri-calcium phosphate absorption. Another commercial method which 
also avoids initial salt precipitation is based on those of Pope (1939) and Harms 
(1948) in which brief (30min, 30°C, pH 3.2) pepsin digestion is followed by a critical 
heat denaturation step (1 hr at 55°C, pH 4.3, 13% ammonium sulphate, 0.12% 
Tricresol) to precipitate non-antitoxic protein. However, this still requires a later salt 
precipitation step, results in 40-50% losses of antitoxin activity, and gives a product of 
variable purity (Saetang et ai., 1997). Similar losses have also been described using a 
process utilising diafiltration and ion-exchange chromatography, although the product 
was highly pure (92-98% by electrophoresis (Benanchi et ai., 1988». A simpler 
method was described by Poulsen and Hjort (1980) in which they attempted to digest 
human serum directly to F(ab')2' and dialysable fragments. However, a large 
proportion of unwanted material was still retained with the F(ab')2' 
To my knowledge pepsin digestion of ovine serum with the complete degradation and 
removal of essentially all unwanted serum proteins without a salt precipitation step 
yet with a high yield ofF(ab')2 has not been described. 
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The following studies were performed to investigate the enzyme digestion of both 
ovine whole antiserum and its IgG fraction as part of the development of a simple 
method to produce pure F(ab')2 at high yield and low cost suitable for both bench scale 
work and large scale production processing. 
4.2 Methods 
4.2.1 Antisera and IgG Preparation 
Antisera used in these studies were raised against venom from the European honey 
bee (Apis melli/era melli/era) and IgG fractions were prepared as described in Chapter 
3 (Jones et al., 1999). Protein concentration of serum was determined using the BCA 
assay (Pierce, Rockford, USA; Smith et al., 1985), with a bovine serum albumin 
standard as described in Chapter 2. 
4.2.2 The Effects of Trypsin 
IgG (30mg/mL in saline) or serum were diluted with an equal volume of digestion 
buffer (100mM Tris, 20mM CaCI2, pH 8.0), placed in a water bath at 37°C for 30 min 
and type IX trypsin (15,200 Units/mg protein) dissolved in digestion buffer at a 
concentration of 50mg/mL was added to give an enzyme to substrate ratio of 1 :50, 
mixed and incubated at 37°C. Samples (1.5mL) were removed at set time intervals 
and the digestion stopped by adding 15J.lL phenylmethylsulphonylfluoride (PMSF) 
dissolved in isopropanol (100mM; James, 1978). 
4.2.3 The Effects of pH on Pepsin Digestion 
Aliquots (15 mL) of either the IgG fraction (30mg/mL) or whole antisera (diluted with 
an equal volume of distilled water) were adjusted to one of a range of pH (3.0, 3.25, 
3.5, 4.0, 4.5, 5.0) at room temperature using 0.4 M HCI and then warmed in a water 
bath at 37°C for 30 min. Porcine pepsin A, 1 :60,000 grade (Sigma, Poole, UK, 
2,260U/mg at 50mg/mL in distilled water) was added while mixing at an enzyme to 
substrate ratio of 1 :50 w/w (45.2 U/mg substrate) and incubated at 37°C. Samples (1.5 
mL) were removed at set intervals (0.5, 1, 2, 4, 8, 24, 48, 72 hr) and enzymatic 
91 
cleavage stopped by adding a small volume (20 - 12SJ.lL) of O.S M N~HP04' in 0.9% 
saline to raise the pH to -6.0, sub-aliquoted and stored at -20°C until required. 
4.2.4 The Effect of Post Digestion pH on Soluble Aggregate Formation 
The antisera and IgG fractions were each adjusted to pH 3.S and digested with pepsin 
for 24 hr, as described above, then immediately sub-ali quoted and stored at -20°C 
without neutralisation. When required, samples were thawed, diluted with the 
appropriate pH buffer (PH 4.0, S.O, 6.0, 7.0, 8.0) and centrifuged or filtered to remove 
any precipitate before running on a Superose 12 column equilibrated with the same 
buffer. 
4.2.5 Pepsin Enzymatic Activity 
Pepsin enzymatic activity was measured using a method based on that described by 
Ryle (1970). Stock bovine haemoglobin (2.5%) substrate was dissolved in distilled 
water by thorough mixing and filtered through a filter paper on a Buchner funnel. This 
solution could be stored for a maximum of 2-3 days at 4°C. Acidified haemoglobin 
was prepared by mixing 4 parts with 1 part of HCI (0.3M) and lmL aliquots were 
dispensed into test tubes. These were briefly warmed to 37°C in a water bath and 
0.2mL of enzyme (or sample) diluted in Clark and Lubs solution (SOmM KCI, pH 2.0) 
added, mixed and incubated for 10 min at 37°C. Trichloroacetic acid (TCA, SmL of a 
4% solution) was added, and the tubes were mixed and incubated for a further S min 
before being centrifuged for 10 min at 3,SOO RPM at RT. The 00 (280nm) of the 
supernatant was then measured using distilled water as a blank. Controls were 
performed for all samples by adding the TCA (SmL) to the acidified haemoglobin 
substrate (lmL) before the enzyme or sample (0.2mL), after which the tubes were 
mixed, incubated at 37°C for S min, centrifuged and the 00 of the supernatant 
measured. 
4.2.6 Pepsin Purity 
Pepsin purity was assessed by SOS-PAGE (as described elsewhere) and by ion-
exchange chromatography. The proportion of active material was assessed by passing 
lOO mg of pepsin through a Mono Q HR anion exchange column equilibrated with 
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20mM piperazine, 10mM NaCl, pH5.0 and eluted with 20mM piperazine, 1M NaCI, 
pH4.75, collecting the fractions and determining their concentrations by OD at 280nm 
using an extinction coefficient for a 1 mglmL solution (tcm path) of 1.47 (Knowles et 
al., 1969). These were then adjusted to pH 2.4 and assayed for pepsin activity. 
4.2.7 Pepsin Inactivation 
Pepsin (50 or 100 mg/mL respectively) was diluted 10 - fold with the appropriate pH 
inactivation saline buffer (50mM Tris, pH 9.0; 50mM Tris, pH 8.0; 100mM 
phosphate, pH 7.0; 100mM citrate, pH 6.0; 100mM citrate, pH 5.0) and incubated at 
37°C for 2 hr before either diluting 1 in 50 with 50 mM KCI, pH 2.4 (Clark and Lubs 
solution) buffer and measuring enzyme activity as described above or diluting 1 in 10 
with pH 3.5 citrate buffered saline, centrifuging and measuring the OD at 280nm to 
determine the amount of precipitated material. 
4.2.8 The Effect of High pH on Pepsin Digested Material 
The effect of high pH on pepsin digested material was assessed by raising the pH to 
7.5, 8.0 or 9.0 with 0.5 M Tris base and incubating for 2 or 24hr at 37°C before 
adjusting the pH to 4.0 with 0.4 M HCI, centrifuging or filtering and running on a 
Superose 12 column in pH 4.0 citrate buffered saline. 
4.2.9 Diafiltration 
Low molecular weight digestion products were removed by ultrafiltration using 
Vivaspin (Sartorius, Goettingen, Germany) 2 mL centrifuge concentrators with 30 
kDa molecular weight cut off polyethersulfone membranes. Large volumes of up to 1 
L were processed using Sartocon-Micro cross flow units (Sartorius, Goettingen, 
Germany) as described in Chapter 2 by washing with 10 volumes of buffer. 
4.2.10 Anion-Exchange Chromatography 
Anion-exchange separations were performed using either a prepacked Mono Q HR 
10/10 column or 50 mL of Q Sepharose Fast Flow with a 10cm bed height in a XK26 
column (Pharmacia, Upsala, Sweden), equilibrated and run with piperazine buffer (20 
mM) containing 150 mM NaCI, pH 6.0. Elution was performed with a gradient of the 
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same buffer containing 2M NaCl. Flow rates of 5mLlmin were used. 
4.2.11 SDS-PAOE 
SDS-PAOE gels were prepared as described in Chapter 2, to monitor the digestion 
components. 
4.2.12 Size Exclusion Chromatography 
Size exclusion chromatography was performed using a FPLC system as described in 
Chapter 2, with columns comprising a cross linked agarose medium (Superose 12 or 
Superose 6 HR 10/30, volume 25 mL). 
4.2.13 Serum Titre Estimation 
Antibody titres directed against the venom were determined by ELISA as described in 
Chapter 2 using an affinity - purified (horse radish peroxidase conjugated) rabbit anti-
sheep F(ab')2 second antibody at a 1 in 2,500 dilution. 
4.3 Results 
4.3.1 The Effects of Trypsin on IgO and Serum 
A ratio of trypsin to substrate of 1 :50 rapidly digested all the IgO to F(ab~2 after just 
30 min. There was further digestion with time until only trace amounts of F(ab~2 
remained after 72 hr (Figure 4.la). Albumin in the whole serum digests was rapidly 
cleaved after just 30 min to a band of - 44 kDa. However, this partially digested 
fragment appeared highly resistant to further proteolysis and was still intact after 72 
hr, by which time the F(ab')2 had been completely broken down (Figure 4.1b). 
4.3.2 Pepsin Purity 
Three grades of pepsin were compared by SDS-PAOE under non-reducing conditions 
and were all shown to consist primarily of a single band representing pepsin A with a 
MW of - 38 kDa (Figure 4.2). Pepsin A (EC 3.4.23.1) is the predominant aspartic 
endopeptidase found in the gastric juice of vertebrates. Commercial grade 
preparations can also contain gastricsin (pepsin C, EC 3.4.23.3) and a minor 
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Figure 4.1 Trypsin digestions as assessed by SDS-PAGE (7.5%). The effects of 
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Figure 4.2 An analysis of different grades of pepsin by SDS-PAGE (12%). Merck 
European Pharmacopoeia grade, 200 & 100llg (lanes 2 & 3) respectively. Sigma 
1 :60,000 grade, (lanes 4 & 5), and Sigma highest grade, (lanes 6 & 7), 5 & 2.51lg per 
lane respectively. Under non-reducing (a) and reducing (b) conditions. 
96 
component called pig gelatinase (pepsin B, EC 3.4.23.2) which have more restricted 
specificities. 
Under these SDS-P AGE conditions both pepsin B and C have been shown in the 
literature to be clearly resolved from pepsin A (Nielsen & Foltmann, 1995). No bands 
could be detected which may have represented these enzymes. 
The Merck European Phannacopoeia grade material also contained a large amount of 
low MW material which ran at the solvent front and was undetectable in either of the 
Sigma products. 
Under reducing conditions (Figure 4.2), by comparison, the band representing pepsin 
A was resolved as two bands of almost identical size with a MW of - 40 kDa. Pepsin 
A is known to have a MW of 34,586Da by mass spectrometry (Jones et ai., 1995) and 
this was, therefore, unexpected and may have resulted from the poor incorporation of 
SDS due to the highly acidic nature of pepsin. 
4.3.3 Pepsin Activity 
When 100mg dry weight of pepsin (Sigma 1:60,000 grade) was applied to a Mono Q 
anion exchange column the unbound and bound fractions contained 7.3 mg and 50.2 
mg by OD respectively. A standard curve of pepsin's enzymatic activity measured 
using a haemoglobin substrate produced similar results on three different days and 
was used to calculate the activities of the eluted material (Figure 4.3). No enzymatic 
activity could be detected in the unbound fraction and, because the minimum 
detectable level of the assay (mean + 2 SD of 10 zero replicates) was 1 mg/L, this 
fraction contained ~ 0.02% of the original activity. The majority of the inactive 
material is thought to result from auto digestion during the manufacturing process, 
cell debris and/or mucosaccharides (not detected at 280nm) from the stomach mucosa 
(Rajagopalan et al., 1966; Hristova, 1968). All the active enzyme was found in the 
bound fraction which contained 100% of the original enzymatic activity. 
4.3.4 The Effects of pH on Pepsin Digestion 
4.3.4.1 IgG 
At pH 5.0, no digestion products of IgO could be detected until after 8 hr (data not 
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Figure 4.3 Pepsin (Sigma 1 :60,000 grade) enzymatic assay standard curve using 
haemoglobin as substrate. Mean ±SD (n=3) 
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a large but incomplete proportion of the IgG digested after 72 hr to a band of - 90 
kDa, presumably representing F(ab')2 (Figure 4.4). Digestion at pH 4.0 proceeded 
more rapidly and after 72 hr no IgG starting material could be detected and a similar 
picture emerged after just 2 hr at pH 3.5. After 72 hr at pH 3.5 a slight band of - half 
the size of the F(ab')2 could be seen which presumably represented the further 
breakdown of the F(ab')2 to Fab'. At pH 3.0 all the IgG starting material had been 
broken down after just 0.5 hr and a progressive decrease in the intensity of the F(ab')2 
band was seen with time. 
A slight band of - 52 kDa could also be detected after 8 hr at pH 4.5 and may 
represent intact Fc. This band was also present for the first 2 hr of digestion at pH 4.0, 
although it must have been rapidly degraded as it could not be detected after this time 
or in lower pH digests. 
Because of differences in the estimated molecular weight of certain proteins under 
non-reducing conditions compared to their known MW, some samples were re-tested 
under reducing conditions in order to calculate their correct MW for identification 
purposes. Serum proteins were identified as transferrin (82kDa), albumin (67kDa), 
and IgG heavy chain (54kDa) or light chain (27-28kDa). 
4.3.4.2 Serum 
The pool of undiluted ovine antisera had a protein concentration of 95 gIL by BeA 
protein assay. The digestion process was easily followed using SDS-P AGE under 
non-reducing conditions (Figure 4.5). Minimal serum digestion was seen after 72 
hours at pH 5.0, but a minor band which was slightly larger than albumin and thought 
to represent ovine transferrin, was rapidly digested after 2 hr (data not shown). At pH 
4.5 a large but incomplete proportion of the JgG band was digested after 72 hr to a 
band of - 90 kDa presumably representing F(ab')2' while albumin was only partially 
digested. Digestion intermediates were also seen over the first 24 hr with bands from 
_ 45 kDa and smaller, the larger of which appeared to be digested to form lower 
molecular weight bands with time until, at 72 hr, only small peptides existed which 
ran at the electrophoresis front. At pH 4.0 the intact albumin was undetectable after 72 
hr and the intermediates were once again seen during the early stages of the digestion 



















Figure 4.4 The effect of pH on the pepsin digestion of IgG, as assessed by SDS-
PAGE (7.5%). Digestion samples at Ohr (lane 2), 0.5hr (lane 3), 2hr (lane 4), 8hr (lane 
5), 24hr (lane 6), 72hr (lane 7), and molecular weight markers (lanes 1 & 8), 205, 116, 

















Figure 4.5 The effect of pH on the pepsin digestion of serum, as assessed by SDS-
PAGE (7.5%). Digestion samples at Ohr (lane 2), 0.5hr (lane 3), 2hr (lane 4), 8hr (lane 
5), 24hr (lane 6), 72hr (lane 7), and molecular weight markers (lanes 1 & 8), 205, 116, 
97, 84, 66, 55, 45 and 36kDa. 
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at pH 3.5 resulted in the complete elimination of both the albumin and transferrin 
bands after only 0.5 hr and intact IgG was undetectable after 2 hr. An albumin 
breakdown product was seen as a band just above the electrophoresis front in the 0.5 _ 
8 hr samples and was found to have a molecular weight of ~ 43 kDa when re-tested on 
a 12% acrylamide gel under reducing conditions (data not shown), which is similar to 
the reported 46kDa human serum albumin fragment produced by pepsin (Bos et al., 
1988). At 24 hr only a F(ab')2 band and very low molecular weight material were 
evident. However, at 72 hr a slight shadow appeared of ~ half the size of the F(ab')2 
representing the further digestion of the F(ab')2 to Fab'. At pH 3.0 both intact albumin 
and IgG were undetectable after just 0.5 hr and only F(ab')2 material was evident. The 
F(ab')2 band, however, appeared to decrease in intensity with time and again a slight 
band appeared of ~ half its size after 24 hr. 
4.3.5 Effects of Digestion on Antigen Binding 
Apparent venom binding activity was measured by an ELISA system using an affinity 
purified second antibody raised specifically against sheep F(ab')2' Samples had 
increased specific titres after the first 30 min of digestion except the pH 3.0 digests 
which showed a progressive decrease in titre from 1: 18,000 for the antisera starting 
material to 1 :7,600 (Figure 4.6). Digests at pH 3.25, and 3.5 displayed an increase in 
titre over the first 8 hours to ~ 1 :28,000 but after this time diverged, so that the lower 
pH digests demonstrated a greater loss of activity with time (e.g. at 72 hr, pH 3.25 
digest had a titre of 1: 12,700). 
4.3.6 The Effect of Post Digestion pH on Soluble Aggregate Formation 
A range of different pH buffers were used to equilibrate a Superose 12 size exclusion 
chromatography column. 
4.3.6.1 IgG digests 
When the JgG digest was run on a size exclusion chromatography column equilibrated 
with pH 4.0 buffer, two major peaks were evident, the first representing the F(ab')2 
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Figure 4.6 The effect of antiserum digestion on ELISA titre. pH 3.5 C"), 3 .25 
(.6.), and 3.0 ~. 
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was followed by several lower molecular weight minor peaks « 8 kDa) (Figure 4.7). 
When the digest was run at pH 5.0 a similar profile was observed, except some of the 
minor low molecular weight peaks appeared closer to the second major peak. 
However, when the pH of the digest was adjusted to pH 6.0, 7.0 and 8.0 a small but 
notable and increasing amount of relatively high molecular weight material was eluted 
first from the column, with a large proportion apparent in the void volume (e.g. ~ -
2,000 kDa). This was confmned by repeating the run on a Superose 6 column which 
showed that the peak was spread over a very high and wide molecular weight range 
which stretched back as far as the F(ab')2 peak. 
There also appeared to be changes in some of the lower molecular weight peaks as the 
pH was changed, which may represent the aggregation process. 
This relatively high molecular weight material was not observed by SDS-PAGE 
(Figure 4.4) which implies that it consists of aggregated low molecular weight 
fragments ofFc. 
4.3.6.2 Serum digests 
A similar picture was seen with the serum digests except that there were more low 
molecular weight peaks present at pH 4.0 and a new peak was evident between the 
two major peaks with a retention time that gave it a molecular weight of - 13 kDa 
indicating that this fragment is formed from the digestion of a non-IgG component 
(Figure 4.8). When the digest was run at pH 5.0 a similar profile was observed, except 
some of the minor low molecular weight peaks again appeared closer to the second 
major peak. However, when the pH of digests was adjusted to pH 6.0, 7.0 and 8.0 a 
small but notable and increasing amount of relatively high molecular weight material 
was eluted first from the column, with a large proportion apparent in the void volume 
(e.g. ~ - 2,000 kDa). This was confirmed by repeating the run on a Superose 6 
column which showed that the peak was spread over a very high and wide molecular 
weight range which stretched back as far as the F(ab')2 peak. A larger proportion of 
this high molecular weight component was seen compared to IgG digests, indicating 
that non IgG fragments also contribute to this peak. 
There also appeared to be changes in some of the lower molecular weight peaks as the 
pH was changed, which may represent the aggregation process. 
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Figure 4.7 The effect of pH after IgG digestion on soluble aggregate formation as 
assessed by size exclusion chromatography. 
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Figure 4.8 The effect of pH after serum digestion on soluble aggregate formation 
as assessed by size exclusion chromatography. 
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This relatively high molecular weight material was not observed by SDS-PAGE 
(Figure 4.5) which again implies that it consists of aggregated low molecular weight 
Fc and non IgG fragments. 
When this peak was collected and run again at pH 8 it appeared as a single high MW 
peak without any low MW material. However, when the pH of this high MW material 
was adjusted to 4.0 and run on the column equilibrated with pH 4.0 buffer, the high 
MW peak was no longer found and only low MW peaks were seen, representing the 
disaggregation of the digestion fragments. 
4.3.7 Pepsin Inactivation 
A pH of 7.0 or higher produced a complete irreversible inactivation of the pepsin 
activity, while pH 5.0 and 6.0 had little or no effect (Table 4.1). However, further 
experiments using much higher pepsin concentrations indicated that a small amount of 
active pepsin was still present after the pH 7.0 treatment (2hr at 37°C) and that pH 8.0 
or higher was required to fully inactivate the material (Table 4.1). 
4.3.8 Precipitation ofInactivated Pepsin 
It was noticed during initial pepsin inactivation experiments that at high pH solutions 
of inactivated pepsin remained crystal clear, but became intensely cloudy when the pH 
was adjusted to 3.5. An experiment was, therefore, performed to assess the 
precipitation of pH denatured pepsin as a potential pepsin removal step. By measuring 
the OD at 280nm of the supernatant after centrifugation, it was calculated that up to 
76% by OD of the original pepsin was precipitated (Table 4.1). The remaining 24% in 
solution may represent impurities and pepsin fragments. 
4.3.9 Effects of High pH on IgG and Serum Digests. 
Unfortunately exposure of digests to pH 8.0 for 2 or more hr at 37°C to inactivate the 
pepsin resulted in the formation of a new peak of ~ 50kDa when assessed by size 
exclusion chromatography which corresponded with a decrease in the F(ab')2 peak. 
This new material could just be detected as a shoulder on the F(ab')2 peak after 2 hr 
and was clearly evident after 24 hr, and was assumed to represent the breakdown of 
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pH Treatment (2 hr, 37°C) 
5.0 6.0 7.0 7.5 8.0 8.5 9.0 
Residual enzymatic 
activity: 
100mg/L Pepsin 1.332 1.216 0.004 nd 0.007 nd 0.027 
25g/L Pepsin nd nd 0.111 0.074 0.012 0.010 -0.001 
Precipitation on 
adjustment to pH 3.5: 
19/L Pepsin 1.090 1.051 0.265 nd 0.239 nd 0.383 
Table 4.1 
(280nm). 
Effects of pH on pepsin. Results expressed in terms of supernatant OD 
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F(ab')2 (Figure 4.9). 
4.3.10 The Minimum pH Required to Stop Pepsin Activity 
Serum samples adjusted to between pH 5.2 and 6.0 were assessed for digestion 
products by SDS-PAGE after incubation with pepsin (1:50) at 37°C for either 3 or 7 
days (Figure 4.10). The transferrin band just above the unaffected albumin band in the 
pH matched controls was not found in any of the pepsin treated samples indicating 
that it is highly susceptible to pepsin cleavage. The IgG band had clearly been 
partially digested at the lower pH's and at 5.5 only a slight reduction in the intensity 
of this band was seen. At pH 6.0 the IgG band appeared identical at 3 and 7 days. 
Because of the detrimental effects on the product of fully denaturing all the pepsin to 
a permanently inactive state by high pH alone it was decided to process the digest at a 
pH where pepsin has minimal activity (e.g. pH 6.0). 
4.3.11 Effects of Salt Concentration on High Molecular Weight Aggregate 
Serum digestions were routinely terminated by adding sufficient 50mM piperazine 
solution to raise the pH to 6.0 and the precipitate formed during digestion removed by 
centrifugation or filtration. When buffer containing 150mM NaCI was used to wash 
the precipitate in order to reduce any losses it was noticed that a larger amount of high 
molecular weight aggregate was seen in the digested material by size exclusion 
chromatography at pH 8.0. The effects of the salt concentration on soluble aggregates 
was, therefore, investigated. 
It was assumed that serum contained 154mM NaCI and any dilution factors were 
taken into account. The concentration of NaCI in the crude unfiltered digest was 
adjusted by the addition of various ratios of high salt buffer (2M NaCI, 20mM 
piperazine, pH 6.0), mixed and filtered before diluting and running on a size exclusion 
chromatography column at pH 8.0 (Figure 4.11). Control digests that were filtered 
without adjusting the level ofNaCI or those in which the level was further reduced by 
diluting with an equal volume of distilled water both contained a similar very low 
level of high molecular weight aggregate as assessed at pH 8.0. However when the 
salt level was increased to 0.2 or O.4M a progressively increased amount of the high 











Figure 4.9 Effects of pH 8.0 treatment on a serum digest. Without treatment (a), or 
adjusted to pH 8.0 and incubated at 37°C for 2 hr (b), or 24 hr (c). Size exclusion 
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Figure 4.10 The minimum pH required to stop pepsin activity. Serum incubated 
(37°C) at pH 5.2,5.3,5 .5 and 6.0 without pepsin (lanes 1-4), and with pepsin (lanes 5-
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Figure 4.11 Effects of salt concentration on levels of high molecular weight 
aggregate. Crude digest material (pH6.0), with no extra NaCI added (a), or NaCI 
added to give a concentration of O.2M (b), or OAM (c), before filtration. Size 
exclusion chromatography on a Superose 12 column, in Tris/saline pHS.O buffer. 
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soluble high molecular weight aggregate material is unstable and precipitates at low 
salt concentrations and is then easily removed by centrifugation or filtration. For these 
reasons no extra salt was added to the serum digests until after they were centrifuged 
or filtered to remove the precipitate formed during the digestion. Following this work 
a low salt solution was used to wash the precipitate in order to reduce any losses. 
4.3.12 Diafiltration 
Cross flow diafiltration of the digested material with 10 volumes of buffer could 
easily be performed at pH 6.0 without any significant fouling of the membrane by 
precipitated material unlike at a lower pH. All the material with a lower molecular 
weight than the F(ab')2 as assessed by size exclusion chromatography at pH 8.0 passed 
through the ultrafilter to waste, leaving principally F( ab')2 and a small quantity of high 
molecular weight aggregate (Figure 4.12). The amount of protein material was 
assessed by OD(280nrn) and yields calculated. A 50kDa ultrafilter gave yields of 13.2 
and 14.5gIL of serum for serum batch I and II respectively, while a 30kDa ultrafilter 
produced yields of 17.7 and 21.9g/L respectively. Therefore the 30kDa ultrafilter 
increased yields by ..... 30% compared to a SOkDa membrane despite producing 
products of the same purity. 
4.3 .13 Ion-Exchange Chromatography 
4.3.13.1 Preparative scale (Q Sepharose FF) 
Diafiltered digests in 20mM piperazine, lS0mM NaCI, pH 6.0 were separated into 3 
peaks by anion exchange chromatography with a salt gradient (Figure 4.13). The first, 
which passed straight through the column and constituted ..... 90% of the material, 
contained the F(ab')2' The second peak eluted in ..... 0.2SM NaCI and contained the high 
molecular weight aggregate material as assessed by size exclusion chromatography. 
The third peak eluted in ..... O.5M NaCI and contained the pepsin (see below). The 
material from the fIrst peak was then concentrated with a 30kDa MWCO ultrafilter 
and gave a final yield of 19.3g F(ab')2 / L of serum. It was free from high molecular 








Figure 4.12 The removal of low molecular weight fragments by diafiltration. Serum 
digest before (a), and after diafiltration (b), using a 30K MWCO cross flow ultrafilter 
and 20mM piperazine, 150mM NaCI, pH6.0. As assessed by size exclusion 








100 . 0 Buffer B 
0 . 90 
0 .
801 
0 , 70 75 . 0 , 
0 ,60 
0.50 
50 . 0 
0. 40 




I <1 7 10 14 18 22 26 )0 J ~ 38 42 46 
,flU 
4,00 
' . , 
PK III .,,, 
PK fl I. ~o 
1.00 
O.lO'}---I-____ ---\--__________ ________ 
O.OOJ . 
- 0 . 10 
00 : 00 : 00 01 : 0'0: 00 
High Molecular 
Weight Aggregate 
Hr:Hin : Sec 
Time 
. ;" o 
02 : 0'0 : 00 
0,'0 
0,00 
-0 . 50 
mS/cm 
Figure 4.13 Removal of high molecular weight aggregate and pepsin by anion 
exchange chromatography. Q-Sepharose FF ion exchange separation of a diafiItered 
pepsin digested antiserum (a). Peak I, F(ab')2' II high molecular weight aggregate, and 











Figure 4.14 Removal of high molecu!ar weight aggregate by anion-exchange 
chromatography. A diafiltered serum dIgest before (a), and after ion-exchange 
chromatography (b). As assessed by size exclusion chromatography (Superose 12, 
Tris/saline pH8.0). 
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4.3.13.2 Analytical scale (Mono Q) 
A high resolution Mono Q HR column was used to check that all the highly acidic 
components (pepsin and high molecular weight aggregates) had been removed. The 
Sigma 1 :60,000 grade pepsin used in these studies contained two peaks, the smaller 
first peak passed straight through the column and consisted of impurities and a second 
well defined sharp peak which eluted in -O.5M NaCI containing the pepsin. Since 
1.9g of pepsin was added to each litre of antisera, from which 19.3g of the final 
F(ab')2 product was produced, if no pepsin was lost during the processing the product 
would contain 10% pepsin. For these reasons O.2mg of pepsin was compared with 2 
mg ofF(ab')2 preparations (Figure 4.15). Serum digests diafiltered using either a 30 or 
50kDa MWCO ultrafilter still contained large, roughly equivalent, amounts of pepsin 
along with an extra peak which eluted with - 0.2SM NaCI and represented the high 
molecular weight aggregate component. Pepsin was undetectable in the final F(ab')2 
product and none of the final product material was bound by the column indicating 
that it was free from highly acidic components, such as the high molecular weight 
aggregate. 
4.3.14 Processing Yields. 
Two different batches of antisera were processed by identical methods and the yields 
calculated (Figure 4.16). Lower yields were evident from antiserum I compared to 
antiserum II. 
4.3.15 A Comparison of Purity with Commercially Available Antivenoms. 
Size exclusion chromatography of a commercially available antivenom (CSL tiger 
snake) at pH 8.0 revealed the presence of a small quantity of high molecular weight 
material. However, when this was repeated under low pH (4.0) conditions the high 
molecular weight component could no longer be seen (Figure 4.17). This anti venom 
also contained a small peak with a molecular weight of - 280kDa. SDS-PAGE 
analysis of this antivenom showed that it along with other commercial antivenoms 
contained trace amounts of high molecular weight (>205kDa) and low molecular 
weight (-36kDa) components but were free from undigested IgG (Figure 4.18). An 
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Figure 4.15 Residual pepsin as determined with an analytical Mono Q 
chro~atography column. Pepsin (~ .2mg) ~ontr~1 (a), or 2mg of each of the following: 
Pepsm digested serum foIlowing dIafiltratlon wIth a 50kDa MWCO ultrafilter (b), or a 
30kDa MWCO ultrafilter (c), or foIlowing diafiltration (30kDa MWCO) plus ion-
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Figure 4.16 The effect of process on yield. Using 50kDa and 30kDa MWCO 
ultrafilters or diafiltration + ion-exchange chromatography. Serum batch I (hatched 
bars), or II (open bars). 
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Figure 4.17 Size exclusion chromatography of a commercially available antivenom. 
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Figure 4.18 Antivenom purity by SDS-PAGE (7.5%, non-reducing). Ovine F(ab')2 
(lanes 2 & 3), CSL Tiger Snake antivenom (lanes 4 & 5), Behring Europe antivenom 
(lanes 6 & 7), 20 and I O~g respectively and molecular weight markers (lanes I & 8). 
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less impurities and the F(ab')2 was of a slightly smaller size than the equine F(ab')2' 
which is in agreement with calculations from size exclusion chromatography. The 
main impurity in the ovine material had a molecular weight of - 56kDa which was 
also found in one of the other antivenoms. 
4.4 Discussion 
The production of antitoxins for therapeutic use must ideally result in a 'highly pure' 
immunoglobulin fragment, without any Fc or other contaminating proteins or 
aggregates which may lead to side effects. 
Sheep IgG (IgG 1 and IgG2) was found by Davies et al. (1978) to be rapidly digested 
by trypsin to F(abt)2 but only slowly by pepsin at pH 4.7 with residual IgG still intact 
after 48 h at 37°e. We are unaware of any subsequent reports of the digestion of sheep 
IgG (or serum) by these enzymes. 
Although trypsin was confirmed to be highly effective at digesting purified sheep IgG 
in these studies, when tested on whole serum it was found to preferentially digest the 
F(abt)2 rather than a highly resistant fragment of albumin, making it unsuitable as a 
digestion enzyme for antitoxin production from antisera directly. 
Similar to other groups investigating the pepsin digestion of IgG from sheep or other 
species, we also found that the Fc portion was rapidly broken down into low 
molecular weight fragments at pH 4 or below. At pH 4.5, low levels of protein of a 
size similar to intact Fc could be seen in the early stages of digestion. After a 
prolonged digestion, especially at pH 3.0, Fab' was seen as noted by Haber and Stone 
(1967) using rabbit antibody at pH 2.5. Therefore control of the digestion time was an 
important factor for the complete digestion of the material without loss ofF(ab')2' 
Studies of the pepsin digestion of whole ovine serum showed that ovine F(ab')2 is 
markedly more resistant to digestion by pepsin at a pH of 3.5 than the other serum 
proteins, allowing their breakdown without any substantial loss of F(ab')2 or of its 
ability to bind antigen following up to 24 hr digestion. Digestions were, therefore, 
subsequently performed for between 14-24 hr at pH 3.5. Large increases in ELISA 
titre seen in the first hour of digestion are most likely due to the exposure of a part of 
the F(ab')2 around the hinge region previously masked by the Fc domain allowing the 
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labelled second antibody to recognise the entire molecule and, therefore, represent an 
artefact of the assay system (Carrico et al., 1974). 
It is common practice when performing pepsin digestions to terminate the reaction by 
inactivating the enzyme with alkali to pH 7.4 - 8.0 (Hudson & Hay, 1989; Stanworth 
& Turner, 1978; Lin et al., 1993). When high concentrations of pepsin were used, a 
pH of~ 8.0 was required to permanently inactivate all the enzyme after 2 hr at 37°C. 
Unfortunately if the pH of serum or IgG digests was raised to ~ 8.0 for 2hr or more at 
37°C to inactivate the enzyme, a large amount of a new product was formed with a 
molecular weight of - 50kDa which appeared to represent the breakdown of F(ab')2 to 
Fab by an unknown mechanism. Because of the high pH required to denature all the 
pepsin irreversibly to an inactive form and the detrimental effects of these conditions 
on the F(ab')2' this approach was abandoned in favour of stopping the digestion using 
conditions under which pepsin had little or no enzymatic action, e.g. pH 6.0-7.0, and 
then physically removing the pepsin from the product. 
It was discovered during the course of these studies that after an optimal digestion at 
pH 3.5 a small proportion of the low molecular weight digestion products aggregated 
or polymerised to form high molecular weight components at pH 6.0 - 8.0 as assessed 
by size exclusion chromatography. These soluble high molecular weight aggregates 
were found in both IgG and serum digests but with a larger proportion in serum 
digests, indicating that they consist of aggregated small fragments of both Fc and non 
IgG material. Aggregation could not be observed with the SDS-PAGE technique 
which is presumably due to the anionic detergent (SDS) causing the dissociation of 
any aggregated protein. Therefore, the ability to run a size exclusion chromatography 
column over a wide range of pH has allowed a useful insight into the aggregation 
process seen after a digestion, and allowed a process to be devised which removes 
these troublesome components. 
Although aggregates and complement activation have been implicated in adverse 
reactions to antivenom, the exact cause remains elusive. However, numerous studies 
have been performed to elucidate the cause of human intravenous IgG reactions. 
Different types of aggregates have been shown to either cause complement activation 
or produce a hypotensive response in a rat model which results from the activation of 
phagocytes via Fc receptors (Bleeker et al., 1987; 1989; 2000). It has also been shown 
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by Lobatto et al. (1987) that small quantities (lOJ.1g/kg body weight) of soluble IgO 
aggregates experimentally injected i.v. in man are rapidly cleared (tJI2' 26min) from 
the circulation predominantly via the liver. Thus it now appears likely that reactions to 
human IgO may be due to the release of inflammatory mediators caused 
predominantly by phagocyte activation in the liver through the interaction of IgO 
dimers or aggregates with Fc receptors (Bleeker et al., 1987; 1989; 2000; Lobatto et 
al., 1987; Jenei et al., 1991; Sylvestre et al., 1996). It is conceivable that aggregated 
animal Fc fragments found in varying concentrations in antivenoms could produce 
similar effects. Some antivenoms are potent activators of the complement system 
which may be linked to their aggregate concentration. However, clinical studies have 
failed to find evidence of in vivo complement activation following anti venom 
treatment indicating that the amounts used are insufficient to result in a measurable 
effect (Sutherland, 1977; Malasit et al., 1986; Waldesbuhl et al., 1970; Ramasamy et 
al., 1997). Therefore, it seems unlikely that complement activation alone could 
account for the clinical reactions produced by antivenoms. A combination of these 
effects may, however, be responsible for the non IgE mediated reactions produced by 
i.v. antivenom administration. 
European Pharmacopoeia guidelines outline the use of size exclusion chromatography 
to measure aggregate / polymer levels in human intravenous immunoglobulin 
preparations, which should represent not more than 3% of the total area of the 
chromatogram, and also stipulate that anticomplementary activity should be less than 
1 CH50 per mg of immunoglobulin (European Pharmacopoeia, 1997). 
If the salt concentration of the digest was reduced to ~ 60mM NaCI by dilution, it was 
found that a large proportion of the aggregating material became unstable, 
precipitated, and was then easily removed by centrifugation or filtration. This 
reduction in the amount of aggregating material helped in its elimination, as 
diafiltration at pH6.0 was ineffective in this respect. 
Following the preliminary results it seemed logical to utilise a purification step such 
as diafiltration which takes advantage of the large difference in size between the 
unwanted non-aggregated low molecular weight fragments and the F(ab')2' found in 
the pepsin-digested serum. Because of results showing that the crude digest was free 
from high molecular weight aggregates at a low pH, attempts at diafiltration were 
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initially successfully performed at this pH on a small scale using 30kDa MWCO 
centrifuge concentrator units at 4-8°C. However, because of residual pepsin activity 
and the unstable nature of some of the fragments, attempts to process larger quantities 
of material using a cross flow ultrafilter at RT over several hours were unsuccessful , 
as a large amount of precipitate was formed which rapidly clogged the membrane. A 
range of progressively higher pH conditions were tested and eventually pH 6.0 was 
adopted at which the enzyme is virtually inactive and at which the cross flow 
ultrafiltration could be performed unhindered with minimal precipitate formed during 
the course of diafiltration. High yields of F(ab')2 were produced with a membrane of 
the correct pore size (30kDa MWCO) under these conditions, but 34% extra losses 
were produced when a 50kDa MWCO membrane was used. This is particularly 
relevant in the large scale production of therapeutic products where cross flow 
ultrafiltration units are routinely used. Smaller bench scale volumes «20mL) could 
also be processed easily using the centrifugal concentrator units. 
Unfortunately diafiltration was found to be particularly ineffective at removing pepsin 
even when a 50kDa MWCO ultrafilter was used, which may reflect pepsin's ability to 
bind or form complexes with the digestion products (Ryle & Porter, 1959). 
Although the material purified by digestion and diafiltration alone was reasonably 
pure (94% by size exclusion chromatography) and in high yield (21.9g/L serum), a 
further ion exchange step was developed to remove the highly acidic contaminants 
(pepsin and residual aggregated material). 
Because of the exceptionally low (2.2) isoelectric point of pepsin (Jonsson, 1972), it 
will bind to an anion exchange matrix in the presence of 150mM NaCI at pH 6.0. 
Since this pH is below the isoelectric range for most of the F(ab')2 these fragments 
passed straight through the column at this salt concentration. Just as importantly, other 
acidic residual fragments including the high molecular weight aggregates were also 
bound to the column under this concentration and were removed. 
A new commercial process recently introduced by A ventis-Pasteur utilises two ion 
exchange steps to improve the potency, purity and safety (4% side effects) of its 
equine based pepsin digested products, removing the majority of both the low 
molecular weight contaminants and the high molecular weight aggregates previously 
found (Grandgeorge et al., 1996; Pepin-Covatta et al., 1997; Chippaux et al., 1999). 
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This anion exchange step was, therefore, used as a final step to remove any residual 
aggregating fragments and pepsin, and resulted in a product of over 96% purity (by 
size exclusion chromatography) and a yield of 19.3g F(ab')2 / L serum. These yields 
compare favourably with the 6-14g F(ab')2 I L equine plasma reported by Benanchi et 
al. (1988) and the 97% (F(ab')2 + Fab') purity by size exclusion chromatography 
described by Grandgeorge et al. (1996) for the new Aventis-Pasteur antivenom, and 
87% for the old IPSER Europe antivenom. 
As well as producing a highly refined F(ab')2 at high yield, the new method also 
avoids any salt precipitation steps which are time consuming; difficult to perform on a 
large scale under sterile conditions; and may result in large (~18%) losses and the 
formation of aggregates (Schultze et al., 1965; Friesen, 1987). 
To summarise, a new simple high yield method of processing serum to a highly pure 
F(ab')2 was developed which should be suitable for the large scale production of 
therapeutic antibody fragments. This consisted of: 
i) Adjusting the pH of sheep antiserum to 3.5 with 0.36 M HCl. 
ii) Adding pepsin at an enzyme to substrate ratio of 45.2 U/mg substrate (1 :50 w/w) 
and incubating at 37°C for 14 - 18 hr. 
iii) Stopping the digestion by adjusting the pH to 6.0 with 50mM piperazine and 
removing the resulting precipitate by centrifugation or filtration. 
iv) Diafiltration (washing) with at least 10 volumes of piperazine buffer (20mM 
piperazine, 150mM NaCl, pH 6.0) using a 30 kDa molecular weight cut off 
membrane. 
v) Passing the material through an anion exchange column (Q Sepharose FF) 
equilibrated with the piperazine buffer. 
vi) Concentration and formulation. 
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CHAPTERS: 
LATRODECTUS VENOM AND THE DEVELOPMENT OF A NEW 
ANTIVENOM 
5.1 Introduction 
Spiders of the genus Latrodectus are distributed widely across the World and there are 
four major species of 'black widow' spiders found in the United States: Latrodectus 
hesperus, La.mactans, La. variolus and La.geometricus. About 2,500 bites by this 
genus are reported each year to the US poison control centres, which probably 
represents a considerable underestimate of the true number (Litovitz et at., 1991 _ 
2000). 
Poisoning caused by the bite of this spider can run a serious and dramatic course, 
although the victims' lives are not generally in danger. Nonetheless, before the 
introduction of antivenom therapy, and partly due to the underreporting of less severe 
cases, the mortality rate was estimated at 5% (Ingram & Musgrave, 1933). 
A variety of signs and symptoms have been noted but principally consist of agonising 
and often unbearable pain both locally and in parts remote from the bite site, cramping 
pain or spasms, muscular stiffness, sweating, lacrimation, bronchitis, rhinitis, 
hypertension, tachycardia, bradycardia, nausea and vomiting, erythema, oedema, and 
'pins and needles'. The most severe effects usually start to dissipate after about 24 to 
36 hours, but a full recovery is often protracted and may take up to four weeks 
(Maretic & Stanic, 1954; Southcott, 1976; Banham et at., 1994; White et at., 1995). 
All the effects of envenoming are thought to be produced by a 130 kDa molecular 
weight venom component called a.-Iatrotoxin which comprises ~ 3 - 6% of the venom 
and specifically binds with high affinity (Kd ~ 10-10M) to the cell surface proteins, 
latrophilin and neurexin, found on presynaptic neuronal membranes and, thereby, 
stimulates release of neurotransmitters and peptides from neuronal and endocrine cells 
(Grasso, 1976; Gorio et at., 1978; Scheer & Meldolesi, 1985; Meldolesi et al., 1986; 
Rosenthal & Meldolesi, 1989; Grasso & Mastrogiacoma, 1992; Pashkov et at., 1993; 
Grishin, 1998; Lang et at., 1998; Liu & Misler, 1998). This is thought to be brought 
about by modulation of the secretory machinery by the toxin bound receptor causing 
an enhancement of the depolarisation-evoked secretion as well as spontaneous release 
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(Liu & Misler, 1998; Rahman et al., 1999; Saibil, 2000). Recent results using cryo-
electron microscopy have shown that, in a solution containing Ca2+ or Mg2+, the toxin 
forms active tetramers at concentrations above O.3nM (39,...g/L) with an axial channel 
and, using their hydophobic base, can insert into lipid bilayers containing the receptor 
protein to form a pore allowing the influx of calcium ions and the efflux of 
neurotransmitters (Ashton et al., 2000; Orlova et al., 2000; Volynski et al., 2000). 
Treatment of latrodectism is principally directed at relieving the severe pain using 
narcotic analgesics or antivenom, but no large scale controlled studies have been 
performed to determine their relative efficacy (Miller, 1992). Consequently, therapy in 
the United States as elsewhere, has evolved largely from anecdotal experience with 
relatively few patients. Other therapies that have been recommended include hot 
baths, and the administration of calcium gluconate, muscle relaxants, and 
benzodiazepines (Timms & Gibbons, 1986; Miller, 1992; Maretic, 1983; Zukowski, 
1993; Barron, 1960; Clark et aI., 1992; Blair, 1934). 
The use of narcotic analgesics together with benzodiazepines has been advocated for 
pain relief, but requires hospital admission for observation as repeated large doses are 
normally required (Miller, 1992; Clark et al., 1992). However, as severe latrodectism 
can cause breathing difficulties the use of drugs which induce respiratory depression 
may be contra-indicated (Muller, 1993; Zukowski, 1993). 
In contrast, the use of antivenom has repeatedly been found to produce spectaCUlar 
results, with a complete recovery often occurring after just 30 min (Wiener & Fraser, 
1956; Sutherland & Trinca, 1978). Indeed anti venom has been reported to be highly 
effective even when administered many days (90 and ~ 120 days) after the bite in 
victims with an exceptionally prolonged sequela (Southcott, 1961; O'Malley et al., 
1999; Sutherland, 1992; Banham et al., 1994). 
Because the only antivenom available in the United States comprises unrefined horse 
serum its use is limited to patients with signs of severe envenoming or with a high risk 
of developing complications e.g. age under 16 or over 60 years, respiratory difficulty, 
marked hypertension, pregnancy, or distress that does not respond to other measures 
(Miller, 1992; Russell, 1996). This limited use reflects the high incidence of life-
threatening and, occasionally, fatal reactions that may be associated with the systemic 
administration of the available Merck product (Miller, 1992; Clark et al., 1992; 
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Zukowski, 1993; Kobernick, 1984). Nevertheless, the response is usually dramatic, 
with full and lasting relief of symptoms without the need for further anti venom or 
hospital admission, unless reactions to the antivenom occur (Clark et a!., 1992; Miller, 
1992; Zukowski, 1993; Timms & Gibbons, 1986; Sutherland, 1992). 
Stringent restrictions on antivenom use are not found in countries such as Australia, 
where antivenom is widely available and consists of a refined equine F(ab')2 product 
(CSL Red back spider antivenom). Indeed it is used more than any other antivenom in 
this region with relatively few reactions, none of which have proved fatal (Sutherland 
& Trinca, 1978; Sutherland & Lovering, 1979; Sutherland, 1992). 
Highly refined ovine Fab-based therapeutic products such as Digibind™ have an 
excellent safety record with an incidence of adverse reactions of less than 1 % 
(Kirkpatrick, 1991). Such products clearly demonstrate that a safe antibody-based 
treatment could be developed for black widow spider envenoming in North America. 
The current studies were, therefore, carried out in response to urgent requests by 
clinicians for such a safe product (Zukowski, 1993). 
5.2 Methods 
5.2.1 Venom Extraction Methods 
Due to the perceived problems in obtaining and maintaining a spider colony in the 
UK, the electrically stimulated venom and intact venom glands were obtained from a 
specialised supplier in America (Spider Pharm Inc.). 
5.2.1.1 Electrical stimulation 
Spiders were anaesthetised with carbon dioxide to the point where they could be 
picked up without danger to the handler and without trauma to themselves. A small 
suction tube was then placed in the spider's mouth to remove any secreted juices or 
vomit that may be produced during stimulation. Mild electrical stimulation was 
applied and venom extruded from the fang tips collected into a micro-manipulated 
pipette. The volume of pooled venom from a batch of spiders was then measured and 
the pool frozen. When required, batches of venom were thawed, pooled further and 
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diluted in PBS and the protein concentration determined using the BCA assay. The 
pooled batches were sub-aliquoted and frozen. 
5.2.1.2 Venom gland extract 
Venom glands (15 pairs) obtained from adult female La. hesperus spiders were ground 
up in 1 mL of PBS using a pestle and mortar, centrifuged and the protein 
concentration of the supernatant determined using the BCA protein assay. A further 
15 pairs of glands were gently squeezed using a glass rod in 1 mL of PBS and the 
protein concentration of the supernatant determined. 
5.2.2 SDS-PAGE Analysis 
Venoms and antivenoms were assessed by SDS-PAGE as described in Chapter 2, 
using either non-reducing or reducing conditions in which samples were treated with 
mercaptoethanol and heated at 95°C for 10 min. 
5.2.3 Immunisation of Sheep 
5.2.3.1 Latrodectus hesperus venom immunogen 
Antibodies were raised by immunising nine sheep in groups of three with up to a 
maximum of either 0.25mg (low dose group), Img (medium dose group) or 2mg (high 
dose group) every 28 days of La. hesperus venom. Blood samples were taken at set 
time intervals (Table 5.1). 
5.2.3.2 Latrodectus tredecimguttatus venom and a latrotoxin immunogen 
Antibodies were also raised to La. tredecimguttatus venom and the purified 
component a-Iatrotoxin using immunisation doses of up to 2mg and 10J.lg per sheep 
respectively. 
5.2.3.3 Mixed La. hesperus and Loxosceles reclusa venom immunogen 
Three sheep were immunised with 0.25 mg of La. hesperus venom mixed with up to 
8J.lg of Loxosceles reclusa venom per sheep (Table 5.2) as Loxosceles venom has been 
reported to have an adjuvant type effect (Barbaro et al., 1994; Mota & Barbaro, 1995). 
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Immunogen dose (mg) per sheep 
Immunisation I Weeks Post Low Dose Group Medium Dose 
High Dose Group 





Primary 0 0.25 
0.25 0.25 
Immunisation 
Re-Immunisation 4 0.25 
0.5 0.5 
Sample 6 
Re-Immunisation 8 0.25 
1.0 1.0 
Sample 10 




0.25 1.0 2.0 
Sample 18 
Re-Immunisation 20 
0.25 1.0 2.0 
Sample 22 
Re-Immunisation 24 
0.25 1.0 2.0 
Bleed 26 
Re-Immunisation 28 








Table 5.1 La. hesperus venom immunisation protocol. 
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Immunogen (J.lg) per sheep 
Procedure Weeks Post Primary La. hesperus Lo.reclusa 
Immunisation Venom Venom 
Pre-Immunisation Sample 0 
Primary Immunisation 0 250 2 
Re-Immunisation 4 250 4 
Sample 6 
Re-Immunisation 8 250 8 
Sample 10 
Re-Immunisation 12 250 8 
Sample 14 
Re-Immunisation 16 250 8 
Sample 18 
Re-Immunisation 20 250 8 
Sample 22 
Re-Immunisation 24 250 8 
Bleed + Sample 26 
Re-Immunisation 28 250 8 
Bleed + Sample 30 
Table 5.2 Mixed venom immunisation protocol 
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5.2.4 ELISA for Specific Antibody Levels to Whole Venom or a Latrotoxin 
ELISA plates were coated with 2J.tglmL of whole venom and different concentrations 
of a latrotoxin and antiserum samples assessed for specific antibody as described in 
Chapter 2. 
5.2.5 Enzyme Digestion and Processing of Antiserum 
Papain-digested Fab fragments were prepared as described in Chapter 3 and pepsin 
digested F(ab')2 fragments by the method developed in Chapter 4. 
5.2.6 Phrenic Nerve Hemidiaphragm Preparation 
Left phrenic nerve-hemidiaphragm preparations were prepared as described 10 
Chapter 2. 
The ability of the antivenom to neutralise the effects of the venom was assessed by 
premixing a fixed venom concentration (10mgIL) with antivenom and incubating at 
37°C for 30 min before addition to the hemidiaphragm preparation (to). The tissue was 
washed with fresh Krebs buffer after 30 and 60 minutes. 
The ability to reverse the neurotoxicity was assessed by washing out the venom after 
30 min and adding antivenom. 
5.2.7 In vivo Neutralisation 
Murine LDso and EDsos were performed as described in Chapter 2. 
5.3 Results 
5.3.1 Venom Extraction Methods 
The protein concentration of electrically stimulated La. hesperus venom was found to 
vary between 50 - 80 J.tg / J.tL with different batches. 
Ground La.hesperus venom glands produced 1.75 mg of protein from 15 pairs of 
glands (or 117 J.tg per spider) compared to 890J.tg from 15 pairs of gently squeezed 
venom glands (or 59 J.tg per spider). 
The venoms extracted using the three different methods were analysed by SDS-P AGE 
under reducing conditions and compared with a sample of regurgitated fluid obtained 
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from the mouth of La. hesperus spiders during electrical stimulation (Figure 5.1). The 
electrically stimulated venom contained 7 bands, of which the first 4 ran closely on 
the gel with molecular weights of between 100 - 130 kDa and were the predominant 
venom components. The other components had molecular weights of 82, 47 and 
44kDa. The regurgitated material consisted of 5 bands, of which the predominant one 
had a molecular weight of 67 kDa. This 67kDa protein was completely absent from 
the electrically stimulated venom, indicating that it consisted of pure uncontaminated 
venom. The two venom gland preparations appeared identical and contained more 
than 13 bands. The 6 bands seen in the electrically stimulated venom were all present 
in these preparations although in different proportions and numerous new bands were 
found, the predominant one with a molecular weight of 67 kDa. 
5.3.2 A Comparison of Latrodectus Venoms and Antivenoms from Around the 
World. 
5.3.2.1 Latrodectus venoms 
All the venoms from the different species tested by SDS-P AGE contained a major 
band of the same molecular weight as a-Iatrotoxin (Figure 5.2). Only minor 
differences were evident between the two North American species La. hesperus and 
La. mactans with La. mactans containing a larger proportion of a-Iatrotoxin sized 
material. These two venoms were obtained by electrical stimulation from the same 
supplier. The La. hasselti and La. tredecimguttatus venoms were both obtained from 
venom gland homogenates and had a high background compared to the electrically 
stimulated venoms, a smaller proportion of the a-Iatrotoxin sized material and some 
major bands not seen in the North American spider venoms. 
5.3.2.2 Latrodectus antivenoms 
The commercially available North American Merck & Co., Inc. antivenin (Lot 0948J, 
Exp. 17 May 2002) consisted of freeze dried material containing 1: 10,000 thimerosal 
(mercury derivative preservative) and was reconstituted with the water for injection 
provided (2.5mL) and rapidly dissolved to give a clear viscous liquid. The material 
had a protein concentration of 106 mg/mL using the BCA protein assay with a BSA 










2 3 4 5 6 7 
- ----
Figure 5.1 La.hesperus venom extraction methods, as assessed by SDS-PAGE 
(7.5%) under reducing conditions. Electrically stimulated venom (lane 2), venom 
gland homogenate (lane 3), squeezed venom glands (lane 4), regurgitated juices (lane 
5), a latrotoxin (lane 6), and molecular weight markers (lanes I & 7). 
2 3 4 5 6 
-- - --
Figure 5.2 A comparison of Latrodectus venoms from around the World by SDS-
PAGE (10%) under non-reducing conditions. La.hesperus (lane I), La.mactans (lane 
2), La.hasselti (lane 3), La.tredecimguttatus (lane 4), and a latrotoxin, 5 or 2.511g 
(lanes 5 & 6). 
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treatment of a black widow spider bite. The anti venom appeared identical to normal 
horse serum by SDS-PAGE, with two major bands representing IgG and albumin 
(Figure 5.3). The Merck antivenom also appeared to contain a large (-10%) 
Proportion of high molecular weight material by size exclusion chromatography 
(Figure 5.4), the majority of which presumably represents polymerised or aggregated 
material. 
The Australian (CSL) commercially available red back spider antivenom batch 0534 
03801 (like one of their snake antivenoms) had no detectable intact IgG or albumin 
and contained only one major band of F(ab')2 and a small amount of high molecular 
weight material. 
5.3.3. Effects of Venom Immunisation Dose on Titre Against Whole Venom 
The antibody responses of individual sheep demonstrated a considerable variation to 
the La. hesperus immunogen and, initially, were not related directly to dose. Thus the 
maximum titre of 1:1,500,000 was produced by sheep No CN2549 in the low dose 
group, 10 weeks after the primary immunisation (Figure 5.5). A second high 
responding sheep (CN2544) in the medium dose group produced a titre of 1:1,100,000 
10 weeks after the primary immunisation while all the other sheep produced titres 
between 1 :600,000 - 1 :800,000 at this time point. Due to this variability, the small 
number of sheep per dose group and the staggered immunisation schedule, there was 
no relationship between the venom immunogen dose and response until after the 
maximum immunisation doses were injected at week 16 (Figure 5.6). After this time 
the average response for each group appeared to be directly related to the dose of 
immunogen. Statistical analysis of the individual titres against La. hesperus venom by 
analysis of covariance (ANeDV A) using SPSS software for the complete sets of data 
between weeks 22 and 42 revealed a highly significant difference in response between 
the low and high dose groups (P<O.OOl) and a significant difference between the low 
and medium groups (P=0.009). No significant difference (P=0.053) was found 
between the high and medium dose groups. 
5.3.4 Effects of Venom Immunisation Dose on Titre Against ex Latrotoxin 
An antigen coating concentration of 500ng/mL of ex latrotoxin was chosen which 
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Figure 5.3 A comparison of commercial antivenoms by SDS-PAGE (10%). 
Normal horse serum (lane 1), Merck black widow anti venom (lane 2), CSL red back 





Figure 5.4 Merck Black Widow spider antivenom as assessed by size exclusion 
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Figure 5.5 Individual anti-La. hesperus venom ELISA titres. High (a), medium (b) 
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Figure 5.6 Effect of immunogen dose on titre against La. hesperus venom. High 
(-), medium (.A), and low CY) dose immunisations ±SEM (n=3). 
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produced a high absorbance reading with specific antisera and relatively low non-
specific binding (Figure 5.7). Maximum titres against a latrotoxin for individual 
sheep immunised with the low, medium and high doses of venom ranged between 
1:31,000 to 1:85,000, 1:57,000 to 1:103,000 and 1:58,000 to 1:69,000 respectively 
(Figure 5.8). The sheep demonstrated a considerable variation in their response to a 
latrotoxin, with sheep No CN2549 and CN2544 from the low and medium dose 
groups producing the highest titres at week 10 of 1 :85,000 and 1: 100,000 respectively. 
There were, however, variations in the proportion of antibodies against the whole 
venom that were specific for a latrotoxin; for instance, despite two low dose group 
sheep No CN2547 and CN2548 producing identical titres against the whole venom at 
week 10, antisera from sheep CN2548 had over double the level of antibodies specific 
for a-Iatrotoxin. Due to this variability, the small number of sheep per dose group and 
the staggered immunisation schedule there was again no immediate relationship 
between the venom immunogen dose and average response until after the maximum 
immunisation doses were injected at week 16 (Figure 5.9). Statistical analysis 
(ANCOY A) of the data between weeks 18 and 30 revealed a significant (P=0.009) 
difference in titres to a-Iatrotoxin between the high and low dose groups. However, 
there was no significant difference between the titres produced by the medium dose 
group compared to either the low (P=0.297) or high (P=0.330) dose groups. 
5.1.5 Effects of Mixed Yenom Immunisation on Antibody Titre. 
5.3.5.1 Specific titres to La. hesperus venom 
Of the three sheep immunised with the mixed immunogen (La. hesperus and 
Lo.reclusa venoms), sheep No CN2568 produced the highest antibody titres of up to 
2,460,000 against La. hesperus venom (Figure 5.10a). No significant (ANCOYA, 
P=0.307) difference overall could be found in specific titres to La.hesperus venom 
produced by sheep immunised with either La. hesperus venom alone or the mixed 
immunogen, although the titres for week 26 and 30 were significantly (P=0.025) 
greater in the mixed immunogen group (Figure 5.l1a). 
5.3.5.2 Specific titres to a latrotoxin 
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Figure 5.11 The effects of a mixed immunogen on 'specific ELISA titres. Titres to 
La.hesperus venom (a), or ex latrotoxin (b). Sheep immunised with either, 0.25mg 
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produced the highest antibody titres of up to 277,000 against ex-Iatrotoxin (Figure 
5.l0b). Significantly (P=0.007) greater antibody titres overall were found against ex-
latrotoxin using the mixed immunogen compared to sheep immunised with the same 
dose of La. hesperus venom alone (Figure 5.llb). 
5.3.6 Antivenom Processing 
5.3.6.1 Sodium sulphate precipitation 
FollOwing the sodium sulphate precipitation step it was estimated by OD (using an 
extinction coefficient of 1.5) that the week 30 high dose antiserum contained - 37 gIL 
of IgG. This however represents an over estimate as it is known that salt precipitation 
alone results in an impure IgG (Otero et ai., 1999; Rojas et ai., 1994). 
5.3.6.2 Papain digestion 
The 24 hr papain digestion of the above purified IgG fraction resulted in material 
prinCipally consisting of Fab plus some high molecular weight dimers / aggregates 
and some smaller fragments which may represent over digested Fab or Fc fragments 
(Figure 5.12). A yield of 17.8 g per L of serum was calculated from the OD but due to 
the relatively impure nature of the material this represents an overestimate of the Fab 
Yield. 
5.3.6.3 Pepsin digestion 
FollOwing the new pepsin method of digesting the antiserum for 14 hr and washing 
the material using a cross flow ultrafiltration unit (30kDa MWCO), a yield of 17.4g of 
F(ab')2 per L of antiserum was obtained with a purity of 95% by size exclusion 
chromatography (Figure 5.13a). A similar yield of 17.5g/ L was produced following 
digestion for 18 hr and, therefore, the 14 hr digestion was adopted. This material still 
contained a small quantity of high molecular weight aggregate but due to the highly 
acidic nature of this component it was removed along with pepsin on passage through 
an anion exchange column at pH 6.0 in the presence of 150mM NaC!. The unbound 
F(ab')2 material was then concentrated on a cross flow ultrafiltration unit with a 
resultant overall yield of 16.1g of F(ab')2 per L of antiserum with a purity of 98% by 
siZe exclusion chromatography (Figure 5.13b). 
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Fab 
Figure 5.12 Anti La.hesperus (high dose) Fab as assessed by SIze exclusion 







~igure 5.13 Purity of F(ab')2 as assessed by size exclusion chromatography. After 
d1afiltration (a), followed by ion-exchange chromatography (b). 
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Pepsin was undetectable in this product as assessed with an analytical ion exchange 
(Mono Q) chromatography column (Figure 5.14). 
5.3.7 Effects of Venom and Antivenom on a Nerve Muscle Preparation 
5.3.7.1 Venom 
The nerve stimulated response was potentiated by 1 mglL of La. tredecimguttatus 
venom reaching a maximum of 115% at 30 min and the amplitude of the twitches 
became less regular with signs of occasional spontaneous partial twitches (Figure 
5.15a). A transient initial potentiation was produced by 3.3 mgIL followed by a slight 
inhibition. A 10 mg/L concentration produced a rapid blockade within 30 min with an 
82% maximum blockade (Figure 5.15a). 
A significant potentiation of the directly stimulated muscle contractions was produced 
OVer the first 65 min compared to controls by 10 mglL (ANCOVA, P=0.034), 3.3 
mgIL (P=O.002) and ImglL (P=O.OOl) of La. tredecimguttatus venom. These effects 
were of an immediate but transient nature and most pronounced at 35 min (Figure 
5.15b). 
5.3.7.2 Effects of high calcium Krebs on the venom 
In the presence of a high calcium concentration (4 mM) the venom (10 mglL) resulted 
in a significant (ANCOVA, P<O.OOI) increase in blockade of the nerve stimulated 
response With up to 96% inhibition compared to 82% for 1.9 mM calcium (Figure 
5.16). There was no significant difference (P=O.971) between the effects on the 
directly stimulated preparation. 
5.3.7.3 Antivenom neutralisation 
The effects of the venom (lOmgIL) were almost fully neutralised by pre-mixing with 
50mgIL of anti-La. hesperus high dose Fab and a smaller amount of neutralisation was 
produced by the medium dose Fab (Figure 5.17). However, there was transient initial 
potentiation which suggests (Figure 5.15) that neutralisation of the 10mgIL venom 
Was not complete. Only an approximately 50% neutralisation was produced by the 
low dose Fab. Effects of the venom (lOmglL) were, however, fully neutralised by pre-
mixing with 200mg/L of Fab raised against La. hesperus venom using either the high 
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Fig~re 5.14 Analytical anion-exchange chromatography using a Mono Q column. 
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Figure 5.15 Effects of La. tredecimguttatus venom on the mouse hemidiaphragm. 
Nerve stimulation (a). or direct muscle stimulation (b). using 1 (e). 3.3 (~). or 
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Figure 5.16 The effect of calcium concentration on La.tredecimguttatus venom 
(lOmglL). Normal (1.9mM) calcium (open symbols) and high (4.0mM) calcium 
(closed symbols) concentrations. Direct muscle (squares) and nerve (triangles) 
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Figure 5.17 The effect of immunisation dose on specific neutralising antibody 
levels as assessed on nerve diaphragm preparations. Venom (lOmg/L) only ( ... ), or 
premixed with 5Omg/L of anti-La. hesperus high dose Fab (+), medium dose Fab (_), 
or low dose Fab ('Y) ±SEM (n=4-6). Nerve stimulated (a), or direct stimulation (b). 
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or low immunisation schedules (Figure 5.18). 
Fab antibody fragments (200 mg/L) raised against La. tredecimguttatus venom 
neutralised the inhibitory action of the venom and caused a transient potentiation over 
the first 30 min of the nerve stimulated response, but venom effects were fully 
neutralised by a 400mgIL concentration (Figure 5.19). Anti-a-Iatrotoxin Fab was also 
shown to neutralise the venom. 
5.3.7.4 Effect of mixed immunogen 
No significant (P=0.497) difference could be found between the neutralising ability of 
50mgIL of Fab antivenom produced by immunising with either La.hesperus venom 
alone or combined with Loxosceles venom (Figure 5.20). 
5.3.7.5 A comparison of the neutral ising properties of Fab and F(ab')2 with a 
commercial antivenom 
A 50mgIL concentration of the Merck black widow antivenom was found to neutralise 
the effects of the venom (1 OmglL) to the same extent as the high dose La. hesperus 
Fab at the same concentration (Figure 5.21). When just 25mgIL of the antivenoms 
were tested approximately 50% neutralisation was found, although the commercial 
antivenom had a slightly weaker neutralising effect. However, F(ab')2 produced from 
the same high dose La. hesperus antisera at a concentration of 25mgIL neutralised the 
venom to about the same extent as 50 mglL of the other antivenoms. 
5.3.7.6 Delayed antivenom treatment 
Antivenom (200mg/L or 1000mg/L, high dose Fab) added 30 min after lOmg/L of 
venom had no effect on the established nerve blockade over 3 hr (Figure 5.22). 
However, the potentiation produced by ImglL of venom over the first hour was 
rapidly inhibited when 200mg/L or more of antivenom was added after 30 min 
(Figure 5.23). 
5.3.8 In vivo Toxicity 
La. tredecimguttatus venom batch PA 734 had an LDso of 0.59 mg/kg (11.2 J..tg/mouse, 
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Figure 5.18 Antivenom neutralisation of La.tredecimguttatus venom (lOmglL). 
Venom only (II), plus anti-La. hesperus high (.), or low C.) dose Fab (200mglL). 
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Figure 5.19 Neutralising effects of antibodies raised against La. tredecimguttatus 
venom and a latrotoxin. Diaphragm preparations, bathed in 10mgIL venom only (D), 
or plus anti-La.tredecimguttatus Fab, 200mgIL (~), 400mgIL (V), or anti-a latrotoxin 
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Figure 5.20 The effect of a mixed venom immunogen on specific neutralising 
antibody levels against Latrodectus venom. Nerve stimulated diaphragm preparations, 
bathed in lOmg/L venom only (£), ±SEM (n=6), or plus 50mg/L anti-La. hesperus 
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Figure 5.21 A comparison of the neutral ising properties of Fab and F(ab')2 with a 
commercial antivenom. Venom only (A). (n=6), or plus 2Smg/L (e) and SOmg/L (+) 
of anti-La. hesperus (high dose) Fab. or 2Smg/L (T) F(ab')2' or plus 2Smg/L (D) and 







































Figure 5.22 The irreversible nerve blockade produced by La.tredecimguttatus 
venom (lOmglL). The effects of washing (a), or premixing with 200mgIL La.hesperus 






























Figure 5.23 Effects of the delayed addition of antivenom on the neurotoxic action 
of 1mg/L of venom. Venom control (a), and the addition of200mg/L of La. hesperus 
high dose Fab, after 30 min (b). Direct stimulation (D). 
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of 1.19 mg/kg (22.7J.lg/mouse, 95% confidence limits from probit analysis 16.6 -
29.4). 
Animals rapidly displayed signs of envenoming with a change in behaviour and their 
general appearance. Within an hour profuse sweating could be clearly seen in some 
animals, their fur appeared wet and the eyes were closed (Figure 5.24a). Some 
animals displayed a marked piloerection and some were heavily lacrimating. Isolated 
muscular spasms were evident from time to time and movement had an unnatural 
jerky appearance with eventual hind limb paralysis in the higher dose groups. Despite 
the freely available food and water none of the animals were observed to eat or drink 
during the 24hr period and they lost weight (-20%). The ear veins also appeared 
dilated and by the end of the experiment the animals were almost totally inactive with 
stiffened bodies / increased muscle tone and often irregular or laboured breathing. 
Despite the array of severe effects, death appeared to be due to respiratory paralysis as 
indicated by the irregular or laboured breathing. As all the animals displayed these 
severe early effects they could not be used as an early indication of mortality and most 
of the animals that died did so in the latter stages of the 24 hr. The only exception to 
this was in the preliminary dose finding study where excessively large doses induced 
hyperactivity leading to convulsions and a rapid death. 
5.3.9 In vivo Neutralisation by an Antivenom 
The La.hesperus (high dose), F(ab'h antivenom was substantially more potent by EDso 
testing than any of the other antivenoms and the relative order of potency for the other 
antivenoms was: La.hesperus (high dose), F(ab')2 > Merck> La.hesperus (high dose), 
Fab> La. tredecimguttatus, Fab > a-Iatrotoxin, Fab > La.hesperus (mixed venoms), 
Fab / La. hesperus (low dose), Fab (Table 5.3). 
The week 30 La.hesperus (high dose) antiserum from which the Fab and F(ab')2 were 
processed had an EDso value of 1.64J.lL per mouse (95% confidence limits from probit 
analysis 0.90 - 2.59). From this data and the potency of the purified antibody 
fragments the neutral ising yield could be calculated as 78 and 37% for the F(ab')2 and 
Fab preparations respectively (Table 5.4). 
Despite the neutral ising effect of the antivenoms, all the animals within the EDso dose 




Figure 5.24 Effects of Latrodectus tredecimguttatus venom in vivo. (a) Displaying 
~rofuse sweating, closed eyes, dilated ear veins and inactivity, four hours after the iv 
lfljection of lO.5).lg and (b) a control mouse. 
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EDso against 2LDso of La. tredecimgultatus venom 
Antivenom mg/kg flglmouse 95% confidence limits 
Merck Black Widow AN 3.36 64 51 - 75 flg/mouse 
La. hesperus (High), F(ab')2 1.80 34 19 - 59 flg/mouse 
La. hesperus (High), Fab 4.13 78 56 - 107 flg/mouse 
La.hesperus (Low), Fab 9.92 189 171 - 214 flg/mouse 
La. hesperus (Mixed), Fab 9.84 187 130 - 233 flg/mouse 
a-Iatrotoxin, F ab 7.37 140 69 - 244 flg/mouse 
La. tredecimguttatus, Fab 6.68 127 106 - 145 flg/mouse 
Table 5.3 Neutralisation of lethal venom effects in vivo. (95% confidence limits 
from probit analysis.) 
Yield 
Number of Mouse EDso Units I L % Original Neutralising 
Serum Processed Activity 
Antiserum 609,756 100.0 
Fab 228,205 37.4 
F(ab')2 473,529 77.7 
Table 5.4 Antivenom neutralising yields for Fab and F(ab')2 processed from a 
batch of week 30 anti-La. hesperus (high dose) serum. 
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antivenom doses (600, 2,500 or 5,000I!g/mouse) premixed with two LDso of venom 
(22.4l!g), were closely observed for signs of envenoming (Table 5.5). An antivenom 
dose of 600f,lg per mouse of both the Merck and F(ab')2 antivenoms completely 
neutralised any signs of envenoming, or a ratio of 27J.lg of anti venom to each f,lg of 
venom. These animals were observed feeding and drinking normally and appeared 
completely unaffected. 
5.4 Discussion 
Although the venoms from different Latrodectus species displayed slight differences 
they all appeared to contain an identical band representing a.-Iatrotoxin. It has been 
shown by various authors that antivenoms raised against different subspecies from 
around the world are all highly effective in cross neutral ising the toxic effects of other 
Latrodectus venoms both in mice and in man with the complete relief of all symptoms 
(Wiener, 1961; Keegan, 1955; Finlayson & Hollow, 1945; Graudins et al., 2001). 
Venoms obtained by electrical stimulation had a cleaner appearance on SDS-PAGE 
with less background protein than those obtained from venom gland homogenates. 
The use of such a clean venom preparation, free from regurgitated mouth part juices 
or cell debris, for immunisation may have helped the sheep to produce such high 
levels of specific antibody. 
Commercial antivenoms currently available for the treatment of envenoming by 
Latrodectus spiders are raised in horses and vary in purity from unrefined antiserum 
such as the Merck antivenom tested here, to purified F(ab')2 preparations such as 
C.S.L. 's Red Back Spider Antivenom. Horses are highly sensitive to this venom, 
producing severe life-threatening effects if too much venom is administered initially 
(Maretic & Stanic, 1954; Wiener, 1961). However, no untoward effects have been 
noted during this or other work raising antibodies in sheep with similar venom doses 
(Smith & D'Amour, 1939; Maretic & Stanic, 1954). 
The individual antibody responses of sheep immunised with La. hesperus venom were 
highly variable as assessed using an ELISA detection system against either the whole 
venom or a.-latrotoxin with maximum titres of up to 1:1,500,000 and 1:100,000 
respectively. Although the highest immunisation doses generally produced higher titre 
164 
Signs of Envenoming After 24 hr 
Antivenom 600Jlg Dose 2,500Jlg Dose 5,OOOJ.lg Dose 
Merck Black Widow Antivenom - - ND 
La.hesperus (High), F(ab')2 - ND ND 
La. hesperus (High), Fab ++ - ND 
a.-Iatrotoxin, Fab +++ + + 
La. tredecimguttatus, Fab +/- - ND 
Table S.S Neutralisation of the signs of envenoming by two LDso of venom in 
vivo. No signs (-), minor signs (+/-), definite signs (+), severe signs (++), very severe 
signs (+++), and not done (NO). 
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antisera against the whole venom than those sheep immunised with lower doses, this 
difference became less clearly defined when titres against a-Iatrotoxin were 
compared. 
The mouse phrenic nerve-diaphragm preparation was used as a specific assay for 
neurotoxicity. It showed the potentiating (stimulatory) effects of low venom 
concentrations (Img/L) but nerve blockade by higher concentrations (lOmg/L) 
presumably due to the rapid depletion of neurotransmitter following a latrotoxin pore 
formation. The neurotoxic effects of the venom were neutralised by 200 - 400 mg/L of 
all the antivenoms tested and the relative order of potency produced by immunising 
with different La.hesperus venom doses was high dose (2mg/sheep) > medium dose 
» low dose. Concentrations as low as 50 mg/L of both the commercial Merck 
antivenom and the La.hesperus high dose Fab or just 25 mg/L of F(ab')2 produced 
using the new process neutralised the nerve blockade produced by lOmg/L of venom. 
These results show that an equally effective antivenom could be processed from sheep 
antisera using an established papain digestion procedure, and a significantly more 
effective F(ab')2 antivenom with about twice the activity using the new process. 
Despite these neutralising effects, anti venom was incapable of reversing the nerve 
blockade produced by the 10mg/L venom concentration in vitro. This may be a 
reflection of the high venom concentrations which are in excess of the maximum 
levels expected clinically and which produce a nerve blockade by depleting the nerve 
terminal of neurotransmitter containing vesicles. The stimulatory type effects seen at 
low venom concentrations (lmgIL) are more likely responsible for the symptoms of 
envenoming as opposed to lethality and could be rapidly reversed by high 
concentrations of antivenom (200mgIL). 
The venom produced a mixed array of signs of envenoming in mice, with some 
animals sweating profusely while others were unaffected in this respect; this may 
reflect the use of out-bred mice. An array of different signs and symptoms have also 
been noted clinically in man, again with a profuse sweating seen in some individuals 
but absent in others (Maretic, 1983; Clark et al., 1992). This may reflect differences in 
the relative density of a latrotoxin receptors found on different nerve types (Sugita et 
al., 1999), with the unnatural spontaneous stimulation of these nerves producing the 
various effects. The predominant and consistent clinical feature is severe pain, which 
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may indicate that sensory nerve endings have a high receptor density and are, 
therefore, highly sensitive to the venom. A direct effect on these sensory nerve 
endings has been clearly demonstrated experimentally by various groups both in vivo 
and in vitro (Queiroz & Duchen, 1982; Waterman & Maggi, 1995). 
The venom had a toxicity of 0.59mg/kg as assessed using the mouse LDso assay over 
24hr with most of the animals dying in the latter part of the 24 hr indicating that the 
lethal effects of the venom were of slow onset. Other groups assay this venom over 8 
days with most animals dying after 2 to 3 days, indicating that a higher toxicity could 
be found by assaying the venom over a longer time period (Wiener, 1956; Finlayson 
& Hollow, 1945). Before the introduction of antivenoms, human fatalities following 
Latrodectus envenoming have occurred 3 - 30 days after the bite in adults, but just 36 
or 6 hr later in 3 year or 3 month old victims respectively (Ingram & Musgrave, 
1933). 
It could be calculated from the relative EDso values that 141mg of F(ab')2 produced 
using the new process would be equivalent to one vial of the Merck anti venom. As 
each vial of commercial antivenom is produced with a potency expressed in terms of 
LDso neutralisation, and, therefore, assuming that this measure correlates with the 
clinical efficacy of the material it would also represent sufficient material for the 
treatment of a single black widow spider bite. As this material was processed with a 
yield of 16.1g of F(ab')2 per L of antisera, each litre of antisera could theoretically 
produce - 114 treatments. A high yield process such as this which retains 78% of the 
original EDso neutral ising power of the serum is particularly important in order to 
reduce the production costs and compares with a 37% yield produced by a papain 
digestion method. The increase in yield alone would be expected to halve the total 
production cost, and the elimination of the salt precipitation step would also be 
expected to reduce the processing time and costs. This increase in yield would halve 
the number of sheep required for immunisation and therefore the amount of venom 
needed which is extremely difficult and expensive (-$155/mg) to obtain in large 
quantities. 
A commercial Squibbs antivenom (Anti-Black Widow Spider Serum) produced in the 
1930's in America was also raised in sheep, by immunising each animal with the 
venom gland extracts from 3,000 spiders over a 6 month period (Smith & D'Amour, 
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1939). They obtained 126J.Lg of venom per spider (D'Amour et al., 1936) which is 
similar to the 117J.Lg per spider found here. From this it can be calculated that 378mg 
of venom was used to immunise a single sheep over 6 months or -63mg per month 
and resulted in an antiserum of which lmL could neutralise 45 rat LDso or 5.7mg of 
venom (D'Amour, 1936). This hyper-immunisation with - 32 times more venom than 
was used in the high dose group here, may have been necessary if no adjuvant was 
used, and produced a less potent anti venom than the high dose group, which could 
neutralise 610 mouse LDso or 6.8mg of venom per mL of serum. 
It Was also reported that 3.5 hr after the subcutaneous injection of a rat with the 
venom from two spiders (-252J.Lg), one mL of Squibbs (week 10) antiserum was 
required intra-peritoneally in order to produce a full recovery, and indicates that 23 
times more antivenom is required to reverse the signs of envenoming compared to 
preventing lethality by premixing (D'Amour et al., 1936; D'Amour, 1936). 
The present experimental results show that with premixing, only 6 times more Merck 
antivenom is required for neutralising the blockade of the phrenic nerve in vitro or 
preventing the lethal effects in mice in vivo. However 9 times the EDso is required to 
completely neutralise all the signs of envenoming in vivo. One vial of the Merck 
product contained -265mg of protein which is known to be sufficient for the 
treatment of a single black widow spider bite and from the EDso assay calculated to be 
capable of neutral ising 46mg of venom. The large excess in this antivenom may, 
therefore, be necessary clinically to reverse the signs and symptoms of neurotoxicity 
if only a small proportion of the antibodies are specific for the critical region of the 
neurotoxin responsible for clinical features such as pain and which is left exposed on 
the nerve terminal membrane allowing antibody binding. Some excess of anti venom 
is also likely to be required clinically to allow for dilution in the circulation and 
antivenom clearance. An amount of antivenom - 100 times the weight of venom 
delivered may typically be required for snake antivenoms. 
Latrodectus venom contains 7 high molecular mass (11 0-140kOa) toxic proteins (ex-
latrocrustatoxin, ex, ~, y, 8, and e-Iatroinsectotoxin, and ex-Iatrotoxin) which contain 
some highly homologous amino acid sequences. For instance ex-Iatrotoxin shares 37 
and 34% of its sequence with 8-latroinsectotoxin and ex-Iatroinsectotoxin respectively 
(Grishin, 1998). The presence of these identical amino acid sequences on most of the 
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venom components would be expected to induce a strong immune response and may 
help to explain the exceptionally potent nature of the anti venoms when premixed, as 
assessed by either neurotoxicity neutralisation or EDso, and suggest perhaps the 
binding to a common structural component necessary for pore formation (Pescatori & 
Grasso, 2000). However, the continued presence of severe signs of envenoming using 
concentrations of - 8 times the La.hesperus (high dose) Fab EDso suggest that the 
toxin was still capable of binding its receptor and producing an effect despite carrying 
a bound antibody fragment which prevented the lethal effects. 
Evidence for at least four functional domains (1. Receptor binding, 2. Alteration of 
plasma membrane calcium permeability, 3. Acceleration of neurotransmitter release, 
4. Bilayer lipid membrane ion-channels) of the a latrotoxin molecule have been 
demonstrated with monoclonal antibodies. One such antibody (4C4.1mAb) 
neutralised the toxicity of both a latrotoxin and whole venom in mice without 
inhibiting the toxin's ability to bind its receptors by interacting with a structural 
component involved in pore formation (Pashkov et ai., 1993; Cattaneo & Grasso, 
1986; Pescatori & Grasso, 2000). However, this antibody appears incapable of 
modifying the toxin's action after binding (Cattaneo & Grasso, 1986; Pescatori & 
Grasso, 2000). Interestingly several of these monoclonal antibodies will not bind the 
denatured toxin, implying the need for active non-denatured toxin in the immunisation 
procedure (pashkov et ai., 1993). Further evidence for the multi -functional effects of 
the toxin have been demonstrated indirectly by the venom's precipitation with methyl 
alcohol which could subsequently only produce a temporary hind limb paralysis 
without any of the other normally severe effects in rats (D'Amour et ai., 1936). 
Clinically, low blood calcium levels are known to be associated with symptoms 
including muscle aches, seizures and spasms as well as tetany (general stiffening and 
spasms of the muscles) and are treated with calcium injections or supplements. 
Because of the similarity of these clinical features with some of those produced by 
Latrodectus envenoming, intravenous calcium gluconate has long been recommended 
for pain relief after envenoming (Maretic, 1983; Timms & Gibbons, 1986). However, 
in the current studies it has been shown that a high calcium Krebs solution enhances 
significantly in vitro venom neurotoxicity, consistent with the work of Palmer (1975) 
using the rat phrenic nerve diaphragm. This finding agrees with several clinical 
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investigators who have had inconsistent results with calcium injections (Key, 1981; 
Russell, 1962; Clark et 01., 1992). For instance Key (1981) found calcium gluconate 
to be effective in only six of 13 patients and, since the symptoms found following 
Latrodectus envenoming are known to "wax and wane", many patients may appear to 
improve regardless of treatment if they are observed for only a limited period after 
envenoming (Maretic, 1983; Clark et 01., 1992). 
An investigation of potential adjuvant type effects produced by Loxosceles venom in 
sheep revealed about 2- to 3-fold higher specific ELISA antibody titres against a 
latrotoxin. However, no significant difference was found in the neutralising effect 
when assessed on nerve muscle preparations or in vivo. These findings clearly indicate 
differences between specific antibody binding levels and neutralising antibody levels 
and highlight why bioassay neutralisation is a critical component in the testing of 
antivenoms. The lethal effects of this venom in mice appeared to be due to respiratory 
paralysis, which may account for the good correlation found between EDso results and 
those with the isolated phrenic nerve diaphragm preparation. The use of the phrenic 
nerve diaphragm preparation may, therefore, provide a much needed more humane 
alternative to the standard mouse EDso testing of these antivenoms which induce 
considerable pain and suffering in the test animals. 
Observations made during the EDso tests showed that none of the animals were free 
from the severe signs of envenoming and as the practical use of the anti venom is in 
ameliorating symptoms and not predominantly used to prevent the lethal effects, the 
use of the EDso test does not appear very relevant to the clinical use of this particular 
anti venom. With larger antivenom doses of greater than 18 times the EDso any signs 
of envenoming were prevented by all except the anti-a latrotoxin Fab. The use of a 
test system which measures the neutralisation of all the signs of envenoming would, 
therefore, have a greater relevance to the clinical setting. However, a humane in vitro 
equivalent would provide a more ethically acceptable test system. 
The F(ab')2 produced using the new process had - twice the potency of the Fab 
prepared from the same batch of antiserum. This is a reflection of the highly pure 
nature of the F(ab')2 compared to the Fab which would still be expected to contain 
most of the 16% papain used in the digestion plus an unknown amount of Fe. Salt 
precipitation may also have caused the loss of some of the neutralising activity, and it 
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is now widely accepted that salt precipitation can damage the IgO and lead to the 
formation of aggregates which may induce reactions in the clinical setting (Otero et 
al., 1999; Rojas et al., 1994). Because of the small difference in size (23kDa vs 46kDa 
for papain as compared with Fab) and the high isoelectric point of papain (PI 8.75), 
the two cannot be efficiently separated by either diafiltration or during the 
conventional anion-exchange step used to remove Fc (Allen, 1996; Glazer & Smith, 
1971: Hristova, 1968). Also papain, unlike pepsin, is a known allergen in man (Quarre 
et al., 1995; Baur et al., 1995). 
Although the Merck, Black Widow Spider Antivenom has repeatedly been shown to 
be highly effective at rapidly alleviating all the clinical features of envenoming, the 
high incidence of reactions despite the relatively small quantity of material 
administered has dramatically influenced the willingness of clinicians to use this 
product in North America (Moss & Binder, 1987). This product is also known to 
induce a large degree of in vitro complement activation and was found to contain a 
large amount of high molecular weight aggregates which have been strongly 
implicated in the anaphylactoid reactions produced by human intravenous 
immunoglobulin preparations (Sutherland, 1977; Bleeker et al., 1987; 1989; 2000; 
Lobatto et al., 1987; Jenei et al., 1991; Sylvestre et al., 1996). 
The new ovine F(ab')2 antivenom raised to La. hesperus venom as described here was 
twice as effective as the Merck material by weight, essentially free from aggregates 
and pepsin and may provide a much needed safe and effective alternative antivenom 
for use in North America. 
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CHAPTER 6: 
FINAL DISCUSION AND CONCLUSIONS 
When antivenoms were first developed over a hundred years ago they all consisted of 
unrefined horse antiserum which, due to the large amount of foreign protein 
administered, frequently caused severe serum sickness one to two weeks later. 
Immediate type reactions were also encountered which were assumed to result from 
an IgE mediated response since, before the introduction of antibiotics and effective 
vaccination programmes, horse antisera were routinely used for a range of infections 
(e.g. anti-diphtheria, tetanus, scarlet fever, poliomyelitis, meningococcus), often 
prophylactically (Kojis, 1942). A large number of patients had, therefore, previously 
been exposed to horse serum proteins which is necessary for a true IgE mediated 
response. However, some patients developed immediate type reactions despite no 
previous exposure to horse serum protein (Kojis, 1942). 
Subsequently processes were developed to reduce the amount of foreign protein 
administered with a consequent reduction in the incidence of reactions. These 
included sodium and ammonium sulphate precipitation of the immunoglobulin 
fraction and this was followed later by the introduction of pepsin to remove the Fc 
part of the antibody molecule. These methods to produce purified F(ab')2 preparations 
were adopted by most antivenom manufacturers and remain essentially unchanged. As 
a result, the severe serum sickness reactions once frequently seen have largely been 
resigned to the history books. However, the risk of immediate type reactions remains. 
Experimental work in the 1960's using a guinea pig model of IgE mediated 
anaphylaxis clearly demonstrated that crude plasma was the most potent sensitising 
agent followed by Fc fragments or impure F(ab')2 preparations, while pure F(ab')2 
preparations had by far the weakest activity (Hristova, 1968). Presumably this 
contributed to the notion that all the early reactions were IgE mediated type I 
hypersensitivity reactions to equine serum proteins. However, their prevalence in 
populations never exposed to equine material and the absence of specific cutaneous 
hypersensitivity in most reactive patients prompted a search for other mechanisms 
(Malasit et al., 1986). 
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Sutherland (1977) found that most antivenoms, including Merck's black widow 
product, were anticomplementary in vitro, which led him and others to recommend 
the slow intravenous infusion of diluted antivenom to reduce complement activation 
(Reid, 1980). However, it has subsequently been shown (Malasit et al., 1986) that the 
incidence and severity of early reactions are similar whether the antivenom is given by 
intravenous injection over 10 min or diluted and given as an intravenous infusion over 
30 min and, although the antivenom activated complement in vitro, there was no 
significant evidence of in vivo complement activation. 
It has been found that certain ovine Fab antivenoms could induce similar early 
reactions in patients never exposed to ovine serum products (Meyer et al., 1997; 
Ariaratnam et al., 1999; 2001). However, Digibind™, a highly refined ovine Fab 
product has an excellent safety record (Kirkpatrick, 1991), indicating that a well 
formulated, highly refined Fab product free from contaminants should be safe. A new 
process, recently introduced by Aventis-Pasteur, utilises two ion exchange steps to 
improve the potency, purity and safety (4% side effects) of its equine-based pepsin 
digested products, removing the majority of both the low molecular weight 
contaminants and the high molecular weight aggregates previously found 
(Grandgeorge et al., 1996; Pepin-Covatta et al., 1997; Chippaux et al., 1999). 
Reactions produced with this antivenom were all mild early events, without a single 
case of serum sickness (Chippaux et al., 1999). This indicates that some of the minor 
contaminants or aggregates found in antivenoms must be exceptionally potent at 
stimulating immediate type reactions by an as yet unknown mechanism. 
Numerous studies have been performed to elucidate the cause of early reactions 
produced when human immunoglobulin preparations were infused intravenously. 
Different types of aggregate have been shown to either cause complement activation 
or produce a hypotensive response in a rat model which correlates with clinical 
reactions and results from the activation of phagocytic cells via Fc receptors (Bleeker 
et al., 1987; 1989; 2000; Spycher et al., 1999). Aggregates which activate 
complement are known to be rapidly coated with C3b and the opsonised complex 
bound via the C3b to erythrocyte CRI receptors. The immune complexes are then 
safely cleared from the circulation and neutralised in the liver following Fc receptor 
binding without erythrocyte destruction (Nardin et al., 1999). It has also been shown 
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by Lobatto et a1. (1987) that small quantities (lOllg/kg body weight) of complement 
activating soluble human IgO aggregates experimentally injected i.v. in man are 
rapidly cleared (tl12, 26min) from the circulation, predominantly via the liver without 
causing any adverse effects. It now appears likely that reactions to human IgO are due 
to the release of inflammatory mediators caused by phagocytic cell activation through 
the interaction of IgG dimers or aggregates with Fc receptors (Bleeker et a1., 1987; 
1989; 2000; Lobatto et a1., 1987; Jenei et a1., 1991; Sylvestre et a1., 1996). 
European Pharmacopoeia guidelines outline the use of size exclusion chromatography 
to measure aggregate / polymer levels in human intravenous immunoglobulin 
preparations, which should represent not more than 3% of the total area of the 
chromatogram. The guidelines also stipulate that anticomplementary activity should 
be less than 1 CH50 per mg of immunoglobulin (European Pharmacopoeia, 1997). 
During the present work the Merck antivenom was found to contain a large (-10%) 
amount of high MW material which, in the light of the above evidence, is most likely 
responsible for the majority of immediate anaphylactoid reactions seen clinically with 
this product. Although this anti venom has a high anticomplementary level in vitro, so 
little is administered clinically (- 265 mg) that it is unlikely that any significant large 
scale complement activation would be seen in vivo. A more likely explanation for the 
immediate type reactions is an interaction with Fc receptors, as shown with human 
intravenous immunoglobulin products. 
Pepsin and papain digested anti venoms contain no intact IgG which could cause these 
reactions. Furthermore, as pure monomer Fab and F(ab')2 preparations have been 
administered safely to humans, reactions must result from contaminants or aggregates. 
No evidence could be found in the literature for Fc receptor binding by aggregated 
Fab or F(ab')2' and reactions are, therefore, more likely to result from minor 
contaminants such as low molecular weight fragments of Fc. The method of enzyme 
cleavage and the anion exchange step developed in the new process may provide the 
key to reducing immediate type reactions by removing any residual aggregating 
fragments of Fc. 
The successful use of the hypotensive model developed by Bleeker et a1. (1987) has 
allowed the identification of components in human iv immunoglobulin preparations 
responsible for immediate type reactions and similar work should be repeated with 
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some typical antivenoms in order to identify conclusively the minor contaminant(s) 
responsible for antivenom reactions. This would help enormously with the 
development of improved methods for their removal and the subsequent elimination 
of these life-threatening side effects. 
As no specific therapy is available for the toxic effects produced by mass bee attacks 
(Franca et 01., 1994; Schumacher et 01., 1996), a large volume of antisera was 
generated and used to develop a new, simple platform technology for producing 
antivenoms in high yield at low cost. This newly-developed ovine Apis mellifera 
antivenom had high levels of specific antibodies to the venom which neutralised its 
myotoxic, phospholipase A2 and in vivo activities. It also contained high levels of 
antibodies directed against the main toxic component of bee venom, melittin, and may 
provide the first specific therapy for the treatment of mass envenoming by either 
European or Africanised bees. 
Methods of processing the ovine antisera usmg pepsin were investigated. By 
determining the conditions necessary for the preferential breakdown of Fc and serum 
components other than F(ab')2' it was possible to avoid any time consuming salt 
precipitation steps which are difficult to perform on a large scale under sterile 
conditions and may be associated with large (-18%) losses and aggregate formation 
(Schultze et 01., 1965; Friesen, 1987). Diafiltration was then optimized to remove 
most of the unwanted low MW fragments and the conditions for anion-exchange 
chromatography optimised to remove any remaining acidic impurities such as pepsin 
and high MW aggregates. The whole manufacturing process resulted in a F( ab')2 
product with a purity comparable to the best commercial antivenoms (-97% 
(Grandgeorge et 01., 1996» but with higher yields (up to 19.3g per L of serum) than 
previously reported (up to 14g per L of plasma (Benanchi et 01., 1988». 
Spiders of the genus Latrodectus (black widows) are distributed widely and about 
2,500 bites are reported each year in the USA (Litovitz et 01., 1991-2000). The 
neurotoxic effects of its venom were studied on the isolated phrenic nerve diaphragm 
preparation. Low venom concentrations (lmg/L) were stimulatory while high venom 
concentrations (10mgIL) caused nerve blockade which was potentiated by increased 
calcium levels. 
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Although effective, the Merck black widow spider antivenom, which is unprocessed 
horse serum, causes unacceptable risks. The second purpose of this project was to 
prepare an improved Latrodectus spider anti venom using the new platform 
technology. 
Different immunisation schedules were studied in sheep to optimise their humoral 
immune response. Animals immunised with 2mg La.hesperus venom produced the 
highest levels of specific antibodies as assessed by ELISA, using an isolated nerve 
diaphragm, and by in vivo studies in mice. A pure F(ab')2 antivenom was produced in 
high yield from this antisera with the new manufacturing process which retained 78% 
of its original in vivo EDso neutral ising power, could neutralise all the non-lethal in 
vivo effects produced by the venom and was - twice as effective as the Merck 
antivenom. 
Because a single toxin (a-Iatrotoxin) is known to cause the clinical effects of 
Latrodectus envenoming it is possible to produce an immunotherapeutic product 
comprising humanized monoclonal antibody (Pescatori & Grasso, 2000). However, 
the high production costs would make such a product prohibitively expensive in some 
countries. A partially effective antivenom was produced in the present studies by 
immunising sheep with just 10J.1g of a latrotoxin, since its high cost (- £2,600 per mg) 
prevented immunisations with higher doses. The recently found DNA sequence to 
encode for the active toxin and its expression in a cell line (Ichtchenko et al., 1998; 
Volynski et al., 1999) may allow large quantities of toxin to be produced at relatively 
low cost. A new pioneering immunisation technique has also been developed recently 
in which DNA (3J.1g) encoding part of a snake venom toxin was fired intracellularly 
into a mouse with a gene gun and the expressed toxin fragment shown to produce an 
antibody response comparable to that produced by conventional immunisation of a 
rabbit with the intact toxin (Harrison et al., 2000). Such a method may provide a new 
approach to developing a Latrodectus antivenom which avoids the need for large 
amounts of venom, but further studies are required to investigate its effectiveness (i) 
in larger species such as sheep and (ii) with more complex toxins such as a-Iatrotoxin 
which is - five times the size of the fragment used by Harrison and his group (2000). 
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To summarise, effective new antisera were raised in sheep against the black widow 
spider and bee venoms and a new, simple method of processing the sera developed 
which provided highly pure F(ab')2 in high yield which should be suitable for the large 
scale production of these and other anti venoms. 
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